Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.71 |
| ▸ | GAA | P10253 | 2/20 | 0.71 |
| ▸ | RAB9A | P51151 | 4/20 | 0.65 |
| ▸ | NPC1 | O15118 | 3/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | GSK3B | P49841 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | FABP7 | O15540 | 1/20 | 0.56 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.56 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1567446 | 0.89 | KDM4E (0.58) | KDM4EGAARAB9ANPC1CYP1A2 | |
| SCHEMBL30393282 | 0.85 | KDM4E (0.82) | KDM4EGAARAB9ANPC1CYP1A2 | |
| SCHEMBL11291466 | 0.85 | NPC1 (0.79) | KDM4EGAARAB9ANPC1CYP1A2 | |
| SCHEMBL1276481 | 0.85 | KDM4E (0.82) | KDM4EGAARAB9ANPC1CYP1A2 | |
| SCHEMBL79802 | 0.83 | KDM4E (1.00) | KDM4EGAARAB9ANPC1CYP1A2 | |
| SCHEMBL194475 | 0.83 | KDM4E (0.71) | KDM4EGAARAB9ANPC1CYP1A2 | |
| SCHEMBL1566759 | 0.82 | KDM4E (0.62) | KDM4EGAARAB9ANPC1CYP1A2 | |
| SCHEMBL24334044 | 0.82 | KDM4E (0.69) | KDM4EGAARAB9ANPC1CYP1A2 | |
| SCHEMBL171544 | 0.82 | KDM4E (0.69) | KDM4EGAARAB9ANPC1CYP1A2 | |
| SCHEMBL11157388 | 0.82 | KDM4E (0.69) | KDM4EGAARAB9ANPC1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1409 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7312211-B2 | Pryanone compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2007-12-25 | — | — | US | claimed |
| US-20050032792-A1 | Compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-02-10 | — | — | US | claimed |
| US-20050026904-A1 | Pryanone compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-02-03 | — | — | US | claimed |
| US-6841571-B2 | Compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-01-11 | — | — | US | claimed |
| EP-1444226-A1 | COMPOUNDS USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2004-08-11 | — | — | EP | claimed |
| EP-1434769-A2 | COMPOUNDS USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2004-07-07 | — | — | EP | claimed |
| US-20040063679-A1 | Compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. | 2004-04-01 | — | — | US | claimed |
| US-20040053921-A1 | Amidino and guanidino peptidyl compounds useful for treating autoimmune diseases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-03-18 | — | — | US | claimed |
| US-20030225270-A1 | Compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-12-04 | — | — | US | claimed |
| US-20030225271-A1 | Compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-12-04 | — | — | US | claimed |
| JP-2003529546-A | — | — | 2003-10-07 | — | — | JP | claimed |
| EP-1218372-B1 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES | BOEHRINGER INGELHEIM PHARMA (US) | 2003-07-02 | — | — | EP | claimed |
| WO-2003037892-A1 | COMPOUNDS USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-05-08 | — | — | WO | claimed |
| WO-2003029200-A2 | COMPOUNDS USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-04-10 | — | — | WO | claimed |
| US-6420364-B1 | TREATING AUTOIMMUNE DISEASES,ALZHEIMER'S DISEASE, ATHEROSCLEROSIS, OSTEOPOROSIS, | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2002-07-16 | — | — | US | claimed |
| EP-1218372-A1 | NOVEL SPIROHETEROCYCLIC COMPOUNDS USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES | Boehringer Ingelheim Pharmaceuticals, Inc. (US) | 2002-07-03 | — | — | EP | claimed |
| US-20020058809-A1 | Compounds useful as reversible inhibitors of cysteine proteases | EMMANUEL MICHEL JOSE (US) | 2002-05-16 | — | — | US | claimed |
| WO-2001019816-A1 | NOVEL SPIROHETEROCYCLIC COMPOUNDS USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2001-03-22 | — | — | WO | claimed |
| US-4292238-A | Alkylation of benzthiazole-azo-phenylamine dyestuffs | BAYER AKTIENGESELLSCHAFT (DE) | 1981-09-29 | — | — | US | claimed |
| EP-3632441-B1 | METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND | DAY ONE BIOPHARMACEUTICALS INC (US) | 2024-07-17 | — | — | EP | disclosed |
| CN-118344346-A | Heterocyclic compounds and their use | 武田药品工业株式会社 | 2024-07-16 | — | — | CN | disclosed |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| EP-3782986-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2024-07-10 | — | — | EP | disclosed |
| CN-118290408-A | Heterocyclic compounds and their use | 武田药品工业株式会社 | 2024-07-05 | — | — | CN | disclosed |
| US-20240217957-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-07-04 | — | — | US | disclosed |
| CN-118271297-A | Heterocyclic compounds and their use | 武田药品工业株式会社 | 2024-07-02 | — | — | CN | disclosed |
| CN-118271298-A | Heterocyclic compounds and their use | 武田药品工业株式会社 | 2024-07-02 | — | — | CN | disclosed |
| US-12024505-B2 | Heterocyclic compounds useful as modulators of acetylcholine receptors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-07-02 | — | — | US | disclosed |
| WO-2024128000-A1 | ISOPOLYOXOTUNGSTATE SALT COMPOUND, SOLVATE THEREOF OR MIXTURE OF SAID COMPOUND AND SOLVATE, AND METHOD FOR PRODUCING SAID COMPOUND, SOLVATE OR MIXTURE | 東京応化工業株式会社 | 2024-06-20 | — | — | WO | disclosed |
| US-12012419-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-06-18 | — | — | US | disclosed |
| US-20240182474-A1 | SUBSTITUTED IMIDAZO [1,2-b] PYRIDAZINES AND [1, 2, 4] TRIAZOLO [ 4,3-b] PYRIDAZINES AS CAMKII INHIBITORS | CARDURION PHARMACEUTICALS, INC. | 2024-06-06 | — | — | US | disclosed |
| WO-2024116086-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-06-06 | — | — | WO | disclosed |
| US-20240174610-A1 | SUBSTITUTED PIPERIDINE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-05-30 | — | — | US | disclosed |
| US-20240174677-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-05-30 | — | — | US | disclosed |
| EP-4034257-B1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2024-05-22 | — | — | EP | disclosed |
| US-11986480-B2 | Heterocyclic compound | TOHOKU UNIVERSITY (JP) | 2024-05-21 | — | — | US | disclosed |
| US-11987586-B1 | Pyrrolo[1,2-c]imidazole derivatives as orexin type 2 receptor agonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-05-21 | — | — | US | disclosed |
| CN-118005619-A | Process for producing heterocyclic compound | 武田药品工业株式会社 | 2024-05-10 | — | — | CN | disclosed |
| WO-2024095133-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-05-10 | — | — | WO | disclosed |
| US-11970483-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-04-30 | — | — | US | disclosed |
| CN-112313327-B | Proliferation inhibitors | 千纸鹤治疗公司 | 2024-04-19 | — | — | CN | disclosed |
| CN-110799190-B | Heterocyclic compounds | 卡都瑞恩医药有限公司 | 2024-04-19 | — | — | CN | disclosed |
| US-11958845-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-04-16 | — | — | US | disclosed |
| US-11952344-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-04-09 | — | — | US | disclosed |
| US-20240109874-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2024-04-04 | — | — | US | disclosed |
| CN-113149883-B | Process for preparing pyrrole compounds | 武田药品工业株式会社 | 2024-04-02 | — | — | CN | disclosed |
| US-11945799-B2 | 4-ethynylpyridine derivatives useful as GCN2 inhibitors | IP2IPO INNOVATIONS LIMITED (GB) | 2024-04-02 | — | — | US | disclosed |
| US-11939327-B2 | Heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-03-26 | — | — | US | disclosed |
| US-20240092784-A1 | CONDENSED HETEROCYCLIC COMPOUND | NISSAN CHEMICAL CORPORATION (JP) | 2024-03-21 | — | — | US | disclosed |
| US-20240066047-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-02-29 | — | — | US | disclosed |
| CN-113395993-B | Heterocyclic compounds and their use | 武田药品工业株式会社 | 2024-02-20 | — | — | CN | disclosed |
| WO-2024033845-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-02-15 | — | — | WO | disclosed |
| CN-117447464-A | Method for producing optically active compound | 首日生物制药公司 | 2024-01-26 | — | — | CN | disclosed |
| CN-110753689-B | Process for producing heterocyclic compound | 武田药品工业株式会社 | 2024-01-26 | — | — | CN | disclosed |
| EP-3660003-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2024-01-24 | — | — | EP | disclosed |
| CN-112752760-B | Heterocyclic compounds | 武田药品工业株式会社 | 2024-01-19 | — | — | CN | disclosed |
| CN-111918863-B | Heterocyclic compounds | 武田药品工业株式会社 | 2024-01-05 | — | — | CN | disclosed |
| US-11851449-B2 | Heterocyclic amide compounds having an RORvt inhibitory action | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-12-26 | — | — | US | disclosed |
| US-20230399356-A1 | ANTIBODY DRUG CONJUGATES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-12-14 | — | — | US | disclosed |
| EP-3693360-B1 | HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICALS CO (JP) | 2023-12-13 | — | — | EP | disclosed |
| US-20230390265-A1 | IRAK4 Inhibitors and Topical Uses Thereof | DERMIRA, INC. | 2023-12-07 | — | — | US | disclosed |
| EP-3693368-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2023-12-06 | — | — | EP | disclosed |
| US-11834409-B2 | Heterocyclic NMDA antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-12-05 | — | — | US | disclosed |
| US-11827601-B2 | Heterocyclic NMDA antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-11-28 | — | — | US | disclosed |
| US-20230357220-A1 | 3-((1H-PYRAZOL-4-YL)METHYL)-6′-(PHENYL)-2H-(1,2′-BIPYRIDIN)-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS GPR139 ANTAGONISTS FOR USE IN A METHOD OF TREATMENT OF E.G. DEPRESSION | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-11-09 | — | — | US | disclosed |
| US-20230348435-A1 | 1-((1H-PYRAZOL-4-YL)METHYL)-3-(PHENYL)-1,3-DIHYDRO-2H-IMIDAZOL-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS GPR139 ANTAGONISTS FOR THE TREATMENT OF E.G. DEPRESSION | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-11-02 | — | — | US | disclosed |
| CN-111032047-B | Method for producing optically active compound | 多特疗法-1公司 | 2023-10-27 | — | — | CN | disclosed |
| US-11795172-B2 | Substituted imidazo[1,2-b]pyridazines and [1,2,4]triazolo[4,3-b]pyridazines as CaMKII inhibitors | CARDURION PHARMACEUTICALS, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| CN-116940354-A | Fused heteroaryl compounds and their use as CaMKII inhibitors | 卡都瑞恩医药股份有限公司 | 2023-10-24 | — | — | CN | disclosed |
| CN-116916962-A | Antibody drug conjugates | 武田药品工业株式会社 | 2023-10-20 | — | — | CN | disclosed |
| WO-2023199091-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-19 | — | — | WO | disclosed |
| EP-3816153-B1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2023-10-18 | — | — | EP | disclosed |
| US-20230322669-A1 | METHOD FOR PRODUCING PYRROLE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-12 | — | — | US | disclosed |
| US-20230322683-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-12 | — | — | US | disclosed |
| EP-4257577-A2 | METHOD FOR PRODUCING PYRROLE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2023-10-11 | — | — | EP | disclosed |
| US-RE49686-E1 | Nitrogen-containing heterocyclic compound and use of same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-10 | — | — | US | disclosed |
| EP-3895707-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2023-10-04 | — | — | EP | disclosed |
| US-20230303543-A1 | NOVEL STIRIPENTOL DERIVATIVE AND USE THEREOF | NATIONAL UNIVERSITY CORPORATION OKAYAMA UNIVERSITY (JP) | 2023-09-28 | — | — | US | disclosed |
| US-20230303541-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF ACETYLCHOLINE RECEPTORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-09-28 | — | — | US | disclosed |
| EP-4240488-A1 | ANTIBODY DRUG CONJUGATES | Takeda Pharmaceutical Company Limited (JP) | 2023-09-13 | — | — | EP | disclosed |
| US-20230278999-A1 | HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-09-07 | — | — | US | disclosed |
| US-20230271939-A1 | 4-ETHYNYLPYRIDINE DERIVATIVES USEFUL AS GCN2 INHIBITORS | IP2IPO INNOVATIONS LIMITED (GB) | 2023-08-31 | — | — | US | disclosed |
| EP-3896060-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2023-08-16 | — | — | EP | disclosed |
| US-11725024-B2 | Antibody drug conjugates | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-08-15 | — | — | US | disclosed |
| US-20230250082-A1 | 4-ETHYNYLPYRIDINE DERIVATIVES USEFUL AS GCN2 INHIBITORS | IP2IPO INNOVATIONS LIMITED (GB) | 2023-08-10 | — | — | US | disclosed |
| US-20230242529-A1 | HETEROCYCLIC COMPOUND | FIMECS, INC. (JP) | 2023-08-03 | — | — | US | disclosed |
| EP-4219500-A1 | CONDENSED HETEROCYCLIC COMPOUND | Nissan Chemical Corporation (JP) | 2023-08-02 | — | — | EP | disclosed |
| EP-4216948-A1 | FUSED HETEROARYL COMPOUNDS AND THEIR USE AS CAMKII INHIBITORS | Cardurion Pharmaceuticals, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| CN-111757756-B | Inhibitors of IL-17A activity and uses thereof | 学校法人东海大学 | 2023-08-01 | — | — | CN | disclosed |
| US-11713311-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-08-01 | — | — | US | disclosed |
| EP-3643718-B1 | HETEROCYCLIC COMPOUND AND ITS USE AS POSITIVE ALLOSTERIC MODULATOR OF THE CHOLINERGIC MUSCARINIC M1 RECEPTOR. | TAKEDA PHARMACEUTICALS CO (JP) | 2023-07-26 | — | — | EP | disclosed |
| US-11702419-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-07-18 | — | — | US | disclosed |
| EP-3428150-B1 | AROMATIC RING COMPOUND HAVING A CHOLINERGIC MUSCARINE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATOR ACTIVITY | TAKEDA PHARMACEUTICALS CO (JP) | 2023-07-12 | — | — | EP | disclosed |
| CN-111918866-B | Heterocyclic compounds | 千纸鹤治疗公司 | 2023-07-04 | — | — | CN | disclosed |
| WO-2023113038-A1 | OLIGONUCLEOTIDE PRODUCTION METHOD | リードファーマ株式会社 | 2023-06-22 | — | — | WO | disclosed |
| US-20230183227-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-06-15 | — | — | US | disclosed |
| CN-110709401-B | Heterocyclic compounds | 武田药品工业株式会社 | 2023-06-13 | — | — | CN | disclosed |
| EP-4190401-A1 | NOVEL STIRIPENTOL DERIVATIVE AND USE THEREOF | National University Corporation Okayama University (JP) | 2023-06-07 | — | — | EP | disclosed |
| US-11666594-B2 | Antibody-drug conjugates comprising a cyclic dinucleotide | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-06-06 | — | — | US | disclosed |
| CN-116171276-A | 3- ((1H-pyrazol-4-yl) methyl) -6'- (phenyl) -2H- [1,2' -bipyridin ] -2-one derivatives and related compounds as GRP139 antagonists in methods of treating E.G. depression | 武田药品工业株式会社 | 2023-05-26 | — | — | CN | disclosed |
| US-11655241-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-05-23 | — | — | US | disclosed |
| US-20230149560-A1 | LIPID COMPOSITIONS FOR DELIVERY OF STING AGONIST COMPOUNDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230150934-A1 | HETEROCYCLIC NMDA ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-05-18 | — | — | US | disclosed |
| CN-116134038-A | IRAK4 inhibitors and topical use thereof | 德米拉公司 | 2023-05-16 | — | — | CN | disclosed |
| US-11649206-B2 | Method for producing pyrrole compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-05-16 | — | — | US | disclosed |
| CN-116113629-A | 4-ethynyl pyridine derivatives as GCN2 inhibitors | IP2IPO创新有限公司 | 2023-05-12 | — | — | CN | disclosed |
| US-20230143246-A1 | LIQUID PREPARATIONS OF AMINES AND ORGANIC ACIDS STABILIZED BY SALTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-05-11 | — | — | US | disclosed |
| US-20230143604-A1 | QW DOSING OF GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-05-11 | — | — | US | disclosed |
| EP-3018123-B1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2023-05-10 | — | — | EP | disclosed |
| US-20230134307-A1 | HETEROCYCLIC NMDA ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-05-04 | — | — | US | disclosed |
| EP-4172163-A1 | IRAK4 INHIBITORS AND TOPICAL USES THEREOF | Dermira, Inc (US) | 2023-05-03 | — | — | EP | disclosed |
| US-11639354-B2 | Heterocyclic compound | FIMECS, INC. (JP) | 2023-05-02 | — | — | US | disclosed |
| US-20230125380-A1 | Topical Compositions Comprising IRAK4 Inhibitors for Use in Treating Dermatological Conditions Characterised by Inflammation | DERMIRA, INC. | 2023-04-27 | — | — | US | disclosed |
| US-20230117295-A1 | NITROGEN CONTAINING HETEROCYCLES AS CDK12 INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-04-20 | — | — | US | disclosed |
| EP-4161915-A1 | 4-ETHYNYLPYRIDINE DERIVATIVES USEFUL AS GCN2 INHIBITORS | IP2IPO Innovations Limited (GB) | 2023-04-12 | — | — | EP | disclosed |
| EP-4159212-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | Fulcrum Therapeutics, Inc. (US) | 2023-04-05 | — | — | EP | disclosed |
| CN-115916812-A | GIP receptor agonist peptide compounds and uses thereof | 武田药品工业株式会社 | 2023-04-04 | — | — | CN | disclosed |
| CN-110325543-B | Cyclic dinucleotides as STING (stimulator of interferon genes) agonists | 武田药品工业株式会社 | 2023-03-31 | — | — | CN | disclosed |
| EP-4153581-A1 | 3-((1H-PYRAZOL-4-YL)METHYL)-6'-(PHENYL)-2H-(1,2'-BIPYRIDIN)-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS GPR139 ANTAGONISTS FOR USE IN A METHOD OF TREATMENT OF E.G. DEPRESSION | Takeda Pharmaceutical Company Limited (JP) | 2023-03-29 | — | — | EP | disclosed |
| EP-4153583-A1 | 1-((1H-PYRAZOL-4-YL)METHYL)-3-(PHENYL)-1,3-DIHYDRO-2H-IMIDAZOL-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS GPR139 ANTAGONISTS FOR THE TREATMENT OF E.G. DEPRESSION | Takeda Pharmaceutical Company Limited (JP) | 2023-03-29 | — | — | EP | disclosed |
| US-20230088365-A1 | PROCESS FOR PRODUCING PYRROLE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-03-23 | — | — | US | disclosed |
| US-20230063805-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-03-02 | — | — | US | disclosed |
| US-11584737-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-02-21 | — | — | US | disclosed |
| US-20230040770-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2023-02-09 | — | — | US | disclosed |
| US-20230042358-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-02-09 | — | — | US | disclosed |
| US-20230037557-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-02-09 | — | — | US | disclosed |
| US-20230037538-A1 | ANTI-ALS COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-02-09 | — | — | US | disclosed |
| EP-4126921-A2 | QD DOSING OF GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2023-02-08 | — | — | EP | disclosed |
| EP-4126920-A2 | GIF RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2023-02-08 | — | — | EP | disclosed |
| US-11560372-B2 | Heterocyclic compounds useful as modulators of acetylcholine receptors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-01-24 | — | — | US | disclosed |
| US-20230002318-A1 | HETEROCYCLIC NMDA ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-01-05 | — | — | US | disclosed |
| US-20220411449-A1 | Method for Preparing Heteroleptic Triarylbismuthanes and Compounds Produced by the Same | UNIVERSITY OF HAWAII | 2022-12-29 | — | — | US | disclosed |
| US-20220411413-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2022-12-29 | — | — | US | disclosed |
| US-20220409734-A1 | ANTIBODY DRUG CONJUGATES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-12-29 | — | — | US | disclosed |
| EP-3663281-B1 | HETEROCYCLIC COMPOUND AND APPLICATION THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2022-12-28 | — | — | EP | disclosed |
| US-20220402935-A1 | HETEROCYCLIC COMPOUND | FIMECS, INC. (JP) | 2022-12-22 | — | — | US | disclosed |
| US-20220388995-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-12-08 | — | — | US | disclosed |
| US-11518763-B2 | Macrocyclic compound and use thereof | SCOHIA PHARMA, INC. (JP) | 2022-12-06 | — | — | US | disclosed |
| CN-115335395-A | QD administration of GIP receptor agonist peptide compounds and uses thereof | 武田药品工业株式会社 | 2022-11-11 | — | — | CN | disclosed |
| CN-115197160-A | Heterocyclic compounds | 武田药品工业株式会社 | 2022-10-18 | — | — | CN | disclosed |
| EP-4066893-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2022-10-05 | — | — | EP | disclosed |
| CN-110573512-B | Heterocyclic compounds | 武田药品工业株式会社 | 2022-09-06 | — | — | CN | disclosed |
| CN-111051295-B | Heterocyclic compounds and their use | 武田药品工业株式会社 | 2022-09-02 | — | — | CN | disclosed |
| CN-115003670-A | Heterocyclic compounds | 武田药品工业株式会社 | 2022-09-02 | — | — | CN | disclosed |
| CN-114929223-A | Topical composition comprising an IRAK4 inhibitor for the treatment of skin conditions characterized by inflammation | 德米拉公司 | 2022-08-19 | — | — | CN | disclosed |
| CN-111148746-B | Heterocyclic compounds | 武田药品工业株式会社 | 2022-08-05 | — | — | CN | disclosed |
| EP-4034536-A1 | 2-ISOINDOL-1,3,4-OXADIAZOLE DERIVATIVES USEFUL AS HDAC6 INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2022-08-03 | — | — | EP | disclosed |
| CN-114835619-A | Process for preparing azole compounds | 武田药品工业株式会社 | 2022-08-02 | — | — | CN | disclosed |
| CN-110200903-B | Liquid formulations of amines and organic acids stabilized with salts | 武田药品工业株式会社 | 2022-07-29 | — | — | CN | disclosed |
| US-20220227830-A1 | QD DOSING OF GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-07-21 | — | — | US | disclosed |
| EP-3612527-B1 | HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF ACETYLCHOLINE RECEPTORS | TAKEDA PHARMACEUTICALS CO (JP) | 2022-07-20 | — | — | EP | disclosed |
| US-11390634-B2 | Fused heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-07-19 | — | — | US | disclosed |
| CN-110461828-B | IP6K inhibitors | 武田药品工业株式会社 | 2022-07-19 | — | — | CN | disclosed |
| CN-114748622-A | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD | 弗尔康医疗公司 | 2022-07-15 | — | — | CN | disclosed |
| CN-114732910-A | P38 kinase inhibitor reduces DUX4 and downstream gene expression for treatment of FSHD | 弗尔康医疗公司 | 2022-07-12 | — | — | CN | disclosed |
| CN-114728900-A | Heterocyclic NMDA antagonists | 武田药品工业株式会社 | 2022-07-08 | — | — | CN | disclosed |
| EP-4019089-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 1, 4-BENZOTHIAZEPINE-1-OXIDE DERIVATIVE | Aetas Pharma Co. Ltd. (JP) | 2022-06-29 | — | — | EP | disclosed |
| CN-109790122-B | Heterocyclic compounds | 武田药品工业株式会社 | 2022-06-24 | — | — | CN | disclosed |
| CN-107108506-B | Heterocyclic compounds | 武田药品工业株式会社 | 2022-06-21 | — | — | CN | disclosed |
| US-20220168330-A1 | ANTIBODY DRUG CONJUGATES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-06-02 | — | — | US | disclosed |
| EP-4005638-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2022-06-01 | — | — | EP | disclosed |
| EP-4006037-A1 | HETEROCYCLIC COMPOUND | Fimecs, Inc. (JP) | 2022-06-01 | — | — | EP | disclosed |
| EP-4005637-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2022-06-01 | — | — | EP | disclosed |
| EP-3514149-B1 | HETEROCYCLIC AMIDE COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2022-05-18 | — | — | EP | disclosed |
| WO-2022097117-A1 | ANTIBODY DRUG CONJUGATES | TAKEDA PHARMACEUTICAL COMPANY LTD. (JP) | 2022-05-12 | — | — | WO | disclosed |
| US-20220135638-A1 | GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-05-05 | — | — | US | disclosed |
| US-20220133704-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | FULCRUM THERAPEUTICS INC (US) | 2022-05-05 | — | — | US | disclosed |
| US-11319286-B2 | Heterocyclic compound and application thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-05-03 | — | — | US | disclosed |
| CN-110582499-B | Heterocyclic compounds | 武田药品工业株式会社 | 2022-04-29 | — | — | CN | disclosed |
| CN-109477094-B | Peptide compounds | 武田药品工业株式会社 | 2022-04-26 | — | — | CN | disclosed |
| US-20220119391-A1 | MACROCYCLIC COMPOUND AND USE THEREOF | SCOHIA PHARMA, INC. (JP) | 2022-04-21 | — | — | US | disclosed |
| EP-3984994-A1 | SUBSTITUTED PIPERIDINE COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2022-04-20 | — | — | EP | disclosed |
| CN-111601593-B | P38 kinase inhibitor reduces DUX4 and downstream gene expression for treatment of FSHD | 弗尔康医疗公司 | 2022-04-15 | — | — | CN | disclosed |
| US-11291659-B2 | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD | Fulcrum Therapeutics, Inc. (US) | 2022-04-05 | — | — | US | disclosed |
| US-20220098180-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-03-31 | — | — | US | disclosed |
| US-20220089525-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-03-24 | — | — | US | disclosed |
| CN-114181136-A | Substituted piperidine compounds and uses thereof | 武田药品工业株式会社 | 2022-03-15 | — | — | CN | disclosed |
| US-11274101-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-03-15 | — | — | US | disclosed |
| CN-114173824-A | Antibody drug conjugates | 武田药品工业株式会社 | 2022-03-11 | — | — | CN | disclosed |
| US-11254700-B2 | GSK-3β inhibitors and use thereof in methods of treatment | UNIVERSITY OF HAWAII (US) | 2022-02-22 | — | — | US | disclosed |
| US-11242348-B2 | — | — | 2022-02-08 | — | — | US | disclosed |
| US-11236099-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-02-01 | — | — | US | disclosed |
| US-11230541-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-01-25 | — | — | US | disclosed |
| US-20220017514-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-01-20 | — | — | US | disclosed |
| US-20220016215-A1 | GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-01-20 | — | — | US | disclosed |
| US-20220017530-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-01-20 | — | — | US | disclosed |
| CN-109415384-B | Fused heterocyclic compound | 武田药品工业株式会社 | 2022-01-11 | — | — | CN | disclosed |
| WO-2022006129-A1 | IRAK4 INHIBITORS AND TOPICAL USES THEREOF | DERMIRA, INC. (US) | 2022-01-06 | — | — | WO | disclosed |
| WO-2021261471-A1 | THERAPEUTIC AGENT FOR OBSESSIVE-COMPULSIVE DISORDER | 国立大学法人京都大学 | 2021-12-30 | — | — | WO | disclosed |
| EP-3929187-A2 | PROCESS FOR PRODUCING PYRROLE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2021-12-29 | — | — | EP | disclosed |
| WO-2021250399-A1 | 4-ETHYNYLPYRIDINE DERIVATIVES USEFUL AS GCN2 INHIBITORS | IP2IPO INNOVATIONS LIMITED (GB) | 2021-12-16 | — | — | WO | disclosed |
| US-11197858-B2 | Substituted amines for treating cardiac diseases | CARDURION PHARMACEUTICALS, LLC (US) | 2021-12-14 | — | — | US | disclosed |
| US-20210380565-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-12-09 | — | — | US | disclosed |
| EP-3919055-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2021-12-08 | — | — | EP | disclosed |
| EP-3917616-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2021-12-08 | — | — | EP | disclosed |
| EP-3915638-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2021-12-01 | — | — | EP | disclosed |
| US-11186565-B2 | Aromatic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-11-30 | — | — | US | disclosed |
| CN-108884043-B | Substituted piperidine compounds and uses thereof | 武田药品工业株式会社 | 2021-11-26 | — | — | CN | disclosed |
| WO-2021234450-A1 | 1-((1H-PYRAZOL-4-YL)METHYL)-3-(PHENYL)-1,3-DIHYDRO-2H-IMIDAZOL-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS GPR139 ANTAGONISTS FOR THE TREATMENT OF E.G. DEPRESSION | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-11-25 | — | — | WO | disclosed |
| WO-2021234451-A1 | 3-((1H-PYRAZOL-4-YL)METHYL)-6'-(PHENYL)-2H-(1,2'-BIPYRIDIN)-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS GPR139 ANTAGONISTS FOR USE IN A METHOD OF TREATMENT OF E.G. DEPRESSION | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-11-25 | — | — | WO | disclosed |
| US-20210363130-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-11-25 | — | — | US | disclosed |
| US-20210353686-A1 | INSULIN-PRODUCING CELLS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-11-18 | — | — | US | disclosed |
| US-11174301-B2 | Peptide compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-11-16 | — | — | US | disclosed |
| US-20210347769-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND | DAY ONE BIOPHARMACEUTICALS, INC. | 2021-11-11 | — | — | US | disclosed |
| US-20210347786-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-11-11 | — | — | US | disclosed |
| US-20210340114-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-11-04 | — | — | US | disclosed |
| US-20210332053-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-10-28 | — | — | US | disclosed |
| WO-2021216572-A1 | LIPID COMPOSITIONS FOR DELIVERY OF STING AGONIST COMPOUNDS AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2021-10-28 | — | — | WO | disclosed |
| EP-3895707-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2021-10-20 | — | — | EP | disclosed |
| EP-3896060-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2021-10-20 | — | — | EP | disclosed |
| EP-3890738-A1 | MACROCYCLIC COMPOUND AND USE THEREOF | Scohia Pharma, Inc. (JP) | 2021-10-13 | — | — | EP | disclosed |
| US-20210309609-A1 | METHOD FOR PRODUCING PYRROLE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-10-07 | — | — | US | disclosed |
| WO-2021193984-A2 | QD DOSING OF GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-09-30 | — | — | WO | disclosed |
| WO-2021193983-A2 | QW DOSING OF GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-09-30 | — | — | WO | disclosed |
| US-20210292308-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF ACETYLCHOLINE RECEPTORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-09-23 | — | — | US | disclosed |
| CN-113395993-A | Heterocyclic compounds and their use | 武田药品工业株式会社 | 2021-09-14 | — | — | CN | disclosed |
| US-20210276949-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-09-09 | — | — | US | disclosed |
| US-20210277030-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-09-09 | — | — | US | disclosed |
| US-20210254014-A1 | GROWTH INHIBITOR | KYOTO UNIVERSITY (JP) | 2021-08-19 | — | — | US | disclosed |
| EP-3594202-B1 | SUBSTITUTED PYRROLIDINE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2021-08-11 | — | — | EP | disclosed |
| EP-3594203-B1 | SUBSTITUTED PYRROLIDINE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2021-08-04 | — | — | EP | disclosed |
| EP-3856768-A2 | GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2021-08-04 | — | — | EP | disclosed |
| EP-3856339-A1 | GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2021-08-04 | — | — | EP | disclosed |
| EP-3858838-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2021-08-04 | — | — | EP | disclosed |
| EP-3858823-A1 | CONDENSED-CYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2021-08-04 | — | — | EP | disclosed |
| EP-3858828-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2021-08-04 | — | — | EP | disclosed |
| CN-109715613-B | Heterocyclic compounds | 武田药品工业株式会社 | 2021-07-30 | — | — | CN | disclosed |
| EP-3854869-A1 | INSULIN-PRODUCING CELLS | Takeda Pharmaceutical Company Limited (JP) | 2021-07-28 | — | — | EP | disclosed |
| CN-113149883-A | Process for preparing azole compounds | 武田药品工业株式会社 | 2021-07-23 | — | — | CN | disclosed |
| CN-113164468-A | Macrocyclic compounds and uses thereof | 思可海雅药品公司 | 2021-07-23 | — | — | CN | disclosed |
| US-11066362-B2 | Method for producing pyrrole compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-07-20 | — | — | US | disclosed |
| US-11065231-B2 | Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2021-07-20 | — | — | US | disclosed |
| CN-113121399-A | Process for preparing azole compounds | 武田药品工业株式会社 | 2021-07-16 | — | — | CN | disclosed |
| EP-3848353-A1 | MEDICAMENTS FOR THE TREATMENT OF OPHTHALMIC DISEASES | Takeda Pharmaceutical Company Limited (JP) | 2021-07-14 | — | — | EP | disclosed |
| US-11059780-B2 | Substituted pyrrolidine compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-07-13 | — | — | US | disclosed |
| US-11053262-B2 | Heterocyclic amide compounds having RORyT inhibitory action | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-07-06 | — | — | US | disclosed |
| US-20210198240-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-07-01 | — | — | US | disclosed |
| US-20210179603-A1 | CYCLOPROPANAMINE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2021-06-17 | — | — | US | disclosed |
| US-20210179614-A1 | HETEROCYCLIC COMPOUND | FIMECS, INC. (JP) | 2021-06-17 | — | — | US | disclosed |
| US-11034700-B2 | Substituted pyrrolidine compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-06-15 | — | — | US | disclosed |
| EP-3831811-A1 | HETEROCYCLIC COMPOUND | Fimecs, Inc. (JP) | 2021-06-09 | — | — | EP | disclosed |
| EP-3287441-B1 | ACYLATED 4-AMINOPIPERIDINES AS INHIBITORS OF SERINE PALMITOYLTRANSFERASE | TAKEDA PHARMACEUTICALS CO (JP) | 2021-06-09 | — | — | EP | disclosed |
| US-11028048-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-06-08 | — | — | US | disclosed |
| WO-2021106975-A1 | HETEROCYCLIC COMPOUND | 武田薬品工業株式会社 | 2021-06-03 | — | — | WO | disclosed |
| CN-112867787-A | Insulin producing cells | 武田药品工业株式会社 | 2021-05-28 | — | — | CN | disclosed |
| WO-2021094832-A1 | HETEROCYCLIC NMDA ANTAGONISTS | TAKEDA PHARAMACEUTICAL COMPANY LIMITED (JP) | 2021-05-20 | — | — | WO | disclosed |
| WO-2021097159-A1 | METHOD FOR PREPARING HETEROLEPTIC TRIARYLBISMUTHANES AND COMPOUNDS PRODUCED BY THE SAME | UNIVERSITY OF HAWAII (US) | 2021-05-20 | — | — | WO | disclosed |
| US-20210139491-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-05-13 | — | — | US | disclosed |
| US-20210137962-A9 | CYCLIC DINUCLEOTIDE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-05-13 | — | — | US | disclosed |
| EP-3816153-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2021-05-05 | — | — | EP | disclosed |
| EP-3816154-A1 | HETEROCYCLIC COMPOUND AND APPLICATION THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2021-05-05 | — | — | EP | disclosed |
| CN-112752760-A | Heterocyclic compounds | 武田药品工业株式会社 | 2021-05-04 | — | — | CN | disclosed |
| EP-3812456-A1 | GROWTH INHIBITOR | Kyoto University (JP) | 2021-04-28 | — | — | EP | disclosed |
| US-10988469-B2 | Method for producing optically active compound | DOT THERAPEUTICS-1, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| US-20210115048-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-04-22 | — | — | US | disclosed |
| WO-2021075476-A1 | HETEROCYCLIC COMPOUND | 武田薬品工業株式会社 | 2021-04-22 | — | — | WO | disclosed |
| US-20210115067-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-04-22 | — | — | US | disclosed |
| US-10980825-B2 | Cyclic dinucleotide | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-04-20 | — | — | US | disclosed |
| US-10981934-B2 | Fused heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-04-20 | — | — | US | disclosed |
| US-20210106607-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-04-15 | — | — | US | disclosed |
| US-10975043-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-04-13 | — | — | US | disclosed |
| CN-106573877-B | Cationic lipids | 武田药品工业株式会社 | 2021-04-13 | — | — | CN | disclosed |
| US-10968231-B2 | Substituted cyclyl-acetic acid derivatives for the treatment of metabolic disorders | SCOHIA PHARMA, INC. (JP) | 2021-04-06 | — | — | US | disclosed |
| US-10968178-B2 | IP6K inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-04-06 | — | — | US | disclosed |
| US-10968213-B2 | Cyclopropanamine compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-04-06 | — | — | US | disclosed |
| US-20210094944-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-04-01 | — | — | US | disclosed |
| WO-2021060567-A1 | 2-ISOINDOL-1,3,4-OXADIAZOLE DERIVATIVES USEFUL AS HDAC6 INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-04-01 | — | — | WO | disclosed |
| WO-2021059017-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-04-01 | — | — | WO | disclosed |
| CN-107848971-B | Heterocyclic compounds | 武田药品工业株式会社 | 2021-03-26 | — | — | CN | disclosed |
| US-20210087186-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-03-25 | — | — | US | disclosed |
| EP-3366679-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2021-03-24 | — | — | EP | disclosed |
| CN-112533898-A | Heterocyclic compounds | 日商泛美克斯股份有限公司 | 2021-03-19 | — | — | CN | disclosed |
| US-20210070705-A1 | PROCESS FOR PRODUCING PYRROLE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-03-11 | — | — | US | disclosed |
| EP-3782986-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2021-02-24 | — | — | EP | disclosed |
| EP-3512861-B1 | CYCLIC DINUCLEOTIDES AS STING (STIMULATOR OF INTERFERON GENES) AGONISTS | TAKEDA PHARMACEUTICALS CO (JP) | 2021-02-17 | — | — | EP | disclosed |
| EP-3774800-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2021-02-17 | — | — | EP | disclosed |
| EP-3778587-A1 | HETEROCYCLIC COMPOUND | Kyoto University (JP) | 2021-02-17 | — | — | EP | disclosed |
| US-10919891-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-02-16 | — | — | US | disclosed |
| CN-108431004-B | Heterocyclic compounds | 武田药品工业株式会社 | 2021-02-12 | — | — | CN | disclosed |
| CN-108026088-B | Oxadiazole derivatives as HDAC inhibitors | 武田药品工业株式会社 | 2021-02-12 | — | — | CN | disclosed |
| WO-2021020363-A1 | HETEROCYCLIC COMPOUND | 武田薬品工業株式会社 | 2021-02-04 | — | — | WO | disclosed |
| WO-2021020362-A1 | HETEROCYCLIC COMPOUND | 武田薬品工業株式会社 | 2021-02-04 | — | — | WO | disclosed |
| WO-2021020585-A1 | HETEROCYCLIC COMPOUND | ファイメクス株式会社 | 2021-02-04 | — | — | WO | disclosed |
| CN-112313327-A | Proliferation inhibitor | 国立大学法人京都大学 | 2021-02-02 | — | — | CN | disclosed |
| WO-2021015221-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 1, 4-BENZOTHIAZEPINE-1-OXIDE DERIVATIVE | 株式会社アエタスファルマ | 2021-01-28 | — | — | WO | disclosed |
| US-20210024512-A1 | HETEROCYCLIC COMPOUND | KYOTO UNIVERSITY (JP) | 2021-01-28 | — | — | US | disclosed |
| US-10899752-B2 | 2,3-dihydro-4H-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic M1 receptor | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-01-26 | — | — | US | disclosed |
| US-10898737-B2 | Substituted piperidine compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-01-26 | — | — | US | disclosed |
| US-20210009572-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2021-01-14 | — | — | US | disclosed |
| EP-3756689-A1 | IL-17A ACTIVITY INHIBITOR AND USE THEREOF | Tokai University Educational System (JP) | 2020-12-30 | — | — | EP | disclosed |
| US-10875862-B2 | — | — | 2020-12-29 | — | — | US | disclosed |
| US-20200392223-A1 | IL-17A ACTIVITY INHIBITOR AND USE THEREOF | TOKAI UNIVERSITY EDUCATIONAL SYSTEM (JP) | 2020-12-17 | — | — | US | disclosed |
| US-20200392149-A1 | SUBSTITUTED PYRROLIDINE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-12-17 | — | — | US | disclosed |
| EP-2866788-B1 | LIQUID PREPARATIONS OF AMINES AND ORGANIC ACIDS STABILIZED BY SALTS | TAKEDA PHARMACEUTICALS CO (JP) | 2020-12-16 | — | — | EP | disclosed |
| US-10865200-B2 | Nitrogen-containing heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-12-15 | — | — | US | disclosed |
| CN-108368127-B | Compounds and their use as EP4 receptor antagonists | 武田药品工业株式会社 | 2020-12-11 | — | — | CN | disclosed |
| US-20200383963-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | Fulcrum Therapeutics, Inc. | 2020-12-10 | — | — | US | disclosed |
| US-20200385345-A1 | SUBSTITUTED PYRROLIDINE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-12-10 | — | — | US | disclosed |
| US-20200385346-A1 | HETEROCYCLIC COMPOUND AND APPLICATION THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-12-10 | — | — | US | disclosed |
| EP-3747885-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2020-12-09 | — | — | EP | disclosed |
| US-20200377458-A1 | IP6K INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-12-03 | — | — | US | disclosed |
| US-20200377509-A1 | SUBSTITUTED CYCLYL-ACETIC ACID DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-12-03 | — | — | US | disclosed |
| EP-3210973-B1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF OPHTHALMIC DISEASES | TAKEDA PHARMACEUTICALS CO (JP) | 2020-12-02 | — | — | EP | disclosed |
| US-RE48334-E1 | Nitrogen-containing heterocyclic compound and use of same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-12-01 | — | — | US | disclosed |
| US-10844011-B2 | Process for producing pyrrole compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-11-24 | — | — | US | disclosed |
| WO-2020229982-A1 | ANTIBODY DRUG CONJUGATES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-11-19 | — | — | WO | disclosed |
| CN-111936495-A | Heterocyclic compounds and their use | 武田药品工业株式会社 | 2020-11-13 | — | — | CN | disclosed |
| EP-3313836-B1 | 2,3-DIHYDRO-4H-1,3-BENZOXAZIN-4-ONE DERIVATIVES AS MODULATORS OF CHOLINERGIC MUSCARINIC M1 RECEPTOR | TAKEDA PHARMACEUTICALS CO (JP) | 2020-11-11 | — | — | EP | disclosed |
| CN-111918863-A | Heterocyclic compounds | 武田药品工业株式会社 | 2020-11-10 | — | — | CN | disclosed |
| CN-111918866-A | Heterocyclic compounds | 国立大学法人京都大学 | 2020-11-10 | — | — | CN | disclosed |
| US-20200339577-A1 | 1-SUBSTITUTED 1,2,3,4-TETRAHYDRO-1,7-NAPHTHYRIDIN-8-AMINE DERIVATIVES AND THEIR USE AS EP4 RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-10-29 | — | — | US | disclosed |
| US-20200331948-A1 | GSK-3ß INHIBITORS AND USE THEREOF IN METHODS OF TREATMENT | UNIVERSITY OF HAWAII (US) | 2020-10-22 | — | — | US | disclosed |
| US-10807987-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-10-20 | — | — | US | disclosed |
| US-10800754-B2 | Heterocyclic amide compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-10-13 | — | — | US | disclosed |
| CN-111757756-A | Inhibitors of IL-17A activity and uses thereof | 学校法人东海大学 | 2020-10-09 | — | — | CN | disclosed |
| US-20200317659-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND | DAY ONE BIOPHARMACEUTICALS, INC. | 2020-10-08 | — | — | US | disclosed |
| US-20200317692-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-10-08 | — | — | US | disclosed |
| WO-2020196828-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | 武田薬品工業株式会社 | 2020-10-01 | — | — | WO | disclosed |
| US-10787462-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-09-29 | — | — | US | disclosed |
| EP-3710443-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 POLYPEPTIDES | Arvinas Operations, Inc. (US) | 2020-09-23 | — | — | EP | disclosed |
| US-10774083-B2 | Heterocyclic amide compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-09-15 | — | — | US | disclosed |
| EP-3366684-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2020-09-02 | — | — | EP | disclosed |
| EP-3287454-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2020-09-02 | — | — | EP | disclosed |
| EP-3279191-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2020-09-02 | — | — | EP | disclosed |
| CN-111601593-A | P38 kinase inhibitor reduces DUX4 and downstream gene expression for treatment of FSHD | 弗尔康医疗公司 | 2020-08-28 | — | — | CN | disclosed |
| US-20200270243-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-08-27 | — | — | US | disclosed |
| US-10745397-B2 | 1-Substituted 1,2,3,4-tetrahydro-1,7-naphthyridin-8-amine derivatives and their use as EP4 receptor antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-08-18 | — | — | US | disclosed |
| US-20200255439-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-08-13 | — | — | US | disclosed |
| EP-3693368-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2020-08-12 | — | — | EP | disclosed |
| EP-3691620-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | Fulcrum Therapeutics, Inc. (US) | 2020-08-12 | — | — | EP | disclosed |
| EP-3693360-A1 | HETEROCYCLIC COMPOUNDS | Takeda Pharmaceutical Company Limited (JP) | 2020-08-12 | — | — | EP | disclosed |
| EP-2963019-B1 | METHOD FOR PRODUCING PYRIDINE-3-SULFONYL CHLORIDE | TAKEDA PHARMACEUTICALS CO (JP) | 2020-08-12 | — | — | EP | disclosed |
| US-20200247801-A1 | HETEROCYLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-08-06 | — | — | US | disclosed |
| US-20200247747-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-08-06 | — | — | US | disclosed |
| WO-2020158958-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-08-06 | — | — | WO | disclosed |
| WO-2020158762-A1 | HETEROCYCLIC COMPOUND | 武田薬品工業株式会社 | 2020-08-06 | — | — | WO | disclosed |
| EP-3689879-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2020-08-05 | — | — | EP | disclosed |
| CN-107207444-B | Bicyclic compounds | 武田药品工业株式会社 | 2020-07-24 | — | — | CN | disclosed |
| US-20200231579-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-07-23 | — | — | US | disclosed |
| US-20200230137-A1 | SUBSTITUTED AMINES FOR TREATING CARDIAC DISEASES | CARDURION PHARMACEUTICALS, LLC (US) | 2020-07-23 | — | — | US | disclosed |
| US-10710989-B2 | Method for producing heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-07-14 | — | — | US | disclosed |
| US-20200207734-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-07-02 | — | — | US | disclosed |
| US-20200207715-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-07-02 | — | — | US | disclosed |
| US-10696651-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-06-30 | — | — | US | disclosed |
| EP-1787991-B2 | PYRROLO[2,3-c]PYRIDINE COMPOUND, PROCESS FOR PRODUCING THE SAME, AND USE | TAKEDA PHARMACEUTICALS CO (JP) | 2020-06-24 | — | — | EP | disclosed |
| WO-2020122092-A1 | HETEROCYCLIC COMPOUND | 武田薬品工業株式会社 | 2020-06-18 | — | — | WO | disclosed |
| WO-2020122093-A1 | HETEROCYCLIC COMPOUND | 武田薬品工業株式会社 | 2020-06-18 | — | — | WO | disclosed |
| WO-2020116660-A1 | MACROCYCLIC COMPOUND AND USE THEREOF | SCOHIA PHARMA, INC. (JP) | 2020-06-11 | — | — | WO | disclosed |
| EP-3661923-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2020-06-10 | — | — | EP | disclosed |
| EP-3663281-A1 | HETEROCYCLIC COMPOUND AND APPLICATION THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2020-06-10 | — | — | EP | disclosed |
| EP-3661931-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2020-06-10 | — | — | EP | disclosed |
| EP-3660003-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2020-06-03 | — | — | EP | disclosed |
| US-20200163970-A1 | HETEROCYCLIC COMPOUND | TOHOKU UNIVERSITY (JP) | 2020-05-28 | — | — | US | disclosed |
| US-20200157062-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-05-21 | — | — | US | disclosed |
| EP-3134386-B1 | ISOINDOLINE-1-ONE DERIVATIVES AS CHOLINERGIC MUSCARINIC M1 RECEPTOR POSITIVE ALLOESTERIC MODULATOR ACTIVITY FOR THE TREATMENT OF ALZHEIMERS DISEASE | TAKEDA PHARMACEUTICALS CO (JP) | 2020-05-20 | — | — | EP | disclosed |
| US-10654874-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-05-19 | — | — | US | disclosed |
| US-20200148637-A1 | METHOD FOR PRODUCING PYRROLE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-05-14 | — | — | US | disclosed |
| EP-3436444-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2020-05-13 | — | — | EP | disclosed |
| CN-111148746-A | Heterocyclic compounds | 武田药品工业株式会社 | 2020-05-12 | — | — | CN | disclosed |
| US-20200140462-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-05-07 | — | — | US | disclosed |
| US-20200140505-A1 | PEPTIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMTED (JP) | 2020-05-07 | — | — | US | disclosed |
| US-20200131174-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-04-30 | — | — | US | disclosed |
| EP-3178807-B1 | CATIONIC LIPID | TAKEDA PHARMACEUTICALS CO (JP) | 2020-04-29 | — | — | EP | disclosed |
| EP-3643718-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2020-04-29 | — | — | EP | disclosed |
| US-20200121652-A1 | COMPOUNDS HAVING CASPASE INHIBITORY ACTIVITY, PHARMACEUTICAL AGENT CONTAINING SAID COMPOUNDS AND FOR TREATING OR PREVENTING CORNEAL ENDOTHELIAL SYMPTOMS, DISORDERS, OR DISEASES, AND APPLICATION OF SAID PHARMACEUTICAL AGENT | THE DOSHISHA (JP) | 2020-04-23 | — | — | US | disclosed |
| EP-3639855-A1 | COMPOUNDS HAVING CASPASE INHIBITORY ACTIVITY, PHARMACEUTICAL AGENT CONTAINING SAID COMPOUNDS AND FOR TREATING OR PREVENTING CORNEAL ENDOTHELIAL SYMPTOMS, DISORDERS, OR DISEASES, AND APPLICATION OF SAID PHARMACEUTICAL AGENT | The Doshisha (JP) | 2020-04-22 | — | — | EP | disclosed |
| CN-111051295-A | Heterocyclic compounds and their use | 武田药品工业株式会社 | 2020-04-21 | — | — | CN | disclosed |
| CN-111032651-A | Heterocyclic compounds | 武田药品工业株式会社 | 2020-04-17 | — | — | CN | disclosed |
| CN-111032047-A | Process for producing optically active compound | 千年制药公司 | 2020-04-17 | — | — | CN | disclosed |
| US-20200115336-A1 | PROCESS FOR PRODUCING PYRROLE COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2020-04-16 | — | — | US | disclosed |
| EP-3632441-A2 | METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND | Millennium Pharmaceuticals, Inc. (US) | 2020-04-08 | — | — | EP | disclosed |
| US-10610520-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-04-07 | — | — | US | disclosed |
| WO-2020067575-A1 | GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-04-02 | — | — | WO | disclosed |
| WO-2020067557-A2 | GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-04-02 | — | — | WO | disclosed |
| WO-2020067456-A1 | HETEROCYCLIC COMPOUND | 武田薬品工業株式会社 | 2020-04-02 | — | — | WO | disclosed |
| WO-2020067455-A1 | HETEROCYCLIC COMPOUND | 武田薬品工業株式会社 | 2020-04-02 | — | — | WO | disclosed |
| WO-2020067457-A1 | CONDENSED-CYCLIC COMPOUND | 武田薬品工業株式会社 | 2020-04-02 | — | — | WO | disclosed |
| CN-110917130-A | Liquid formulations of amines and organic acids stabilized with salts | 武田药品工业株式会社 | 2020-03-27 | — | — | CN | disclosed |
| WO-2020059892-A1 | INSULIN-PRODUCING CELLS | 武田薬品工業株式会社 | 2020-03-26 | — | — | WO | disclosed |
| EP-3325475-B1 | OXADIAZOLE DERIVATIVES USEFUL AS HDAC INHIBITORS | TAKEDA PHARMACEUTICALS CO (JP) | 2020-03-18 | — | — | EP | disclosed |
| EP-2694472-B1 | SULFONAMIDE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2020-03-11 | — | — | EP | disclosed |
| EP-2603513-B1 | HETEROCYCLIC COMPOUND AND USE THEREOF AS AMPA RECEPTOR POSITIVE ALLOSTERIC MODULATOR | TAKEDA PHARMACEUTICALS CO (JP) | 2020-03-11 | — | — | EP | disclosed |
| US-10584097-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-03-10 | — | — | US | disclosed |
| EP-3617208-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2020-03-04 | — | — | EP | disclosed |
| EP-3617209-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2020-03-04 | — | — | EP | disclosed |
| US-10577382-B2 | Fused heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-03-03 | — | — | US | disclosed |
| EP-3613734-A2 | PROCESS FOR PRODUCING PYRROLE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2020-02-26 | — | — | EP | disclosed |
| EP-3612527-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF ACETYLCHOLINE RECEPTORS | Takeda Pharmaceutical Company Limited (JP) | 2020-02-26 | — | — | EP | disclosed |
| US-10570091-B2 | Method for producing pyrrole compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-02-25 | — | — | US | disclosed |
| CN-110799190-A | Heterocyclic compounds | 卡都瑞恩医药有限责任公司 | 2020-02-14 | — | — | CN | disclosed |
| US-20200039957-A1 | AROMATIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-02-06 | — | — | US | disclosed |
| WO-2020027225-A1 | HETEROCYCLIC COMPOUND | ファイメクス株式会社 | 2020-02-06 | — | — | WO | disclosed |
| EP-3604267-A1 | AROMATIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2020-02-05 | — | — | EP | disclosed |
| EP-3601256-A1 | IP6K INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2020-02-05 | — | — | EP | disclosed |
| EP-3601329-A1 | GIP RECEPTOR ACTIVATING PEPTIDE | Takeda Pharmaceutical Company Limited (JP) | 2020-02-05 | — | — | EP | disclosed |
| EP-3600327-A1 | HETEROCYCLIC COMPOUND | Cardurion Pharmaceuticals, LLC (US) | 2020-02-05 | — | — | EP | disclosed |
| EP-3239150-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2020-02-05 | — | — | EP | disclosed |
| EP-3601260-A1 | SUBSTITUTED CYCLYL-ACETIC ACID DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS | Takeda Pharmaceutical Company Limited (JP) | 2020-02-05 | — | — | EP | disclosed |
| CN-110753689-A | Process for producing heterocyclic compound | 武田药品工业株式会社 | 2020-02-04 | — | — | CN | disclosed |
| US-10548877-B2 | Aromatic ring compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-02-04 | — | — | US | disclosed |
| US-10548899-B2 | Quinazolinone and benzotriazinone compounds with cholinergic muscarinin M1 receptor positive allosteric modulator activity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-02-04 | — | — | US | disclosed |
| US-10543212-B2 | Substituted amines for treating cardiac diseases | CARDURION PHARMACEUTICALS, LLC (US) | 2020-01-28 | — | — | US | disclosed |
| US-10544111-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-01-28 | — | — | US | disclosed |
| CN-110719903-A | Aromatic ring compound | 武田药品工业株式会社 | 2020-01-21 | — | — | CN | disclosed |
| CN-110709401-A | Heterocyclic compounds | 武田药品工业株式会社 | 2020-01-17 | — | — | CN | disclosed |
| CN-110709414-A | GIP receptor activating peptide | 武田药品工业有限公司 | 2020-01-17 | — | — | CN | disclosed |
| US-20200017444-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-01-16 | — | — | US | disclosed |
| CN-110678458-A | Substituted cyclyl-acetic acid derivatives for the treatment of metabolic disorders | 武田药品工业株式会社 | 2020-01-10 | — | — | CN | disclosed |
| EP-3066094-B1 | PYRAZOLE FOR THE TREATMENT AUTOIMMUNE DISORDERS | TAKEDA PHARMACEUTICALS CO (JP) | 2020-01-08 | — | — | EP | disclosed |
| EP-3325490-B1 | 1-SUBSTITUTED 1,2,3,4-TETRAHYDRO-1,7-NAPHTHYRIDIN-8-AMINE DERIVATIVES AND THEIR USE AS EP4 RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICALS CO (JP) | 2019-12-18 | — | — | EP | disclosed |
| CN-110582499-A | Heterocyclic compounds | 武田药品工业株式会社 | 2019-12-17 | — | — | CN | disclosed |
| CN-110573512-A | Heterocyclic compounds | 武田药品工业株式会社 | 2019-12-13 | — | — | CN | disclosed |
| CN-105209485-B | Peptide compounds | 武田药品工业株式会社 | 2019-12-10 | — | — | CN | disclosed |
| CN-107835800-B | Cyclic compound | 武田药品工业株式会社 | 2019-11-26 | — | — | CN | disclosed |
| US-10472376-B2 | Amide compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-11-12 | — | — | US | disclosed |
| CN-106414396-B | The method for preparing heterocyclic compound | 武田药品工业株式会社 | 2019-11-08 | — | — | CN | disclosed |
| EP-3241826-B1 | PROCESS FOR PRODUCING PYRROLE COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2019-10-30 | — | — | EP | disclosed |
| EP-3275874-B1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2019-10-30 | — | — | EP | disclosed |
| US-10457670-B2 | Isoindoline-1-one derivatives as cholinergic muscarinic M1 receptor positive alloesteric modulator activity for the treatment of Alzheimers disease | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-10-29 | — | — | US | disclosed |
| EP-3205645-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2019-10-23 | — | — | EP | disclosed |
| US-20190315735-A1 | CYCLOPROPANAMINE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2019-10-17 | — | — | US | disclosed |
| EP-3210971-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2019-10-16 | — | — | EP | disclosed |
| US-10435445-B2 | Peptide compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-10-08 | — | — | US | disclosed |
| CN-106795118-B | Heterocyclic compound and their purposes as relevant orphan receptor (ROR) the GAMMA-T inhibitor of retinoids | 武田药品工业株式会社 | 2019-10-08 | — | — | CN | disclosed |
| US-10435399-B2 | HDAC6 inhibitory heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-10-08 | — | — | US | disclosed |
| US-20190300536-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-10-03 | — | — | US | disclosed |
| WO-2019189945-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-10-03 | — | — | WO | disclosed |
| WO-2019189555-A1 | HETEROCYCLIC COMPOUND | 武田薬品工業株式会社 | 2019-10-03 | — | — | WO | disclosed |
| WO-2019189553-A1 | HETEROCYCLIC COMPOUND | 国立大学法人京都大学 | 2019-10-03 | — | — | WO | disclosed |
| US-10428056-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-10-01 | — | — | US | disclosed |
| US-10428023-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-10-01 | — | — | US | disclosed |
| US-10414761-B2 | Cyclopropanamine compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-09-17 | — | — | US | disclosed |
| US-10406146-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-09-10 | — | — | US | disclosed |
| CN-110200903-A | With the liquid preparation of salt stable amine and organic acid | 武田药品工业株式会社 | 2019-09-06 | — | — | CN | disclosed |
| US-20190263832-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-08-29 | — | — | US | disclosed |
| US-20190263843-A1 | SUBSTITUTED PIPERIDINE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-08-29 | — | — | US | disclosed |
| WO-2019163945-A1 | IL-17A ACTIVITY INHIBITOR AND USE THEREOF | 学校法人東海大学 | 2019-08-29 | — | — | WO | disclosed |
| US-20190248776-A1 | 2,3-DIHYDRO-4H-1,3-BENZOXAZIN-4-ONE DERIVATIVES AS MODULATORS OF CHOLINERGIC MUSCARINIC M1 RECEPTOR | TAKEDA PHARMACEUTICALS CO (JP) | 2019-08-15 | — | — | US | disclosed |
| CN-106536508-B | For treat Alzheimer disease have the active compound of cholinergic muscarinic M1 receptor positive allosteric regulator | 武田药品工业株式会社 | 2019-08-09 | — | — | CN | disclosed |
| US-20190241566-A1 | HETEROCYCLIC AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-08-08 | — | — | US | disclosed |
| WO-2019151269-A1 | HETEROCYCLIC COMPOUND | 武田薬品工業株式会社 | 2019-08-08 | — | — | WO | disclosed |
| US-20190241547-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2019-08-08 | — | — | US | disclosed |
| EP-3156397-B1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2019-08-07 | — | — | EP | disclosed |
| EP-2907802-B1 | CYCLOPROPANAMINE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2019-08-07 | — | — | EP | disclosed |
| US-10370357-B2 | Method for producing sulfonyl chloride compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-08-06 | — | — | US | disclosed |
| EP-3512861-A2 | CYCLIC DINUCLEOTIDES AS STING (STIMULATOR OF INTEFERON GENES) AGONISTS | Takeda Pharmaceutical Company Limited (JP) | 2019-07-24 | — | — | EP | disclosed |
| EP-3514150-A1 | HETEROCYCLIC AMIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2019-07-24 | — | — | EP | disclosed |
| EP-3514149-A1 | HETEROCYCLIC AMIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2019-07-24 | — | — | EP | disclosed |
| US-10357484-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-07-23 | — | — | US | disclosed |
| US-10342786-B2 | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD | Fulcrum Therapeutics, Inc. (US) | 2019-07-09 | — | — | US | disclosed |
| US-20190202883-A1 | PEPTIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-07-04 | — | — | US | disclosed |
| EP-3239142-B1 | CONDENSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2019-07-03 | — | — | EP | disclosed |
| US-10336864-B2 | Production method for poly(amino acid) | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-07-02 | — | — | US | disclosed |
| US-20190192549-A1 | CYCLIC DINUCLEOTIDE | TAKEDA PHARMACEUTICALS CO (JP) | 2019-06-27 | — | — | US | disclosed |
| EP-3498693-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2019-06-19 | — | — | EP | disclosed |
| US-10323026-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-06-18 | — | — | US | disclosed |
| US-10323027-B2 | 2,3-dihydro-4H-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic M1 receptor | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-06-18 | — | — | US | disclosed |
| US-20190169166-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-06-06 | — | — | US | disclosed |
| US-10308643-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-06-04 | — | — | US | disclosed |
| US-10308605-B2 | Proton pump inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-06-04 | — | — | US | disclosed |
| US-10301292-B2 | Bicyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-05-28 | — | — | US | disclosed |
| US-20190151295-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 POLYPEPTIDES | ARVINAS OPERATIONS, INC. | 2019-05-23 | — | — | US | disclosed |
| US-10287305-B2 | Substituted piperidine compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-05-14 | — | — | US | disclosed |
| US-20190135799-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-05-09 | — | — | US | disclosed |
| CN-109715613-A | Heterocyclic compound | 武田药品工业株式会社 | 2019-05-03 | — | — | CN | disclosed |
| US-20190125728-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-05-02 | — | — | US | disclosed |
| US-20190127324-A1 | 5-ARYL-1H-PYRROLE-3-CARBONITRILE AND A PHARMACEUTICAL PRODUCT USING THE SAME | TAKEDA PHARMACEUTICALS CO (JP) | 2019-05-02 | — | — | US | disclosed |
| US-20190119225-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-04-25 | — | — | US | disclosed |
| US-20190105311-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | Fulcrum Therapeutics, Inc. | 2019-04-11 | — | — | US | disclosed |
| US-20190106437-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-04-11 | — | — | US | disclosed |
| WO-2019071147-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | Fulcrum Therapeutics, Inc. (US) | 2019-04-11 | — | — | WO | disclosed |
| US-20190105312-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | Fulcrum Therapeutics, Inc. | 2019-04-11 | — | — | US | disclosed |
| EP-3467106-A1 | PEPTIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2019-04-10 | — | — | EP | disclosed |
| US-10252997-B2 | Monocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-04-09 | — | — | US | disclosed |
| US-10252974-B2 | Cationic lipid | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-04-09 | — | — | US | disclosed |
| US-20190083467-A1 | AROMATIC RING COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-03-21 | — | — | US | disclosed |
| CN-109415384-A | Condensed heterocyclic compouds | 武田药品工业株式会社 | 2019-03-01 | — | — | CN | disclosed |
| US-10208046-B2 | Nitrogen-containing heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-02-19 | — | — | US | disclosed |
| US-10202376-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-02-12 | — | — | US | disclosed |
| US-20190040010-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-02-07 | — | — | US | disclosed |
| WO-2019027054-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-02-07 | — | — | WO | disclosed |
| WO-2019027058-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-02-07 | — | — | WO | disclosed |
| EP-3436444-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2019-02-06 | — | — | EP | disclosed |
| EP-3438109-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2019-02-06 | — | — | EP | disclosed |
| US-20190031611-A1 | SUBSTITUTED PIPERIDINE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-01-31 | — | — | US | disclosed |
| US-10189785-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICALS COMPANY LIMITED (JP) | 2019-01-29 | — | — | US | disclosed |
| EP-3428150-A1 | AROMATIC RING COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2019-01-16 | — | — | EP | disclosed |
| US-20190008836-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-01-10 | — | — | US | disclosed |
| US-10173977-B2 | 5-aryl-1H-pyrrole-3-carbonitrile and a pharmaceutical product using the same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-01-08 | — | — | US | disclosed |
| US-20180362516-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2018-12-20 | — | — | US | disclosed |
| EP-3411358-A1 | SUBSTITUTED PIPERIDINE COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2018-12-12 | — | — | EP | disclosed |
| US-20180346452-A1 | ISOINDOLINE-1-ONE DERIVATIVES AS CHOLINERGIC MUSCARINIC M1 RECEPTOR POSITIVE ALLOESTERIC MODULATOR ACTIVITY FOR THE TREATMENT OF ALZHEIMERS DISEASE | TAKEDA PHARMACEUTICALS CO (JP) | 2018-12-06 | — | — | US | disclosed |
| CN-108884043-A | Substituted piperidine compounds and uses thereof | 武田药品工业株式会社 | 2018-11-23 | — | — | CN | disclosed |
| US-10131653-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-11-20 | — | — | US | disclosed |
| US-20180319819-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-11-08 | — | — | US | disclosed |
| US-20180319812-A1 | HETEROCYCLIC COMPOUND | ACTION MEDICAL TECHNOLOGIES, LLC | 2018-11-08 | — | — | US | disclosed |
| WO-2018194181-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF ACETYLCHOLINE RECEPTORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-10-25 | — | — | WO | disclosed |
| US-20180303841-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-10-25 | — | — | US | disclosed |
| EP-3087067-B1 | 4-(PIPERRAZIN-1-YL)-PYRROLIDIN-2-ONE COMPOUNDS AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | TAKEDA PHARMACEUTICALS CO (JP) | 2018-10-24 | — | — | EP | disclosed |
| US-10106556-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-10-23 | — | — | US | disclosed |
| US-20180298070-A1 | PEPTIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-10-18 | — | — | US | disclosed |
| US-10098866-B2 | Pharmaceutical preparation containing copolyvidone | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-10-16 | — | — | US | disclosed |
| US-10093629-B2 | Heterocyclic compounds and their use as retinoid-related orphan receptor (ROR) gamma-T inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-10-09 | — | — | US | disclosed |
| US-20180280389-A1 | HETEROCYCLIC COMPOUND | CARDURION PHARMACEUTICALS, LLC (US) | 2018-10-04 | — | — | US | disclosed |
| WO-2018183112-A1 | HETEROCYCLIC COMPOUND | CARDURION PHARMACEUTICALS, LLC (US) | 2018-10-04 | — | — | WO | disclosed |
| WO-2018182050-A1 | SUBSTITUTED CYCLYL-ACETIC ACID DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-10-04 | — | — | WO | disclosed |
| WO-2018182051-A1 | IP6K INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-10-04 | — | — | WO | disclosed |
| WO-2018181864-A1 | GIP RECEPTOR ACTIVATING PEPTIDE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-10-04 | — | — | WO | disclosed |
| US-10087150-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-10-02 | — | — | US | disclosed |
| US-10087229-B2 | Peptide compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-10-02 | — | — | US | disclosed |
| US-10081624-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-09-25 | — | — | US | disclosed |
| US-20180263967-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-09-20 | — | — | US | disclosed |
| EP-3366679-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2018-08-29 | — | — | EP | disclosed |
| EP-3366684-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2018-08-29 | — | — | EP | disclosed |
| CN-105899505-B | Pyrazoles for the treatment of autoimmune disorders | 武田药品工业株式会社 | 2018-08-28 | — | — | CN | disclosed |
| US-20180237404-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-08-23 | — | — | US | disclosed |
| US-10053468-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-08-21 | — | — | US | disclosed |
| US-10053456-B2 | Cyclopropanamine compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-08-21 | — | — | US | disclosed |
| CN-108431004-A | Heterocyclic compounds | 武田药品工业株式会社 | 2018-08-21 | — | — | CN | disclosed |
| US-20180222896-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-08-09 | — | — | US | disclosed |
| CN-108368127-A | 1,2,3,4- tetrahydrochysene -1,7- naphthyridines -8- the amine derivatives of 1- substitutions and its purposes as EP4 receptor antagonists | 武田药品工业株式会社 | 2018-08-03 | — | — | CN | disclosed |
| US-20180215754-A1 | 1-SUBSTITUTED 1,2,3,4-TETRAHYDRO-1,7-NAPHTHYRIDIN-8-AMINE DERIVATIVES AND THEIR USE AS EP4 RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-08-02 | — | — | US | disclosed |
| US-10023544-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-07-17 | — | — | US | disclosed |
| US-10017487-B2 | Fused heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-07-10 | — | — | US | disclosed |
| US-20180186736-A1 | METHOD FOR PRODUCING PYRROLE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-07-05 | — | — | US | disclosed |
| EP-3342772-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2018-07-04 | — | — | EP | disclosed |
| US-20180170874-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-06-21 | — | — | US | disclosed |
| US-20180170905-A1 | Method for Producing Sulfonyl Chloride Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-06-21 | — | — | US | disclosed |
| US-10000488-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-06-19 | — | — | US | disclosed |
| US-20180162850-A1 | 2,3-DIHYDRO-4H-1,3-BENZOXAZIN-4-ONE DERIVATIVES AS MODULATORS OF CHOLINERGIC MUSCARINIC M1 RECEPTOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
| US-20180162875-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
| US-20180162853-A1 | CYCLOPROPANAMINE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2018-06-14 | — | — | US | disclosed |
| US-20180155333-A1 | Heterocyclic Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-06-07 | — | — | US | disclosed |
| WO-2018100558-A2 | CYCLIC DINUCLEOTIDE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-06-07 | — | — | WO | disclosed |
| US-20180148446-A1 | PYRROLO [2,3-c] PYRIDINE COMPOUND, PROCESS FOR PRODUCING THE SAME, AND USE | TAKEDA PHARMACEUTICALS CO (JP) | 2018-05-31 | — | — | US | disclosed |
| EP-3327019-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2018-05-30 | — | — | EP | disclosed |
| EP-3325475-A1 | OXADIAZOLE DERIVATIVES USEFUL AS HDAC INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2018-05-30 | — | — | EP | disclosed |
| EP-3325490-A1 | 1-SUBSTITUTED 1,2,3,4-TETRAHYDRO-1,7-NAPHTHYRIDIN-8-AMINE DERIVATIVES AND THEIR USE AS EP4 RECEPTOR ANTAGONISTS | Takeda Pharmaceutical Company Limited (JP) | 2018-05-30 | — | — | EP | disclosed |
| US-9975903-B2 | Condensed heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-05-22 | — | — | US | disclosed |
| US-9969705-B2 | Fused heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-05-15 | — | — | US | disclosed |
| CN-108026031-A | Process for preparing azole compounds | 武田药品工业株式会社 | 2018-05-11 | — | — | CN | disclosed |
| CN-108026088-A | Oxadiazole derivatives as HDAC inhibitors | 武田药品工业株式会社 | 2018-05-11 | — | — | CN | disclosed |
| EP-3318551-A1 | METHOD FOR PRODUCING PYRROLE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2018-05-09 | — | — | EP | disclosed |
| US-9963443-B2 | Radiolabeled compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-05-08 | — | — | US | disclosed |
| US-20180118708-A1 | CYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-05-03 | — | — | US | disclosed |
| EP-3313836-A1 | 2,3-DIHYDRO-4H-1,3-BENZOXAZIN-4-ONE DERIVATIVES AS MODULATORS OF CHOLINERGIC MUSCARINIC M1 RECEPTOR | Takeda Pharmaceutical Company Limited (JP) | 2018-05-02 | — | — | EP | disclosed |
| US-9957251-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-05-01 | — | — | US | disclosed |
| US-9944596-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-04-17 | — | — | US | disclosed |
| CN-107922403-A | 2, 3-dihydro-4H-1, 3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic M1 receptors | 武田药品工业株式会社 | 2018-04-17 | — | — | CN | disclosed |
| EP-3031799-B1 | AROMATIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2018-04-04 | — | — | EP | disclosed |
| US-9932322-B2 | Method for producing sulfonyl chloride compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-04-03 | — | — | US | disclosed |
| CN-105143187-B | The method for preparing sulfonyl chloride compound | 武田药品工业株式会社 | 2018-04-03 | — | — | CN | disclosed |
| CN-107848971-A | Heterocyclic compound | 武田药品工业株式会社 | 2018-03-27 | — | — | CN | disclosed |
| CN-107835800-A | cyclic compound | 武田药品工业株式会社 | 2018-03-23 | — | — | CN | disclosed |
| US-20180079723-A1 | MONOCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-03-22 | — | — | US | disclosed |
| US-20180079741-A1 | PROCESS FOR PRODUCING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS COMPANY LIMITED (JP) | 2018-03-22 | — | — | US | disclosed |
| US-20180079756-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-03-22 | — | — | US | disclosed |
| EP-3296296-A1 | CYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2018-03-21 | — | — | EP | disclosed |
| EP-3294706-A1 | CYCLIC COMPOUNDS | Takeda Pharmaceutical Company Limited (JP) | 2018-03-21 | — | — | EP | disclosed |
| US-9920047-B2 | Cyclopropanamine compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-03-20 | — | — | US | disclosed |
| US-20180072694-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-03-15 | — | — | US | disclosed |
| EP-3287454-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2018-02-28 | — | — | EP | disclosed |
| EP-3287441-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2018-02-28 | — | — | EP | disclosed |
| US-20180050996-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2018-02-22 | — | — | US | disclosed |
| WO-2018030550-A1 | HETEROCYCLIC COMPOUNDS WITH AN ROR(GAMMA)T MODULATING ACTIVITY | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-02-15 | — | — | WO | disclosed |
| US-20180044472-A1 | PRODUCTION METHOD FOR POLY(AMINO ACID) | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-02-15 | — | — | US | disclosed |
| US-9890145-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-02-13 | — | — | US | disclosed |
| EP-3279183-A1 | MONOCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2018-02-07 | — | — | EP | disclosed |
| EP-3279191-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2018-02-07 | — | — | EP | disclosed |
| US-9884875-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-02-06 | — | — | US | disclosed |
| EP-2813508-B1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2018-01-31 | — | — | EP | disclosed |
| EP-3275874-A1 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2018-01-31 | — | — | EP | disclosed |
| US-9878989-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-01-30 | — | — | US | disclosed |
| US-9878981-B2 | Method for producing heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-01-30 | — | — | US | disclosed |
| US-9868725-B2 | Isoindoline-1-one derivatives as cholinergic muscarinic M1 receptor positive alloesteric modulator activity for the treatment of Alzheimer's disease | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-01-16 | — | — | US | disclosed |
| US-20180009746-A1 | PROCESS FOR PRODUCING PYRROLE COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2018-01-11 | — | — | US | disclosed |
| US-20180002322-A1 | BICYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-01-04 | — | — | US | disclosed |
| US-20180000780-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2018-01-04 | — | — | US | disclosed |
| US-20170362223-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-12-21 | — | — | US | disclosed |
| US-20170349605-A1 | CONDENSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-12-07 | — | — | US | disclosed |
| US-9834520-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-12-05 | — | — | US | disclosed |
| US-9828357-B2 | Cyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-11-28 | — | — | US | disclosed |
| US-9815938-B2 | Production method for poly(amino acid) | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-11-14 | — | — | US | disclosed |
| EP-3241826-A2 | PROCESS FOR PRODUCING PYRROLE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2017-11-08 | — | — | EP | disclosed |
| US-9809569-B2 | Process for producing heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-11-07 | — | — | US | disclosed |
| EP-3239150-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2017-11-01 | — | — | EP | disclosed |
| EP-3239142-A1 | CONDENSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2017-11-01 | — | — | EP | disclosed |
| US-9789083-B2 | Nitrogen-containing heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-10-17 | — | — | US | disclosed |
| US-9789084-B2 | Nitrogen-containing heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-10-17 | — | — | US | disclosed |
| WO-2017171100-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-10-05 | — | — | WO | disclosed |
| US-20170283406-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-10-05 | — | — | US | disclosed |
| EP-3225618-A1 | BICYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2017-10-04 | — | — | EP | disclosed |
| US-9775827-B2 | Nitrogen-containing heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-10-03 | — | — | US | disclosed |
| US-9776962-B2 | Aromatic compounds with GPR40 agonistic activity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-10-03 | — | — | US | disclosed |
| CN-107207444-A | Bicyclic compound | 武田药品工业株式会社 | 2017-09-26 | — | — | CN | disclosed |
| US-20170266162-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2017-09-21 | — | — | US | disclosed |
| US-20170258764-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2017-09-14 | — | — | US | disclosed |
| US-20170253591-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-09-07 | — | — | US | disclosed |
| US-9751885-B2 | Cyclopropanamine compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-09-05 | — | — | US | disclosed |
| US-9751878-B2 | Tetrahydronaphthyridine somatostatin receptor 5 antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-09-05 | — | — | US | disclosed |
| EP-3210973-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2017-08-30 | — | — | EP | disclosed |
| EP-2738170-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2017-08-30 | — | — | EP | disclosed |
| EP-3210971-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2017-08-30 | — | — | EP | disclosed |
| US-9745325-B2 | Fused heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-08-29 | — | — | US | disclosed |
| CN-107108506-A | Heterocyclic compounds | 武田药品工业株式会社 | 2017-08-29 | — | — | CN | disclosed |
| US-20170233339-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-08-17 | — | — | US | disclosed |
| EP-3205645-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2017-08-16 | — | — | EP | disclosed |
| WO-2017135306-A1 | SUBSTITUTED PIPERIDINE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-08-10 | — | — | WO | disclosed |
| US-20170226137-A1 | SUBSTITUTED PIPERIDINE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-08-10 | — | — | US | disclosed |
| US-20170216255-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2017-08-03 | — | — | US | disclosed |
| US-9718814-B2 | Cyclopropanamine compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-08-01 | — | — | US | disclosed |
| EP-2765130-B1 | Intermediates for use in a process of producing pyrrole compounds | TAKEDA PHARMACEUTICALS CO (JP) | 2017-07-26 | — | — | EP | disclosed |
| US-9714241-B2 | Cyclopropanamine compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-07-25 | — | — | US | disclosed |
| EP-3192791-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2017-07-19 | — | — | EP | disclosed |
| US-20170197903-A1 | CATIONIC LIPID | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-07-13 | — | — | US | disclosed |
| EP-3187497-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2017-07-05 | — | — | EP | disclosed |
| CN-105612158-B | The somatostatin receptor hypotype 5 (SSTR5) antagonist | 武田药品工业株式会社 | 2017-06-30 | — | — | CN | disclosed |
| US-9682925-B2 | Cyclopropaneamine compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-06-20 | — | — | US | disclosed |
| EP-3178807-A1 | CATIONIC LIPID | Takeda Pharmaceutical Company Limited (JP) | 2017-06-14 | — | — | EP | disclosed |
| EP-2602254-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2017-06-14 | — | — | EP | disclosed |
| US-9675597-B2 | Nitrogen-containing heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-06-13 | — | — | US | disclosed |
| CN-105051005-B | Cyclopropylamine compound and use thereof | 武田药品工业株式会社 | 2017-06-13 | — | — | CN | disclosed |
| EP-2275433-B1 | METASTIN DERIVATIVE AND USE THEREOF | UNIV KYOTO (JP) | 2017-06-07 | — | — | EP | disclosed |
| CN-106795118-A | Heterocyclic compound to they as related orphan receptor (ROR) the GAMMA T inhibitor of retinoids purposes | 武田药品工业株式会社 | 2017-05-31 | — | — | CN | disclosed |
| US-9662316-B2 | Nitrogen-containing heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-05-30 | — | — | US | disclosed |
| US-20170144973-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS RETINOID-RELATED ORPHAN RECEPTOR (ROR) GAMMA-T INHIBITORS | Takenda Pharmaceutical Company Limited (JP) | 2017-05-25 | — | — | US | disclosed |
| US-9655881-B2 | Nitrogen-containing heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-05-23 | — | — | US | disclosed |
| EP-2970331-B1 | SPIRO AZETIDINE ISOXAZOLE DERIVATIVES AND THEIR USE AS SSTR5 ANTAGONISTS | TAKEDA PHARMACEUTICALS CO (JP) | 2017-05-17 | — | — | EP | disclosed |
| US-9650343-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-05-16 | — | — | US | disclosed |
| EP-3164388-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS RETINOID-RELATED ORPHAN RECEPTOR (ROR) GAMMA-T INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2017-05-10 | — | — | EP | disclosed |
| US-20170121286-A1 | METHOD FOR PRODUCING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-05-04 | — | — | US | disclosed |
| US-20170121308-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-05-04 | — | — | US | disclosed |
| EP-3162798-A1 | 5-MEMBERED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2017-05-03 | — | — | EP | disclosed |
| US-20170114042-A1 | RADIOLABELED COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-04-27 | — | — | US | disclosed |
| US-20170114044-A1 | PYRIDAZINONE COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS AND METHODS OF TREATING DISORDERS | TAKEDA PHARMACEUTICALS CO (JP) | 2017-04-27 | — | — | US | disclosed |
| US-9630924-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-04-25 | — | — | US | disclosed |
| US-20170107240-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-04-20 | — | — | US | disclosed |
| EP-3156397-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2017-04-19 | — | — | EP | disclosed |
| CN-106573916-A | Radiolabeled compounds | 武田药品工业株式会社 | 2017-04-19 | — | — | CN | disclosed |
| US-9624170-B2 | 4-(piperrazin-1-yl)-pyrrolidin-2-one compounds as monoacylglycerol lipase (MAGL) inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-04-18 | — | — | US | disclosed |
| US-20170100373-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2017-04-13 | — | — | US | disclosed |
| US-20170100384-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2017-04-13 | — | — | US | disclosed |
| EP-3152198-A1 | RADIOLABELED COMPOUNDS | Takeda Pharmaceutical Company Limited (JP) | 2017-04-12 | — | — | EP | disclosed |
| US-20170096422-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-04-06 | — | — | US | disclosed |
| US-9611244-B2 | Cyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-04-04 | — | — | US | disclosed |
| US-9605000-B2 | Spiro azetidine isoxazole derivatives and their use as SSTR antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-03-28 | — | — | US | disclosed |
| US-20170081305-A1 | PROCESS FOR PRODUCING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-03-23 | — | — | US | disclosed |
| US-20170081332-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-03-23 | — | — | US | disclosed |
| EP-3144308-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2017-03-22 | — | — | EP | disclosed |
| CN-106536508-A | ISOINDOLINE-1-ONE DERIVATIVES AS CHOLINERGIC MUSCARINIC M1 RECEPTOR POSITIVE ALLOESTERIC MODULATOR ACTIVITY FOR THE TREATMENT OF ALZHEIMERS DISEASE | 武田药品工业株式会社 | 2017-03-22 | — | — | CN | disclosed |
| US-20170066737-A1 | CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-03-09 | — | — | US | disclosed |
| WO-2017038909-A1 | HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-03-09 | — | — | WO | disclosed |
| EP-3134386-A1 | ISOINDOLINE-1-ONE DERIVATIVES AS CHOLINERGIC MUSCARINIC M1 RECEPTOR POSITIVE ALLOESTERIC MODULATOR ACTIVITY FOR THE TREATMENT OF ALZHEIMERS DISEASE | Takeda Pharmaceutical Company Limited (JP) | 2017-03-01 | — | — | EP | disclosed |
| CN-106470990-A | pyridazine compounds | 武田药品工业株式会社 | 2017-03-01 | — | — | CN | disclosed |
| US-9579407-B2 | Radiolabeled compounds and their use as radiotracers for quantitative imaging of phosphodiesterase (PDE10A) in mammals | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-02-28 | — | — | US | disclosed |
| US-20170050974-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-02-23 | — | — | US | disclosed |
| EP-3133075-A1 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2017-02-22 | — | — | EP | disclosed |
| CN-106458897-A | Process for producing heterocyclic compound | 武田药品工业株式会社 | 2017-02-22 | — | — | CN | disclosed |
| CN-106459040-A | Heterocyclic compound | 武田药品工业株式会社 | 2017-02-22 | — | — | CN | disclosed |
| US-9573903-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-02-21 | — | — | US | disclosed |
| WO-2017026538-A1 | PRODUCTION METHOD OF PYRAZINE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-02-16 | — | — | WO | disclosed |
| US-20170044132-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-02-16 | — | — | US | disclosed |
| US-20170044143-A1 | ISOINDOLINE-1-ONE DERIVATIVES AS CHOLINERGIC MUSCARINIC M1 RECEPTOR POSITIVE ALLOESTERIC MODULATOR ACTIVITY FOR THE TREATMENT OF ALZHEIMERS DISEASE | TAKEDA PHAMACEUTICAL COMPANY LIMITED (JP) | 2017-02-16 | — | — | US | disclosed |
| EP-3130581-A1 | METHOD FOR PRODUCING HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2017-02-15 | — | — | EP | disclosed |
| EP-3129369-A1 | CYCLOPROPANAMINE COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2017-02-15 | — | — | EP | disclosed |
| CN-106414396-A | Method for producing heterocyclic compound | 武田药品工业株式会社 | 2017-02-15 | — | — | CN | disclosed |
| US-20170037057-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-02-09 | — | — | US | disclosed |
| US-20170027921-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2017-02-02 | — | — | US | disclosed |
| US-20170029417-A1 | CYCLOPROPANAMINE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-02-02 | — | — | US | disclosed |
| EP-3124487-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2017-02-01 | — | — | EP | disclosed |
| US-9556200-B2 | Tricyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-01-31 | — | — | US | disclosed |
| US-20170022222-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-01-26 | — | — | US | disclosed |
| WO-2017014323-A1 | 1-SUBSTITUTED 1,2,3,4-TETRAHYDRO-1,7-NAPHTHYRIDIN-8-AMINE DERIVATIVES AND THEIR USE AS EP4 RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-01-26 | — | — | WO | disclosed |
| US-20170020841-A1 | PHARMACEUTICAL PREPARATION CONTAINING COPOLYVIDONE | TAKEDA PHARMACEUTICALS CO (JP) | 2017-01-26 | — | — | US | disclosed |
| WO-2017014321-A1 | OXADIAZOLE DERIVATIVES USEFUL AS HDAC INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-01-26 | — | — | WO | disclosed |
| US-9550756-B2 | Pyridazinone compounds as phosphodiesterase inhibitors and methods of treating disorders | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-01-24 | — | — | US | disclosed |
| US-20170015655-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-01-19 | — | — | US | disclosed |
| US-20170015654-A1 | PYRIDAZINE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-01-19 | — | — | US | disclosed |
| EP-3118192-A1 | PROCESS FOR PRODUCING HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2017-01-18 | — | — | EP | disclosed |
| EP-3118200-A1 | PYRIDAZINE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2017-01-18 | — | — | EP | disclosed |
| US-20170008874-A1 | Method for Producing Sulfonyl Chloride Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-01-12 | — | — | US | disclosed |
| US-20170001994-A1 | CYCLOPROPANAMINE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2017-01-05 | — | — | US | disclosed |
| EP-2604597-B1 | HETEROCYCLIC COMPOUND AND USE THEREOF INHIBITOR OF PHOSPHODIESTERASE 10A | TAKEDA PHARMACEUTICALS CO (JP) | 2017-01-04 | — | — | EP | disclosed |
| US-9533966-B2 | Cyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-01-03 | — | — | US | disclosed |
| WO-2016208775-A1 | 2,3-DIHYDRO-4H-1,3-BENZOXAZIN-4-ONE DERIVATIVES AS MODULATORS OF CHOLINERGIC MUSCARINIC M1 RECEPTOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-12-29 | — | — | WO | disclosed |
| US-20160376244-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-12-29 | — | — | US | disclosed |
| US-9527807-B2 | Sulfonamide derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-12-27 | — | — | US | disclosed |
| EP-3105228-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2016-12-21 | — | — | EP | disclosed |
| EP-3105213-A1 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2016-12-21 | — | — | EP | disclosed |
| WO-2016199943-A1 | HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-12-15 | — | — | WO | disclosed |
| US-9518042-B2 | Nitrogen-containing heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-12-13 | — | — | US | disclosed |
| US-20160355494-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-12-08 | — | — | US | disclosed |
| US-20160347724-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-12-01 | — | — | US | disclosed |
| EP-2412713-B1 | PYRAZOLE COMPOUND | TAKEDA PHARMACEUTICAL (JP) | 2016-11-30 | — | — | EP | disclosed |
| US-9499568-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-11-22 | — | — | US | disclosed |
| US-9499516-B2 | Nitrogen-containing heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-11-22 | — | — | US | disclosed |
| WO-2016182036-A1 | CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-11-17 | — | — | WO | disclosed |
| US-9493484-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-11-15 | — | — | US | disclosed |
| US-20160326102-A1 | CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-11-10 | — | — | US | disclosed |
| US-20160326133-A1 | CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-11-10 | — | — | US | disclosed |
| US-9487485-B2 | Method for producing sulfonyl chloride compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-11-08 | — | — | US | disclosed |
| US-9487511-B2 | Cyclopropanamine compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-11-08 | — | — | US | disclosed |
| US-20160318864-A1 | 4-(PIPERRAZIN-1-YL)-PYRROLIDIN-2-ONE COMPOUNDS AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-11-03 | — | — | US | disclosed |
| EP-3087067-A1 | 4-(PIPERRAZIN-1-YL)-PYRROLIDIN-2-ONE COMPOUNDS AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2016-11-02 | — | — | EP | disclosed |
| EP-2196459-B1 | 5-MEMBERED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL (JP) | 2016-11-02 | — | — | EP | disclosed |
| US-20160311811-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-10-27 | — | — | US | disclosed |
| US-20160311808-A1 | CYCLOPROPANAMINE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2016-10-27 | — | — | US | disclosed |
| US-20160311814-A1 | CYCLOPROPANAMINE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2016-10-27 | — | — | US | disclosed |
| US-20160264536-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-09-15 | — | — | US | disclosed |
| EP-3066094-A1 | PYRAZOLE FOR THE TREATMENT AUTOIMMUNE DISORDERS | Takeda Pharmaceutical Company Limited (JP) | 2016-09-14 | — | — | EP | disclosed |
| EP-3063139-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2016-09-07 | — | — | EP | disclosed |
| EP-3061754-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2016-08-31 | — | — | EP | disclosed |
| US-9428470-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-08-30 | — | — | US | disclosed |
| EP-2402313-B1 | PROCESS FOR PRODUCING PYRROLE COMPOUND | TAKEDA PHARMACEUTICAL (JP) | 2016-08-24 | — | — | EP | disclosed |
| CN-103965147-B | Benzofuran derivatives | 武田药品工业株式会社 | 2016-08-24 | — | — | CN | disclosed |
| CN-105899505-A | Pyrazoles for the treatment of autoimmune disorders | 武田药品工业株式会社 | 2016-08-24 | — | — | CN | disclosed |
| US-20160237087-A1 | HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-08-18 | — | — | US | disclosed |
| EP-3055309-A1 | ANTAGONISTS OF SOMATOSTATIN RECEPTOR SUBTYPE 5 (SSTR5) | Takeda Pharmaceutical Company Limited (JP) | 2016-08-17 | — | — | EP | disclosed |
| CN-103842332-B | Cyclopropylamine compound | 武田药品工业株式会社 | 2016-08-17 | — | — | CN | disclosed |
| US-20160229814-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-08-11 | — | — | US | disclosed |
| CN-103153995-B | Condensed heterocyclic compouds as phosphodiesterase (PDES) inhibitor | 武田药品工业株式会社 | 2016-08-10 | — | — | CN | disclosed |
| EP-2687529-B1 | CONDENSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL (JP) | 2016-07-13 | — | — | EP | disclosed |
| US-20160176873-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL (JP) | 2016-06-23 | — | — | US | disclosed |
| WO-2016098015-A1 | NEW EFFICIENT METHODS FOR THE SYNTHESIS OF TAXANE DERIVATIVES SUCH AS DOCETAXEL AND THEIR STRUCTURAL ANALOGOUS, AND A METHOD FOR THE PREPARATION THEREOF | KARIMIAN KHASHAYAR (IR) | 2016-06-23 | — | — | WO | disclosed |
| US-20160177032-A1 | PRODUCTION METHOD FOR POLY(AMINO ACID) | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-23 | — | — | US | disclosed |
| US-20160176822-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL (JP) | 2016-06-23 | — | — | US | disclosed |
| US-20160176872-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL (JP) | 2016-06-23 | — | — | US | disclosed |
| EP-3031799-A1 | AROMATIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2016-06-15 | — | — | EP | disclosed |
| US-9365520-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-14 | — | — | US | disclosed |
| US-20160159808-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-09 | — | — | US | disclosed |
| US-20160159773-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-09 | — | — | US | disclosed |
| WO-2016088903-A1 | HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-09 | — | — | WO | disclosed |
| EP-3029031-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2016-06-08 | — | — | EP | disclosed |
| US-20160152598-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL (JP) | 2016-06-02 | — | — | US | disclosed |
| US-20160152603-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL (JP) | 2016-06-02 | — | — | US | disclosed |
| EP-3026051-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2016-06-01 | — | — | EP | disclosed |
| US-9353108-B2 | Tetrahydronaphthyridine somatostatin receptor 5 antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-05-31 | — | — | US | disclosed |
| CN-105612158-A | Antagonists of somatostatin receptor subtype 5 (sstr5) | TAKEDA PHARMACEUTICALS CO | 2016-05-25 | — | — | CN | disclosed |
| US-9346776-B2 | Fused heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-05-24 | — | — | US | disclosed |
| EP-3019487-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2016-05-18 | — | — | EP | disclosed |
| US-20160130215-A1 | CYCLOPROPANEAMINE COMPOUND | TAKEDA PHARMACEUTICAL (JP) | 2016-05-12 | — | — | US | disclosed |
| EP-3018123-A1 | AMIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2016-05-11 | — | — | EP | disclosed |
| EP-3018126-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2016-05-11 | — | — | EP | disclosed |
| EP-3015488-A1 | PRODUCTION METHOD FOR POLYAMINO ACID | Takeda Pharmaceutical Company Limited (JP) | 2016-05-04 | — | — | EP | disclosed |
| US-20160115128-A1 | AROMATIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-04-28 | — | — | US | disclosed |
| US-9321757-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-04-26 | — | — | US | disclosed |
| US-9315458-B2 | Nitrogen-containing heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY, LIMITED (JP) | 2016-04-19 | — | — | US | disclosed |
| EP-3006031-A1 | PYRIDAZINONE COMPOUNDS | Takeda Pharmaceutical Company Limited (JP) | 2016-04-13 | — | — | EP | disclosed |
| EP-3004155-A1 | PEPTIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2016-04-13 | — | — | EP | disclosed |
| CN-102743330-B | Pharmaceutical composition | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2016-03-23 | — | — | CN | disclosed |
| US-9278931-B2 | Cyclopropaneamine compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-03-08 | — | — | US | disclosed |
| US-20160060273-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-03-03 | — | — | US | disclosed |
| CN-105358544-A | Heterocyclic compound | TAKEDA PHARMACEUTICAL | 2016-02-24 | — | — | CN | disclosed |
| US-9266831-B2 | Process for producing pyrrole compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-02-23 | — | — | US | disclosed |
| EP-2258676-B1 | STABLE VINAMIDINIUM SALT AND NITROGEN-CONTAINING HETEROCYCLIC RING SYNTHESIS USING THE SAME | TAKEDA PHARMACEUTICAL (JP) | 2016-02-17 | — | — | EP | disclosed |
| WO-2016021742-A1 | HETEROCYCLIC COMPOUNDS AS EP4 RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-02-11 | — | — | WO | disclosed |
| EP-2970331-A1 | SPIRO AZETIDINE ISOXAZOLE DERIVATIVES AND THEIR USE AS SSTR5 ANTAGONISTS | Takeda Pharmaceutical Company Limited (JP) | 2016-01-20 | — | — | EP | disclosed |
| EP-2975031-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2016-01-20 | — | — | EP | disclosed |
| US-20160009646-A1 | METHOD FOR PRODUCING SULFONYL CHLORIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-01-14 | — | — | US | disclosed |
| EP-2308960-B1 | CELL ADHESION PROMOTING AGENT AND METHOD OF PROMOTING CELL ADHESION | UNIV KYOTO (JP) | 2016-01-13 | — | — | EP | disclosed |
| WO-2016002968-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS RETINOID-RELATED ORPHAN RECEPTOR (ROR) GAMMA-T INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-01-07 | — | — | WO | disclosed |
| US-20160002169-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-01-07 | — | — | US | disclosed |
| EP-2963019-A1 | METHOD FOR PRODUCING SULFONYL CHLORIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2016-01-06 | — | — | EP | disclosed |
| US-9226921-B2 | Fused heterocyclic compounds as phosphodiesterases (PDES) inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-01-05 | — | — | US | disclosed |
| CN-105209485-A | Peptide compounds | TAKEDA PHARMACEUTICAL | 2015-12-30 | — | — | CN | disclosed |
| WO-2015190613-A1 | RADIOLABELED COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-12-17 | — | — | WO | disclosed |
| US-20150353578-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-12-10 | — | — | US | disclosed |
| CN-105143187-A | Method for producing sulfonyl chloride compound | TAKEDA PHARMACEUTICAL | 2015-12-09 | — | — | CN | disclosed |
| US-9199963-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-12-01 | — | — | US | disclosed |
| US-9200051-B2 | Peptide compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-12-01 | — | — | US | disclosed |
| US-9186411-B2 | Pharmaceutical composition | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-11-17 | — | — | US | disclosed |
| CN-105051005-A | Cyclopropylamine compound and use thereof | TAKEDA PHARMACEUTICAL | 2015-11-11 | — | — | CN | disclosed |
| US-20150313881-A1 | Therapeutic Methods for Type I Diabetes | UNIVERSITY OF MASSACHUSETTS | 2015-11-05 | — | — | US | disclosed |
| EP-2393360-B1 | PYRIDAZINONE COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2015-11-04 | — | — | EP | disclosed |
| WO-2015163485-A1 | ISOINDOLINE-1-ONE DERIVATIVES AS CHOLINERGIC MUSCARINIC M1 RECEPTOR POSITIVE ALLOESTERIC MODULATOR ACTIVITY FOR THE TREATMENT OF ALZHEIMERS DISEASE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-10-29 | — | — | WO | disclosed |
| US-20150307451-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-10-29 | — | — | US | disclosed |
| US-20150291577-A1 | CYCLOPROPANAMINE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-10-15 | — | — | US | disclosed |
| WO-2015156417-A1 | CYCLOPROPANAMINE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-10-15 | — | — | WO | disclosed |
| US-9156837-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-10-13 | — | — | US | disclosed |
| EP-2540719-B1 | CYCLIC AMINE COMPOUND AND ACARICIDE | NIPPON SODA CO (JP) | 2015-10-07 | — | — | EP | disclosed |
| US-9150591-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-10-06 | — | — | US | disclosed |
| US-9150588-B2 | Substituted pyridazin-4(1H)-ones as phosphodiesterase 10A inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-10-06 | — | — | US | disclosed |
| US-20150266881-A1 | CYCLOPROPANAMINE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-09-24 | — | — | US | disclosed |
| EP-2336107-B1 | Proton pump inhibitors | TAKEDA PHARMACEUTICAL (JP) | 2015-09-23 | — | — | EP | disclosed |
| CN-104926837-A | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL | 2015-09-23 | — | — | CN | disclosed |
| US-9120777-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-09-01 | — | — | US | disclosed |
| WO-2015122187-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-08-20 | — | — | WO | disclosed |
| WO-2015122188-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-08-20 | — | — | WO | disclosed |
| EP-2907802-A1 | CYCLOPROPANAMINE COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2015-08-19 | — | — | EP | disclosed |
| US-20150225354-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-08-13 | — | — | US | disclosed |
| US-20150225361-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-08-13 | — | — | US | disclosed |
| US-9090586-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-07-28 | — | — | US | disclosed |
| CN-104784180-A | Pharmaceutical composition | TAKEDA PHARMACEUTICAL | 2015-07-22 | — | — | CN | disclosed |
| WO-2015099196-A1 | 4-(PIPERRAZIN-1-YL)-PYRROLIDIN-2-ONE COMPOUNDS AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-07-02 | — | — | WO | disclosed |
| US-20150165027-A1 | LIQUID PREPARATIONS OF AMINES AND ORGANIC ACIDS STABILIZED BY SALTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-06-18 | — | — | US | disclosed |
| CN-103180326-B | Heterocyclic compounds and their use | TAKEDA PHARMACEUTICAL | 2015-06-10 | — | — | CN | disclosed |
| US-9044483-B2 | Cell death inhibition by macrophage migration inhibitory factor and a binding substance thereto | TAKEDA PHARMACEUTICALS COMPANY LIMITED (JP) | 2015-06-02 | — | — | US | disclosed |
| WO-2015068856-A1 | PYRAZOLE FOR THE TREATMENT AUTOIMMUNE DISORDERS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-05-14 | — | — | WO | disclosed |
| US-20150133451-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-05-14 | — | — | US | disclosed |
| US-9029536-B2 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-05-12 | — | — | US | disclosed |
| US-9029388-B2 | Condensed heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-05-12 | — | — | US | disclosed |
| WO-2015064083-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-05-07 | — | — | WO | disclosed |
| EP-2866788-A1 | LIQUID PREPARATIONS OF AMINES AND ORGANIC ACIDS STABILIZED BY SALTS | Takeda Pharmaceutical Company Limited (JP) | 2015-05-06 | — | — | EP | disclosed |
| US-20150119412-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-04-30 | — | — | US | disclosed |
| CN-104582687-A | Liquid formulations of amines and organic acids stabilized with salts | TAKEDA PHARMACEUTICAL | 2015-04-29 | — | — | CN | disclosed |
| WO-2015052910-A1 | ANTAGONISTS OF SOMATOSTATIN RECEPTOR SUBTYPE 5 (SSTR5) | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-04-16 | — | — | WO | disclosed |
| US-20150099777-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-04-09 | — | — | US | disclosed |
| US-20150099757-A1 | PYRIDAZINONE COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS AND METHODS OF TREATING DISORDERS | TAKEDA PHARMACEUTICAL (JP) | 2015-04-09 | — | — | US | disclosed |
| US-8980912-B2 | Cyclic amine compound and acaricide | NIPPON SODA CO., LTD. (JP) | 2015-03-17 | — | — | US | disclosed |
| US-20150073137-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2015-03-12 | — | — | US | disclosed |
| EP-2003124-B1 | Semi-synthesis of taxane intermediates from 9-dihydro-13-acetylbaccatin III | CHATHAM BIOTEC LTD (CA) | 2015-02-25 | — | — | EP | disclosed |
| US-20150051197-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-02-19 | — | — | US | disclosed |
| US-8957069-B2 | Benzofuran derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-02-17 | — | — | US | disclosed |
| US-20150045351-A1 | TRICYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-02-12 | — | — | US | disclosed |
| US-8940758-B2 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-01-27 | — | — | US | disclosed |
| WO-2015005489-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-01-15 | — | — | WO | disclosed |
| EP-2824106-A1 | TRICYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2015-01-14 | — | — | EP | disclosed |
| US-8933105-B2 | Pyrrole compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-01-13 | — | — | US | disclosed |
| US-8916566-B2 | Pyridazinone compounds as phosphodiesterase inhibitors and methods of treating disorders | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-12-23 | — | — | US | disclosed |
| US-8916551-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-12-23 | — | — | US | disclosed |
| EP-2813508-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2014-12-17 | — | — | EP | disclosed |
| US-20140357552-A1 | PEPTIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-12-04 | — | — | US | disclosed |
| WO-2014192284-A1 | PEPTIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-12-04 | — | — | WO | disclosed |
| US-8895588-B2 | Pyrazole compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-11-25 | — | — | US | disclosed |
| US-20140343070-A1 | PROTON PUMP INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-11-20 | — | — | US | disclosed |
| EP-2271624-B9 | IMINOPYRIDINE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2014-11-12 | — | — | EP | disclosed |
| US-8883788-B2 | Fused heterocyclic ring compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-11-11 | — | — | US | disclosed |
| US-20140303378-A1 | PROCESS FOR PRODUCING PYRROLE COMPOUND | TAKEDA PHARMACEUTICAL (JP) | 2014-10-09 | — | — | US | disclosed |
| US-8846713-B2 | Fused heterocyclic compounds as phosphodiesterases (PDEs) inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-09-30 | — | — | US | disclosed |
| EP-1814868-B1 | SEMI-SYNTHESIS OF TAXANE INTERMEDIATES AND THEIR CONVERSION TO PACLITAXEL AND DOCETAXEL | CHATHAM BIOTEC LTD (CA) | 2014-09-24 | — | — | EP | disclosed |
| EP-2781513-A1 | Benzofuran derivatives | Takeda Pharmaceutical Company Limited (JP) | 2014-09-24 | — | — | EP | disclosed |
| WO-2014142363-A1 | SPIRO AZETIDINE ISOXAZOLE DERIVATIVES AND THEIR USE AS SSTR5 ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-09-18 | — | — | WO | disclosed |
| US-8822694-B2 | Process for producing pyrrole compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-09-02 | — | — | US | disclosed |
| US-20140228405-A1 | CYCLOPROPANEAMINE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-08-14 | — | — | US | disclosed |
| US-20140228320-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASES (PDES) INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-08-14 | — | — | US | disclosed |
| EP-2765130-A2 | Process for producing pyrrole compound | Takeda Pharmaceutical Company Limited (JP) | 2014-08-13 | — | — | EP | disclosed |
| CN-103965147-A | Benzofuran derivatives | TAKEDA PHARMACEUTICAL | 2014-08-06 | — | — | CN | disclosed |
| US-8778871-B2 | Metastin derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-07-15 | — | — | US | disclosed |
| US-8778944-B2 | Pyridazinone compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-07-15 | — | — | US | disclosed |
| US-8778934-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-07-15 | — | — | US | disclosed |
| EP-2748158-A1 | RADIOLABELED COMPOUNDS AND THEIR USE AS RADIOTRACERS FOR QUANTITATIVE IMAGING OF PHOSPHODIESTERASE (PDE10A) IN MAMMALS | Takeda Pharmaceutical Company Limited (JP) | 2014-07-02 | — | — | EP | disclosed |
| US-8765909-B2 | Metastin derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-07-01 | — | — | US | disclosed |
| US-20140178304-A1 | RADIOLABELED COMPOUNDS AND THEIR USE AS RADIOTRACERS FOR QUANTITATIVE IMAGING OF PHOSPHODIESTERASE (PDE10A) IN MAMMALS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-06-26 | — | — | US | disclosed |
| EP-2743256-A1 | CYCLOPROPANEAMINE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2014-06-18 | — | — | EP | disclosed |
| CN-102421767-B | Benzofuran derivatives | TAKEDA PHARMACEUTICAL | 2014-06-18 | — | — | CN | disclosed |
| US-20140163001-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-06-12 | — | — | US | disclosed |
| EP-2327692-B9 | 1-heterocyclylsulfonyl, 2-aminomethyl, 5-(hetero-)aryl substituted 1-H-pyrrole derivatives as acid secretion inhibitors | TAKEDA PHARMACEUTICAL (JP) | 2014-06-04 | — | — | EP | disclosed |
| EP-2738170-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2014-06-04 | — | — | EP | disclosed |
| CN-103842332-A | Cyclopropaneamine compound | TAKAEDA CHEMICAL IND LTD | 2014-06-04 | — | — | CN | disclosed |
| EP-2271624-B1 | IMINOPYRIDINE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2014-05-21 | — | — | EP | disclosed |
| EP-2406243-B1 | BENZOFURAN DERIVATIVES | TAKEDA PHARMACEUTICAL (JP) | 2014-05-07 | — | — | EP | disclosed |
| US-20140080817-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-03-20 | — | — | US | disclosed |
| EP-2694472-A2 | SULFONAMIDE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2014-02-12 | — | — | EP | disclosed |
| US-20140024650-A1 | SULFONAMIDE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-01-23 | — | — | US | disclosed |
| EP-2687529-A1 | CONDENSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2014-01-22 | — | — | EP | disclosed |
| WO-2014003199-A1 | LIQUID PREPARATIONS OF AMINES AND ORGANIC ACIDS STABILIZED BY SALTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-01-03 | — | — | WO | disclosed |
| US-20130331409-A1 | CONDENSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-12-12 | — | — | US | disclosed |
| EP-2091932-B1 | SEMI-SYNTHESIS AND ISOLATION OF TAXANE INTERMEDIATES FROM A MIXTURE OF TAXANES | CHATHAM BIOTEC LTD (CA) | 2013-12-11 | — | — | EP | disclosed |
| EP-1944290-B1 | NOVEL 1-2-DIHYDROQUINOLINE DERIVATIVE HAVING GLUCOCORTICOID RECEPTOR BINDING ACTIVITY | SANTEN PHARMACEUTICAL CO LTD (JP) | 2013-12-04 | — | — | EP | disclosed |
| US-8592379-B2 | Metastin derivative and use thereof | KYOTO UNIVERSITY (JP) | 2013-11-26 | — | — | US | disclosed |
| US-8592454-B2 | Nitrogen-containing heterocyclic compound and use of same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-11-26 | — | — | US | disclosed |
| US-20130303553-A1 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2013-11-14 | — | — | US | disclosed |
| US-8575154-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-11-05 | — | — | US | disclosed |
| US-8563575-B2 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-10-22 | — | — | US | disclosed |
| US-20130261156-A1 | PHARMACEUTICAL COMPOSITION | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-10-03 | — | — | US | disclosed |
| US-8513251-B2 | Pyridazinone compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-08-20 | — | — | US | disclosed |
| US-8501812-B2 | Therapeutic methods for type I diabetes | UNIVERSITY OF MASSACHUSETTS (US) | 2013-08-06 | — | — | US | disclosed |
| US-20130190291-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-07-25 | — | — | US | disclosed |
| US-20130184266-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-07-18 | — | — | US | disclosed |
| US-8481569-B2 | Iminopyridine derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-07-09 | — | — | US | disclosed |
| US-20130172328-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASES (PDES) INHIBITORS | CROSSWING INC. (CA) | 2013-07-04 | — | — | US | disclosed |
| US-20130172292-A1 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-07-04 | — | — | US | disclosed |
| CN-103180326-A | Heterocyclic compounds and their use | TAKEDA PHARMACEUTICAL | 2013-06-26 | — | — | CN | disclosed |
| US-8470816-B2 | Nitrogen-containing heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-06-25 | — | — | US | disclosed |
| EP-2604597-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2013-06-19 | — | — | EP | disclosed |
| EP-2603513-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2013-06-19 | — | — | EP | disclosed |
| US-20130150344-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-06-13 | — | — | US | disclosed |
| EP-2602254-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2013-06-12 | — | — | EP | disclosed |
| EP-2602255-A1 | FUSED HETEROCYCLIC RING COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2013-06-12 | — | — | EP | disclosed |
| EP-2601192-A1 | FUSED HETEROCYCLIC COMPOUNDS | Takeda Pharmaceutical Company Limited (JP) | 2013-06-12 | — | — | EP | disclosed |
| CN-103153995-A | Fused heterocyclic compounds as phosphodiesterases (PDES) inhibitors | TAKEDA PHARMACEUTICAL | 2013-06-12 | — | — | CN | disclosed |
| US-20130137700-A1 | FUSED HETEROCYCLIC RING COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-30 | — | — | US | disclosed |
| US-20130137675-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-30 | — | — | US | disclosed |
| US-8436187-B2 | 1-heterocyclylsulfonyl, 3-aminomethyl, 5- (hetero-) aryl substituted 1-H-pyrrole derivatives as acid secretion inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-07 | — | — | US | disclosed |
| US-8435995-B2 | Pyridazinone compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-07 | — | — | US | disclosed |
| EP-2585462-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASES (PDES) INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2013-05-01 | — | — | EP | disclosed |
| EP-1637527-B1 | CANNABINOID RECEPTOR MODULATOR | TAKEDA PHARMACEUTICAL (JP) | 2013-04-17 | — | — | EP | disclosed |
| US-8420635-B2 | Method for preventing or treating a glucocorticoid receptor-related disease | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2013-04-16 | — | — | US | disclosed |
| US-8415368-B2 | Acid secretion inhibitor | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-04-09 | — | — | US | disclosed |
| US-8404643-B2 | Metastin derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-03-26 | — | — | US | disclosed |
| EP-2564833-A1 | Photostabilized pharmaceutical composition | Takeda Pharmaceutical Company Limited (JP) | 2013-03-06 | — | — | EP | disclosed |
| WO-2013027845-A1 | RADIOLABELED COMPOUNDS AND THEIR USE AS RADIOTRACERS FOR QUANTITATIVE IMAGING OF PHOSPHODIESTERASE (PDE10A) IN MAMMALS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-02-28 | — | — | WO | disclosed |
| WO-2012137982-A9 | SULFONAMIDE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-02-14 | — | — | WO | disclosed |
| US-8373007-B2 | Stable vinamidinium salt and nitrogen-containing heterocyclic ring synthesis using the same | TAKEDA PHARMACEUTICAL COMPANY LTD. (JP) | 2013-02-12 | — | — | US | disclosed |
| US-8361968-B2 | Metastin derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-01-29 | — | — | US | disclosed |
| US-8354411-B2 | 1-phenyl-3-pyrazolylpyridazin-4(1H)-one compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-01-15 | — | — | US | disclosed |
| US-20130005710-A1 | AMINOPYRIDINE DERIVATIVE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-01-03 | — | — | US | disclosed |
| EP-2540719-A1 | CYCLIC AMINE COMPOUND AND MITICIDE | Nippon Soda Co., Ltd. (JP) | 2013-01-02 | — | — | EP | disclosed |
| EP-1803709-B1 | PROTON PUMP INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2013-01-02 | — | — | EP | disclosed |
| CN-1816536-B | Cannabinoid receptor modulators | TAKAEDA CHEMICAL IND LTD | 2012-12-26 | — | — | CN | disclosed |
| US-8338462-B2 | 1-heterocyclylsulfonyl, 3-aminomethyl, 5- (hetero-) aryl substituted 1-H-pyrrole derivatives as acid secretion inhibitors | TAKEDA PHARMACEUTICALS COMPANY LIMITED (JP) | 2012-12-25 | — | — | US | disclosed |
| US-8338461-B2 | 1-heterocyclylsulfonyl, 3-aminomethyl, 5-(hetero-)aryl substituted 1-H-pyrrole derivatives as acid secretion inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-12-25 | — | — | US | disclosed |
| US-8334301-B2 | 5-Membered heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-12-18 | — | — | US | disclosed |
| US-20120309964-A1 | CYCLIC AMINE COMPOUND AND ACARICIDE | NIPPON SODA CO., LTD | 2012-12-06 | — | — | US | disclosed |
| US-20120277431-A1 | PYRIDAZINONE COMPOUNDS | TANIGUCHI TAKAHIKO (GB) | 2012-11-01 | — | — | US | disclosed |
| US-20120277204-A1 | PYRIDAZINONE COMPOUNDS | TANIGUCHI TAKAHIKO (GB) | 2012-11-01 | — | — | US | disclosed |
| US-20120277430-A1 | PYRIDAZINONE COMPOUNDS | TANIGUCHI TAKAHIKO (GB) | 2012-11-01 | — | — | US | disclosed |
| EP-2518054-A1 | AMIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2012-10-31 | — | — | EP | disclosed |
| US-8299261-B2 | 1-heterocyclylsulfonyl, 3-aminomethyl, 5-(hetero-) aryl substituted 1-H-pyrrole derivatives as acid secretion inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-30 | — | — | US | disclosed |
| CN-102743330-A | Pharmaceutical composition | TAKEDA PHARMACEUTICAL | 2012-10-24 | — | — | CN | disclosed |
| US-8293930-B1 | One pot synthesis of taxane derivatives and their conversion to paclitaxel and docetaxel | CHATHAM BIOTEC, LIMITED (CA) | 2012-10-23 | — | — | US | disclosed |
| US-8288390-B2 | Benzofuran derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-16 | — | — | US | disclosed |
| WO-2012137982-A2 | SULFONAMIDE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-11 | — | — | WO | disclosed |
| EP-2502909-A1 | AMINOPYRIDINE DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2012-09-26 | — | — | EP | disclosed |
| US-20120232095-A1 | BENZOFURAN DERIVATIVES | TSUKAMOTO TETSUYA (JP) | 2012-09-13 | — | — | US | disclosed |
| US-20120232096-A1 | BENZOFURAN DERIVATIVES | TSUKAMOTO TETSUYA (JP) | 2012-09-13 | — | — | US | disclosed |
| US-20120208846-A1 | Therapeutic Methods For Type I Diabetes | UNIVERSITY OF MASSACHUSETTS | 2012-08-16 | — | — | US | disclosed |
| EP-1797058-B1 | SEMI-SYNTHETIC CONVERSION OF PACLITAXEL TO DOCETAXEL | CHATHAM BIOTEC LTD (CA) | 2012-08-15 | — | — | EP | disclosed |
| EP-2327692-B1 | 1-heterocyclylsulfonyl, 2-aminomethyl, 5-(hetero-)aryl substituted 1-H-pyrrole derivatives as acid secretion inhibitors | TAKEDA PHARMACEUTICAL (JP) | 2012-07-18 | — | — | EP | disclosed |
| EP-2005957-B1 | ACID SECRETION INHIBITOR | TAKEDA PHARMACEUTICAL (JP) | 2012-05-30 | — | — | EP | disclosed |
| US-20120095057-A1 | PYRAZOLE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-19 | — | — | US | disclosed |
| CN-102421767-A | Benzofuran derivatives | TAKEDA PHARMACEUTICAL | 2012-04-18 | — | — | CN | disclosed |
| US-20120088797-A1 | 1-HETEROCYCLYLSULFONYL, 3-AMINOMETHYL, 5- (HETERO-) ARYL SUBSTITUTED 1-H-PYRROLE DERIVATIVES AS ACID SECRETION INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-12 | — | — | US | disclosed |
| US-20120077799-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-29 | — | — | US | disclosed |
| US-20120046277-A1 | BENZOFURAN DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-02-23 | — | — | US | disclosed |
| WO-2012020848-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-02-16 | — | — | WO | disclosed |
| WO-2012018909-A1 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-02-09 | — | — | WO | disclosed |
| US-20120028951-A1 | PYRIDAZINONE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-02-02 | — | — | US | disclosed |
| EP-2412713-A1 | PYRAZOLE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2012-02-01 | — | — | EP | disclosed |
| US-20120015868-A1 | Metastin derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-01-19 | — | — | US | disclosed |
| EP-2406243-A1 | BENZOFURAN DERIVATIVES | Takeda Pharmaceutical Company Limited (JP) | 2012-01-18 | — | — | EP | disclosed |
| EP-2402313-A1 | PROCESS FOR PRODUCING PYRROLE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2012-01-04 | — | — | EP | disclosed |
| WO-2011163355-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASES (PDES) INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-12-29 | — | — | WO | disclosed |
| US-20110319394-A1 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-12-29 | — | — | US | disclosed |
| US-20110312898-A1 | PROPHYLACTIC / THERAPEUTIC AGENT FOR CANCER | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-12-22 | — | — | US | disclosed |
| US-20110306769-A1 | PROCESS FOR PRODUCING PYRROLE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-12-15 | — | — | US | disclosed |
| EP-2393360-A1 | PYRIDAZINONE COMPOUNDS | Takeda Pharmaceutical Company Limited (JP) | 2011-12-14 | — | — | EP | disclosed |
| US-20110301174-A1 | 1-HETEROCYCLYLSULFONYL, 3-AMINOMETHYL, 5- (HETERO-) ARYL SUBSTITUTED 1-H-PYRROLE DERIVATIVES AS ACID SECRETION INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-12-08 | — | — | US | disclosed |
| US-20110301173-A1 | 1-HETEROCYCLYLSULFONYL, 3-AMINOMETHYL, 5- (HETERO-) ARYL SUBSTITUTED 1-H-PYRROLE DERIVATIVES AS ACID SECRETION INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-12-08 | — | — | US | disclosed |
| US-20110288040-A1 | ARYL- OR HETEROARYL-SULFONYL COMPOUNDS AS ACID SECRETION INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-11-24 | — | — | US | disclosed |
| US-8057990-B2 | Prevent, therapy for cancer; complex of tacrine compound and protein | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-11-15 | — | — | US | disclosed |
| EP-2385032-A1 | GPR40 Receptor function regulator | Takeda Pharmaceutical Company Limited (JP) | 2011-11-09 | — | — | EP | disclosed |
| US-8048909-B2 | Proton pump inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-11-01 | — | — | US | disclosed |
| US-20110263589-A1 | Method for preventing or treating a glucocorticoid receptor-related disease | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-10-27 | — | — | US | disclosed |
| EP-2379053-A1 | PROPHYLACTIC/THERAPEUTIC AGENT FOR CANCER | Takeda Pharmaceutical Company Limited (JP) | 2011-10-26 | — | — | EP | disclosed |
| EP-1787991-B1 | PYRROLO[2,3-c]PYRIDINE COMPOUND, PROCESS FOR PRODUCING THE SAME, AND USE | TAKEDA PHARMACEUTICAL (JP) | 2011-10-05 | — | — | EP | disclosed |
| CN-101300229-B | 1-heterocyclylsulfonyl, 2-aminomethyl, 5- (hetero-) aryl substituted 1-h-pyrrole derivatives as acid secretion inhibitors | TAKEDA PHARMACEUTICAL | 2011-10-05 | — | — | CN | disclosed |
| EP-2364979-A1 | Pyrrole compounds | Takeda Pharmaceutical Company Limited (JP) | 2011-09-14 | — | — | EP | disclosed |
| US-8017775-B2 | 1-2-dihydroquinoline derivative having glucocorticoid receptor binding activity | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-09-13 | — | — | US | disclosed |
| US-8008525-B2 | For the 14273 peroxisome proliferator activated receptor; antidiabetic agents, hyperlipidemia, obesity or anorexia; receptor binding assay; drug screening kits | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-08-30 | — | — | US | disclosed |
| CN-102164581-A | Pharmaceutical composition | TAKEDA PHARMACEUTICAL | 2011-08-24 | — | — | CN | disclosed |
| US-7994205-B2 | Aryl-or heteroaryl-sulfonyl compounds as acid secretion inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-08-09 | — | — | US | disclosed |
| US-7985863-B2 | Iminopyridine derivatives and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-07-26 | — | — | US | disclosed |
| US-7985862-B2 | Iminopyridine derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-07-26 | — | — | US | disclosed |
| US-20110178060-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-07-21 | — | — | US | disclosed |
| US-7982044-B2 | Iminopyridine derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-07-19 | — | — | US | disclosed |
| US-7977488-B2 | 1-heterocyclylsulfonyl, 2-aminomethyl, 5-(hetero-) aryl substituted 1-H-pyrrole derivatives as acid secretion inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-07-12 | — | — | US | disclosed |
| EP-2336105-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME | Takeda Pharmaceutical Company Limited (JP) | 2011-06-22 | — | — | EP | disclosed |
| EP-2336107-A2 | Proton pump inhibitors | Takeda Pharmaceutical Company Limited (JP) | 2011-06-22 | — | — | EP | disclosed |
| US-20110144161-A1 | 1-HETEROCYCLYLSULFONYL, 2-AMINOMETHYL, 5- (HETERO-) ARYL SUBSTITUTED 1-H-PYRROLE DERIVATIVES AS ACID SECRETION INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-06-16 | — | — | US | disclosed |
| US-7960369-B2 | Receptor function regulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-06-14 | — | — | US | disclosed |
| US-7960348-B2 | Metastin derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-06-14 | — | — | US | disclosed |
| US-20110130384-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-06-02 | — | — | US | disclosed |
| EP-2327692-A1 | 1-heterocyclylsulfonyl, 2-aminomethyl, 5-(hetero-)aryl substituted 1-H-pyrrole derivatives as acid secretion inhibitors | Takeda Pharmaceutical Company Limited (JP) | 2011-06-01 | — | — | EP | disclosed |
| US-7951548-B2 | IL-13 production inhibitor | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-31 | — | — | US | disclosed |
| US-20110124876-A1 | IMINOPYRIDINE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-26 | — | — | US | disclosed |
| US-20110124874-A1 | IMINOPYRIDINE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-26 | — | — | US | disclosed |
| US-20110124875-A1 | IMINOPYRIDINE DERIVATIVES AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-26 | — | — | US | disclosed |
| US-20110124687-A1 | PHARMACEUTICAL COMPOSITION | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-26 | — | — | US | disclosed |
| EP-2323978-A1 | AMIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2011-05-25 | — | — | EP | disclosed |
| US-20110118172-A1 | METASTIN DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-19 | — | — | US | disclosed |
| US-20110117651-A1 | CELL ADHESION PROMOTING AGENT AND METHOD OF PROMOTING CELL ADHESION | KYOTO UNIVERSITY (JP) | 2011-05-19 | — | — | US | disclosed |
| CN-102066328-A | Iminopyridine derivative and use thereof | TAKEDA PHARMACEUTICAL | 2011-05-18 | — | — | CN | disclosed |
| EP-2309985-A2 | PHARMACEUTICAL COMPOSITION | Takeda Pharmaceutical Company Limited (JP) | 2011-04-20 | — | — | EP | disclosed |
| US-7927821-B2 | Methods of screening for compounds which bind G protein-coupled receptors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-04-19 | — | — | US | disclosed |
| EP-2308960-A1 | CELL ADHESION PROMOTING AGENT AND METHOD OF PROMOTING CELL ADHESION | Kyoto University (JP) | 2011-04-13 | — | — | EP | disclosed |
| EP-1919865-B1 | 1-HETEROCYCLYLSULFONYL, 2-AMINOMETHYL, 5- (HETERO-) ARYL SUBSTITUTED 1-H-PYRROLE DERIVATIVES AS ACID SECRETION INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2011-04-06 | — | — | EP | disclosed |
| EP-2305219-A1 | Pharmaceutical preparations coated with a copolyvidone-containing coating | Takeda Pharmaceutical Company Limited (JP) | 2011-04-06 | — | — | EP | disclosed |
| US-7919260-B2 | Therapy for psychological disorders; schizophrenia; cognition activators; Parkinson's disease; complex of protein and ligand | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-04-05 | — | — | US | disclosed |
| EP-2298731-A1 | AMIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2011-03-23 | — | — | EP | disclosed |
| US-7906661-B2 | Semi-synthetic conversion of paclitaxel to docetaxel | CHATHAM BIOTEC, LIMITED (CA) | 2011-03-15 | — | — | US | disclosed |
| US-20110059888-A1 | METASTIN DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-03-10 | — | — | US | disclosed |
| US-7897572-B1 | Theraputic methods for type I diabetes | UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL (US) | 2011-03-01 | — | — | US | disclosed |
| US-7893283-B2 | Protected taxane chemical intermediates ; one step; using beta-lactam, oxazolidine or oxazoline | CHATHAM BIOTEC, LIMITED (CA) | 2011-02-22 | — | — | US | disclosed |
| US-20110039786-A1 | METASTIN DERIVATIVE AND USE THEREOF | KYOTO UNIVERSITY (JP) | 2011-02-17 | — | — | US | disclosed |
| US-20110039846-A1 | IMINOPYRIDINE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-02-17 | — | — | US | disclosed |
| US-20110039892-A1 | IMINOPYRIDINE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-02-17 | — | — | US | disclosed |
| US-20110034464-A1 | IMINOPYRIDINE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-02-10 | — | — | US | disclosed |
| US-20110028476-A1 | PROTON PUMP INHIBITORS | KAJINO MASAHIRO | 2011-02-03 | — | — | US | disclosed |
| EP-2277900-A1 | METASTIN DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2011-01-26 | — | — | EP | disclosed |
| US-20110015399-A1 | STABLE VINAMIDINIUM SALT AND NITROGEN-CONTAINING HETEROCYCLIC RING SYNTHESIS USING THE SAME | TAKEDA PHARMACEUTICAL COMPANY LTD. (JP) | 2011-01-20 | — | — | US | disclosed |
| EP-2275433-A1 | METASTIN DERIVATIVE AND USE THEREOF | Kyoto University (JP) | 2011-01-19 | — | — | EP | disclosed |
| EP-2271624-A1 | IMINOPYRIDINE DERIVATIVES AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2011-01-12 | — | — | EP | disclosed |
| EP-2269989-A1 | IMINOPYRIDINE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2011-01-05 | — | — | EP | disclosed |
| US-20100331520-A1 | METASTIN DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-12-30 | — | — | US | disclosed |
| EP-2258676-A1 | STABLE VINAMIDINIUM SALT AND NITROGEN-CONTAINING HETEROCYCLIC RING SYNTHESIS USING THE SAME | Takeda Pharmaceutical Company Limited (JP) | 2010-12-08 | — | — | EP | disclosed |
| US-7838694-B2 | Semi-synthesis and isolation of taxane intermediates from a mixture of taxanes | CHATHAM BIOTEC, LIMITED (CA) | 2010-11-23 | — | — | US | disclosed |
| US-20100240743-A1 | CANNABINOID RECEPTOR MODULATOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-23 | — | — | US | disclosed |
| US-20100234357-A1 | Benzofuran derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-16 | — | — | US | disclosed |
| WO-2010104194-A1 | BENZOFURAN DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-16 | — | — | WO | disclosed |
| US-7795267-B2 | Bicyclic piperazine compound having TGR23 antagonistic activity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-14 | — | — | US | disclosed |
| EP-1285651-B1 | MELANIN CONCENTRATING HORMONE ANTAGONISTS | TAKEDA PHARMACEUTICAL (JP) | 2010-09-01 | — | — | EP | disclosed |
| US-7786083-B2 | Metastin derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-31 | — | — | US | disclosed |
| US-20100210696-A1 | 5-MEMBERED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-19 | — | — | US | disclosed |
| WO-2010090737-A1 | PYRIDAZINONE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-12 | — | — | WO | disclosed |
| US-20100197651-A1 | Pyridazinone compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-05 | — | — | US | disclosed |
| US-7767665-B2 | 3-[6-(4-oxo-4H-1,3-benzothiazin-2-yl)-2-pyridyl]propionic acid, having an excellent apoptosis inhibitory and Macrophage migration inhibitory factor (MIF) binding effects, used for preventing and/or treating cancers, AIDS, cardiovascular, neurodegeneartive, bone, kidney and liver disoders | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-03 | — | — | US | disclosed |
| WO-2010076896-A1 | PROPHYLACTIC/THERAPEUTIC AGENT FOR CANCER | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-07-08 | — | — | WO | disclosed |
| US-7750037-B2 | Antidepressant | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-07-06 | — | — | US | disclosed |
| EP-2196459-A1 | 5-MEMBERED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2010-06-16 | — | — | EP | disclosed |
| EP-2190822-A2 | 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2010-06-02 | — | — | EP | disclosed |
| US-20100130737-A1 | Regulating Agent of GPR34 Receptor Function | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-27 | — | — | US | disclosed |
| CN-101058543-B | Process for producing amine derivatives | TAKEDA CHEMICAL INDUSTRIES LTD | 2010-05-26 | — | — | CN | disclosed |
| US-20100076005-A1 | ISOCARBOSTYRIL ALKALOID DERIVATIVES HAVING ANTI-PROLIFERATIVE AND ANTI-MIGRATORY ACTIVITIES | UNIBIOSCREEN SA (BE) | 2010-03-25 | — | — | US | disclosed |
| WO-2010018874-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | WO | disclosed |
| US-20100041891-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | US | disclosed |
| US-7659267-B2 | 1,3-Benzothiazinone derivatives, process for producing the same use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-09 | — | — | US | disclosed |
| WO-2010013823-A2 | PHARMACEUTICAL COMPOSITION | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-04 | — | — | WO | disclosed |
| US-20090326009-A1 | Novel 1-2-Dihydroquinoline Derivative Having Glucocorticoid Receptor Binding Activity | Santen Pharmaceutical Co., (JP) | 2009-12-31 | — | — | US | disclosed |
| US-20090318365-A1 | METASTIN DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-24 | — | — | US | disclosed |
| US-20090298765-A1 | Metastin derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-03 | — | — | US | disclosed |
| US-7625869-B2 | Metastin derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-01 | — | — | US | disclosed |
| US-7625696-B2 | Screening method | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-01 | — | — | US | disclosed |
| US-7622487-B2 | Piperidine derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-24 | — | — | US | disclosed |
| EP-2114917-A2 | PYRROLE COMPOUNDS | Takeda Pharmaceutical Company Limited (JP) | 2009-11-11 | — | — | EP | disclosed |
| US-20090275591-A1 | 1-HETEROCYCLYLSULFONYL, 2-AMINOMETHYL, 5- (HETERO-) ARYL SUBSTITUTED 1-H-PYRROLE DERIVATIVES AS ACID SECRETION INHIBITOR | TAKEDA PHARMACEUTICAL COMPANY LIMTED (JP) | 2009-11-05 | — | — | US | disclosed |
| US-20090274733-A1 | Pharmaceutical preparation containing copolyvidone | TAKEDA PHARMACEUTICAL COMPANY, LTD (JP) | 2009-11-05 | — | — | US | disclosed |
| EP-2113513-A2 | Metastin derivatives and use thereof | Takeda Pharmaceutical Company Limited (JP) | 2009-11-04 | — | — | EP | disclosed |
| US-20090270393-A1 | Iminopyridine Derivatives and Use Thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-29 | — | — | US | disclosed |
| US-20090270326-A1 | Cell Death Inhibitor | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-29 | — | — | US | disclosed |
| WO-2009131245-A1 | IMINOPYRIDINE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-29 | — | — | WO | disclosed |
| CN-101565423-A | Thienopyridine derivatives, production method and use thereof | TAKEDA PHARMACEUTICAL (JP) | 2009-10-28 | — | — | CN | disclosed |
| US-7608627-B2 | I kappa B kinase inhibition; diabetes; (7-Chloro-1H-pyrrolo[2,3-c]pyridin-2-yl)methanol; N-Benzyl-7-chloro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-27 | — | — | US | disclosed |
| US-7601868-B2 | Such as 4-(cyclopropylmethoxy)-N-(2-{4-[1-(1-pyrrolidinyl)ethyl]phenyl}ethyl)benzamide having melanin-concentrating hormone antagonistic action, for prophylaxis and/or treatment of obesity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-13 | — | — | US | disclosed |
| US-7585986-B2 | Semi-synthesis of taxane intermediates and aziridine analogues and their conversion to paclitaxel and docetaxel | CHATHAM BIOTEC, LIMITED (CA) | 2009-09-08 | — | — | US | disclosed |
| US-20090215700-A1 | Metastin derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-08-27 | — | — | US | disclosed |
| EP-2091932-A1 | SEMI-SYNTHESIS AND ISOLATION OF TAXANE INTERMEDIATES FROM A MIXTURE OF TAXANES | Chatham Biotec Ltd. (CA) | 2009-08-26 | — | — | EP | disclosed |
| EP-1348706-B1 | SUBSTITUTED THIAZOLE DERIVATIVES BEARING 3-PYRIDYL GROUPS, PROCESS FOR PREPARING THE SAME AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2009-08-19 | — | — | EP | disclosed |
| EP-2089395-A2 | NEW ISOCARBOSTYRIL ALKALOID DERIVATIVES HAVING ANTI-PROLIFERATIVE AND ANTI-MIGRATORY ACTIVITIES | UnibioScreen S.A. (BE) | 2009-08-19 | — | — | EP | disclosed |
| WO-2009041705-A9 | 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2009-08-13 | — | — | WO | disclosed |
| EP-2081955-A1 | METASTIN DERIVATIVES AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2009-07-29 | — | — | EP | disclosed |
| US-20090186874-A1 | Carboxamide derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-07-23 | — | — | US | disclosed |
| US-20090170116-A1 | IL-13 Production Inhibitor | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-07-02 | — | — | US | disclosed |
| CN-101466666-A | Process for preparing organic oxides | TAKEDA PHARMACEUTICAL (JP) | 2009-06-24 | — | — | CN | disclosed |
| US-20090156646-A1 | PYRIDYLPHENOL COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
| US-20090156642-A1 | 5-Membered heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
| US-20090156572-A1 | Nitrogen-containing heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-06-18 | — | — | US | disclosed |
| WO-2009072643-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-11 | — | — | WO | disclosed |
| CN-100497345-C | 2, 3-dihydro-6-nitroimidazolo [2,1-b] oxazole compounds for the treatment of tuberculosis | OTSUKA PHARMA CO LTD (JP) | 2009-06-10 | — | — | CN | disclosed |
| US-20090143444-A1 | ACID SECRETION INHIBITOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-04 | — | — | US | disclosed |
| EP-2065053-A1 | CELL DEATH INHIBITOR | Takeda Pharmaceutical Company Limited (JP) | 2009-06-03 | — | — | EP | disclosed |
| EP-2003116-A9 | PROCESS FOR THE PRODUCTION OF ORGANIC OXIDES | Takeda Pharmaceutical Company Limited (JP) | 2009-05-20 | — | — | EP | disclosed |
| EP-1562927-B1 | THIO-ANALOGUES OF PACLITAXEL AND INTERMEDIATES THEREOF | CHATHAM BIOTEC LTD (CA) | 2009-05-13 | — | — | EP | disclosed |
| CN-100486957-C | Process for preparing amine derivatives | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2009-05-13 | — | — | CN | disclosed |
| US-20090118335-A1 | Acid Secretion Inhibitor | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-05-07 | — | — | US | disclosed |
| US-20090105152-A1 | METASTIN DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-04-23 | — | — | US | disclosed |
| US-7521545-B2 | Azo compounds and process for production thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-04-21 | — | — | US | disclosed |
| US-20090099334-A1 | METASTIN DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-04-16 | — | — | US | disclosed |
| US-20090093615-A1 | METASTIN DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-04-09 | — | — | US | disclosed |
| US-7514452-B2 | 2-furancarboxylic acid hydrazides and pharmaceutical compositions containing the same | DAINIPPON PHARMACEUTICAL CO., LTD (JP) | 2009-04-07 | — | — | US | disclosed |
| WO-2009041705-A2 | 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-04-02 | — | — | WO | disclosed |
| US-20090082343-A1 | 1,3-BENZOTHIAZINONE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-03-26 | — | — | US | disclosed |
| US-7507841-B2 | Carbamoylamino-substituted 2,3-dihydro-benzofurans, indoles and benzothiophenes, e.g., (+)-N-((3R)-3-(4-isopropylphenyl)-4,6,7-trimethyl-2,3-dihydro-1-benzofuran-5-yl)-3,3-dimethylbutanamide; cerebrovascular disorders | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-03-24 | — | — | US | disclosed |
| US-20090069228-A1 | Screening Method | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-03-12 | — | — | US | disclosed |
| US-7498337-B2 | Acid secretion inhibitor | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-03-03 | — | — | US | disclosed |
| US-20090054655-A1 | Process for the Production of Organic Oxides | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-02-26 | — | — | US | disclosed |
| US-7495018-B2 | Substituted 1,3-thiazole compounds, their production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-02-24 | — | — | US | disclosed |
| US-20090048307-A1 | 5-pyridyl-1, 3-azole compounds, process for producing the same and use there of | OHKAWA SHIGENORI | 2009-02-19 | — | — | US | disclosed |
| US-20090029975-A1 | 1,3-BENZOTHIAZINONE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-01-29 | — | — | US | disclosed |
| US-20090023800-A1 | Cannabinoid receptor modulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-01-22 | — | — | US | disclosed |
| EP-1323716-B1 | PROMOTERS FOR THE PROLIFERATION AND DIFFERENTIATION OF STEM CELLS AND/OR NEURON PRECURSOR CELLS | TAKEDA PHARMACEUTICAL (JP) | 2009-01-14 | — | — | EP | disclosed |
| US-20090012093-A1 | Receptor Function Regulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-01-08 | — | — | US | disclosed |
| US-20090012081-A1 | Agents for promoting the proliferation or differentiation of stem cells or neural progenitor cells | TAKEDA PHARMACEUTICAL COMPANY LTD. (JP) | 2009-01-08 | — | — | US | disclosed |
| EP-2005957-A1 | ACID SECRETION INHIBITOR | Takeda Pharmaceutical Company Limited (JP) | 2008-12-24 | — | — | EP | disclosed |
| US-20080312155-A1 | Metastin Derivatives and Use Thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-18 | — | — | US | disclosed |
| EP-2003124-A1 | Semi-synthesis of taxane intermediates from 9-dihydro-13-acetylbaccatin III | Chatham Biotec Ltd (CA) | 2008-12-17 | — | — | EP | disclosed |
| EP-2003116-A2 | PROCESS FOR THE PRODUCTION OF ORGANIC OXIDES | Takeda Pharmaceutical Company Limited (JP) | 2008-12-17 | — | — | EP | disclosed |
| US-7465815-B2 | Cannabinoid receptor modulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-16 | — | — | US | disclosed |
| US-20080305110-A1 | Novel Ligand of G Protein Coupled Receptor Protein and Use Thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-11 | — | — | US | disclosed |
| US-7456162-B2 | Benzofuran derivatives, their production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-11-25 | — | — | US | disclosed |
| US-20080280938-A1 | Screening Method | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-11-13 | — | — | US | disclosed |
| WO-2008133344-A2 | PIPERIDINE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-11-06 | — | — | WO | disclosed |
| US-20080275085-A1 | Piperidine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-11-06 | — | — | US | disclosed |
| EP-1270545-B1 | PROCESS FOR PRODUCING AMINE DERIVATIVES | TAKEDA PHARMACEUTICAL (JP) | 2008-11-05 | — | — | EP | disclosed |
| CN-101300229-A | 1-heterocyclylsulfonyl, 2-aminomethyl, 5- (hetero-) aryl substituted 1-h-pyrrole derivatives as acid secretion inhibitors | TAKEDA PHARMACEUTICAL (JP) | 2008-11-05 | — | — | CN | disclosed |
| US-20080262042-A1 | 1-[5-(2-Fluoropyridin-3-yl)-1-(phenylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine or a salt thereof; acid secretion inhibitor; potassium-competitive acid blocker | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-10-23 | — | — | US | disclosed |
| US-20080262250-A1 | Semi-Synthesis of Taxane Intermediates and Their Conversion to Paclitaxel and Docetaxel | CHATHAM BIOTEC, LIMITED (CA) | 2008-10-23 | — | — | US | disclosed |
| EP-1727810-B1 | SEMI-SYNTHESIS OF TAXANE INTERMEDIATES FROM 9-DIHYDRO-13-ACETYLBACCATIN III | CHATHAM BIOTEC LTD (CA) | 2008-10-01 | — | — | EP | disclosed |
| WO-2008108380-A2 | PYRROLE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-09-12 | — | — | WO | disclosed |
| EP-1963362-A1 | METASTIN DERIVATIVES AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2008-09-03 | — | — | EP | disclosed |
| US-7420070-B2 | Process for preparing optically active 2,3-dihydrobenzofuran compounds | TAKODA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-09-02 | — | — | US | disclosed |
| EP-1408036-B1 | PROCESS FOR PRODUCING BENZOFURAN DERIVATIVE | TAKEDA PHARMACEUTICAL (JP) | 2008-08-27 | — | — | EP | disclosed |
| EP-1666880-B1 | SCREENING METHOD | TAKEDA PHARMACEUTICAL (JP) | 2008-08-20 | — | — | EP | disclosed |
| US-20080176906-A1 | Substituted Pyrrole Derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-07-24 | — | — | US | disclosed |
| EP-1944290-A1 | NOVEL 1-2-DIHYDROQUINOLINE DERIVATIVE HAVING GLUCOCORTICOID RECEPTOR BINDING ACTIVITY | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2008-07-16 | — | — | EP | disclosed |
| US-7399759-B2 | 1, 3-benzothiazinone derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-07-15 | — | — | US | disclosed |
| US-20080167378-A1 | Receptor Function Regulation Agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-07-10 | — | — | US | disclosed |
| US-20080167314-A1 | Condensed Imidazole Compound And Use Thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-07-10 | — | — | US | disclosed |
| US-20080146824-A1 | Preparation of paclitaxel and docetaxel, 10-deacetylbaccatin III and baccatin III; antileukemic and tumor inhibitory activity | CHATHAM BIOTEC, LIMITED (CA) | 2008-06-19 | — | — | US | disclosed |
| US-20080146602-A1 | Thienopyridine Derivatives, Production Method and Use Thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-06-19 | — | — | US | disclosed |
| US-20080139639-A1 | 3-amino(alkyl)-substituted pyrrole compounds such as N-methyl-1-[1-(phenylsulfonyl)-5-(3-thienyl)-1H-pyrrol-3-yl]methanamine; peptic ulcer, Zollinger-Ellison syndrome, gastritis, gastroesophageal reflux disease, gastric cancer, ulcer caused by non-steroidal anti-inflammatory agent (NSAID) use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-06-12 | — | — | US | disclosed |
| EP-1786798-B1 | ONE POT SYNTHESIS OF TAXANE DERIVATIVES AND THEIR CONVERSION TO PACLITAXEL AND DOCETAXEL | CHATHAM BIOTEC LTD (CA) | 2008-06-11 | — | — | EP | disclosed |
| EP-1919865-A1 | 1-HETEROCYCLYLSULFONYL, 2-AMINOMETHYL, 5- (HETERO-) ARYL SUBSTITUTED 1-H-PYRROLE DERIVATIVES AS ACID SECRETION INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2008-05-14 | — | — | EP | disclosed |
| EP-1921066-A1 | PYRIDYLPHENOL COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2008-05-14 | — | — | EP | disclosed |
| WO-2008050897-A1 | METASTIN DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-05-02 | — | — | WO | disclosed |
| WO-2008043846-A2 | NEW ISOCARBOSTYRIL ALKALOID DERIVATIVES HAVING ANTI-PROLIFERATIVE AND ANTI-MIGRATORY ACTIVITIES | UNIBIOSCREEN SA (BE) | 2008-04-17 | — | — | WO | disclosed |
| EP-1910292-A1 | PIPERIDINE DERIVATIVE AS TACHYKININ RECEPTOR ANTAGONIST | Takeda Pharmaceutical Company Limited (JP) | 2008-04-16 | — | — | EP | disclosed |
| WO-2008032104-A1 | ONE POT SYNTHESIS OF TAXANE DERIVATIVES AND THEIR CONVERSION TO PACLITAXEL AND DOCETAXEL | CHATHAM BIOTEC LTD. (CA) | 2008-03-20 | — | — | WO | disclosed |
| US-20080064715-A1 | 6-Azaindole Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-03-13 | — | — | US | disclosed |
| EP-1897880-A1 | 1,3-BENZOTHIAZINONE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2008-03-12 | — | — | EP | disclosed |
| US-20080051598-A1 | Process for Production of Polysubstituted Cyclobutanes and Polysubstituted Cyclobutenes | NATIONAL UNIVERSITY CORPORATION TOHOKU UNIVERSITY (JP) | 2008-02-28 | — | — | US | disclosed |
| US-20080051590-A1 | Semi-Synthetic Conversion of Paclitaxel to Docetaxel | CHATHAM BIOTEC, LIMITED (CA) | 2008-02-28 | — | — | US | disclosed |
| US-20080033189-A1 | Semi-Synthesis Of Taxane Intermediates And Aziridine Analogues And Their Conversion To Paclitaxel And Docetaxel | CHATHAM BIOTEC, LIMITED (CA) | 2008-02-07 | — | — | US | disclosed |
| US-7323577-B2 | Process for producing benzofuran derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-29 | — | — | US | disclosed |
| US-20080021087-A1 | Cannabinoid receptor modulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2008-01-24 | — | — | US | disclosed |
| US-20080009539-A1 | Azo Compounds and Process for Production Thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2008-01-10 | — | — | US | disclosed |
| US-7312211-B2 | Pryanone compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2007-12-25 | — | — | US | disclosed |
| WO-2007145349-A2 | SUBSTITUTED PYRROLE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-12-21 | — | — | WO | disclosed |
| US-20070293532-A1 | Pyrrolo [2,3-C] Pyridine Compound, Process for Producing the Same, and Use | TAKEDA PHARMACEUTICAL COMPAN6Y LIMITED (JP) | 2007-12-20 | — | — | US | disclosed |
| EP-1860185-A1 | SCREENING METHOD | Takeda Pharmaceutical Company Limited (JP) | 2007-11-28 | — | — | EP | disclosed |
| EP-1857817-A1 | SCREENING METHOD | Takeda Pharmaceutical Company Limited (JP) | 2007-11-21 | — | — | EP | disclosed |
| CN-100349872-C | Method for producing amine derivative | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2007-11-21 | — | — | CN | disclosed |
| EP-1852503-A1 | IL-13 PRODUCTION INHIBITOR | Takeda Pharmaceutical Company Limited (JP) | 2007-11-07 | — | — | EP | disclosed |
| US-20070254877-A1 | Indole Derivative and Use for Treatment of Cancer | TAKADA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-11-01 | — | — | US | disclosed |
| EP-1849465-A1 | AGENT FOR CONTROLLING FUNCTION OF GPR34 RECEPTOR | Takeda Pharmaceutical Company Limited (JP) | 2007-10-31 | — | — | EP | disclosed |
| CN-101058543-A | Process for producing amine derivatives | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2007-10-24 | — | — | CN | disclosed |
| US-7279472-B2 | Compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2007-10-09 | — | — | US | disclosed |
| CN-101048394-A | Semi-synthetic conversion of paclitaxel to docetaxel | CHATHAM BIOTEC LTD (CA) | 2007-10-03 | — | — | CN | disclosed |
| US-7276527-B2 | 5-pyridyl-1,3-azole compounds, process for producing the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-10-02 | — | — | US | disclosed |
| EP-1832588-A1 | CONDENSED IMIDAZOLE COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2007-09-12 | — | — | EP | disclosed |
| US-7265132-B2 | Compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2007-09-04 | — | — | US | disclosed |
| EP-1824841-A1 | SUBSTITUTED PYRROLE DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2007-08-29 | — | — | EP | disclosed |
| US-7256204-B2 | Amine compounds, their production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-08-14 | — | — | US | disclosed |
| WO-2007089031-A1 | PIPERIDINE DERIVATIVES AS TACHYKININ RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-08-09 | — | — | WO | disclosed |
| EP-1814868-A1 | SEMI-SYNTHESIS OF TAXANE INTERMEDIATES AND THEIR CONVERSION TO PACLITAXEL AND DOCETAXEL | Chatham Biotec Ltd. (CA) | 2007-08-08 | — | — | EP | disclosed |
| CN-101010311-A | Azo compounds and process for production thereof | TAKEDA PHARMACEUTICAL (JP) | 2007-08-01 | — | — | CN | disclosed |
| US-20070173498-A1 | Melanin concentrating hormone antagonist | KATO KANEYOSHI | 2007-07-26 | — | — | US | disclosed |
| EP-1803709-A1 | PROTON PUMP INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2007-07-04 | — | — | EP | disclosed |
| WO-2007072997-A1 | METASTIN DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-06-28 | — | — | WO | disclosed |
| US-20070149558-A1 | Benzo-fused 5-membered heterocyclic compounds, their production and use | OHKAWA SHIGENORI | 2007-06-28 | — | — | US | disclosed |
| US-20070149570-A1 | Piperidine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-06-28 | — | — | US | disclosed |
| EP-1797058-A2 | SEMI-SYNTHETIC CONVERSION OF PACLITAXEL TO DOCETAXEL | Chatham Biotec Ltd. (CA) | 2007-06-20 | — | — | EP | disclosed |
| CN-1984916-A | Thienopyridine derivatives, process for producing the same, and use thereof | TAKEDA PHARMACEUTICAL (JP) | 2007-06-20 | — | — | CN | disclosed |
| US-7229986-B2 | Melanin-concentrating hormone antagonist | TAKEDA PHARMACEUTICAL COMPANY LTD. (JP) | 2007-06-12 | — | — | US | disclosed |
| EP-1790636-A1 | PIPERIDINE DERIVATIVES AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2007-05-30 | — | — | EP | disclosed |
| EP-1786798-A1 | ONE POT SYNTHESIS OF TAXANE DERIVATIVES AND THEIR CONVERSION TO PACLITAXEL AND DOCETAXEL | Chatham Biotec Ltd. (CA) | 2007-05-23 | — | — | EP | disclosed |
| EP-1787991-A1 | PYRROLOÝ2,3-c¨PYRIDINE COMPOUND, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Pharmaceutical Company Limited (JP) | 2007-05-23 | — | — | EP | disclosed |
| EP-1783121-A1 | AZO COMPOUNDS AND PROCESS FOR PRODUCTION THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2007-05-09 | — | — | EP | disclosed |
| US-20070099990-A1 | Cannabinoid receptor modulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-05-03 | — | — | US | disclosed |
| US-7208495-B2 | Benzo-fused 5-membered hetrocycle compounds, process for preparation of the same, and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-04-24 | — | — | US | disclosed |
| EP-1775300-A1 | PROCESS FOR PRODUCTION OF POLYSUBSTITUTED CYCLOBUTANES AND POLYSUBSTITUTED CYCLOBUTENES | National University Corporation Tohoku Unversity (JP) | 2007-04-18 | — | — | EP | disclosed |
| US-7202040-B2 | Method for screening compounds which change the binding properties of a protein with a ligand | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-04-10 | — | — | US | disclosed |
| US-7202370-B2 | Semi-synthesis of taxane intermediates from 9-dihydro-13-acetylbaccatin III | CONOR MEDSYSTEMS, INC. (US) | 2007-04-10 | — | — | US | disclosed |
| CN-1942458-A | Semi-synthesis of taxane intermediates and aziridine analogs and conversion thereof to paclitaxel and docetaxel | PHYTOGEN LIFE SCIENCES INC (CA) | 2007-04-04 | — | — | CN | disclosed |
| US-7199124-B2 | JNK inhibitor | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-04-03 | — | — | US | disclosed |
| US-20070072865-A1 | Bicyclic piperazine compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-03-29 | — | — | US | disclosed |
| US-20070073069-A1 | Semi-synthesis and isolation of taxane intermediates from a mixture of taxanes | INNOVATIONAL HOLDINGS LLC | 2007-03-29 | — | — | US | disclosed |
| US-20070060623-A1 | antiulcer agents; proton pump inhibitors; side effect reduction; 1-[4-fluoro-5-phenyl-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine; superior acid secretion inhibitory effect; peptic ulcer, Zollinger-Ellison syndrome, reflux esophagitis, or symptomatic gastroesophageal reflux disease | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-03-15 | — | — | US | disclosed |
| EP-1761539-A1 | INDOLE DERIVATIVE AND USE FOR TREATMENT OF CANCER | Takeda Pharmaceutical Company Limited (JP) | 2007-03-14 | — | — | EP | disclosed |
| WO-2007026916-A1 | 1-HETEROCYCLYLSULFONYL, 2-AMINOMETHYL, 5- (HETERO-) ARYL SUBSTITUTED 1-H-PYRROLE DERIVATIVES AS ACID SECRETION INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-03-08 | — | — | WO | disclosed |
| EP-1758932-A2 | METASTIN DERIVATIVES AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2007-03-07 | — | — | EP | disclosed |
| US-7183415-B2 | Quinoline compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-02-27 | — | — | US | disclosed |
| EP-1751167-A1 | THIENOPYRIDINE DERIVATIVES, PRODUCTION METHOD AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2007-02-14 | — | — | EP | disclosed |
| WO-2007015588-A1 | PIPERIDINE DERIVATIVE AS TACHYKININ RECEPTOR ANTAGONIST | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-02-08 | — | — | WO | disclosed |
| US-20070032668-A1 | Semi-synthesis of taxane intermediates from a mixture of taxanes | INNOVATIONAL HOLDINGS LLC | 2007-02-08 | — | — | US | disclosed |
| US-20070032646-A1 | Novel taxanes and methods related to use and preparation thereof | INNOVATIONAL HOLDINGS LLC | 2007-02-08 | — | — | US | disclosed |
| US-20070026457-A1 | Screening method | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-02-01 | — | — | US | disclosed |
| US-20070027331-A1 | Semi-synthesis of taxane intermediates and aziridine analogues and their conversion to paclitaxel and docetaxel | INNOVATIONAL HOLDINGS LLC | 2007-02-01 | — | — | US | disclosed |
| US-20070027332-A1 | Semi-synthetic conversion of paclitaxel to docetaxel | INNOVATIONAL HOLDINGS LLC | 2007-02-01 | — | — | US | disclosed |
| US-20070027330-A1 | One pot synthesis of taxane derivatives and their conversion to paclitaxel and docetaxel | INNOVATIONAL HOLDINGS LLC | 2007-02-01 | — | — | US | disclosed |
| US-20070027207-A1 | Semi-synthesis of taxane intermediates and their conversion to paclitaxel and docetaxel | INNOVATIONAL HOLDINGS LLC | 2007-02-01 | — | — | US | disclosed |
| CN-1297550-C | Benzofuran derivatives, process for the preparation of the same and uses thereof | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2007-01-31 | — | — | CN | disclosed |
| EP-1180518-B1 | 5-PYRIDYL-1,3-AZOLE COMPOUNDS, PROCESS FOR PRODUCING THE SAME AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2007-01-17 | — | — | EP | disclosed |
| EP-1736775-A1 | NOVEL LIGAND OF G PROTEIN COUPLED RECEPTOR PROTEIN AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2006-12-27 | — | — | EP | disclosed |
| EP-1732566-A2 | 6-AZAINDOLE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2006-12-20 | — | — | EP | disclosed |
| EP-1732911-A2 | SEMI-SYNTHESIS OF TAXANE INTERMEDIATES AND AZIRIDINE ANALOGUES AND THEIR CONVERSION TO PACLITAXEL AND DOCETAXEL | Chatham Biotec Ltd. (CA) | 2006-12-20 | — | — | EP | disclosed |
| CN-1878777-A | 2,3-dihydro-6-nitroimidazo (2,1-b) oxazole compounds for the treatment of tuberculosis | OTSUKA PHARMA CO LTD (JP) | 2006-12-13 | — | — | CN | disclosed |
| EP-1727810-A2 | SEMI-SYNTHESIS OF TAXANE INTERMEDIATES FROM 9-DIHYDRO-13-ACETYLBACCATIN III | Chatham Biotec Ltd. (CA) | 2006-12-06 | — | — | EP | disclosed |
| US-20060252797-A1 | Receptor regulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-11-09 | — | — | US | disclosed |
| US-20060241051-A1 | Metastin derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-10-26 | — | — | US | disclosed |
| US-20060241168-A1 | Antidepressant | OHKAWA SHIGENORI | 2006-10-26 | — | — | US | disclosed |
| US-20060223807-A1 | Therapeutic methods for type I diabetes | UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL, A MASSACHUSETTS CORPORATION (US) | 2006-10-05 | — | — | US | disclosed |
| WO-2006104983-A1 | THERAPEUTIC METHODS FOR TYPE I DIABETES | UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL (US) | 2006-10-05 | — | — | WO | disclosed |
| US-20060223826-A1 | Indole derivatives as somatostatin agonists or antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED INTELLECTUAL PROPERTY DEPARTMENT (JP) | 2006-10-05 | — | — | US | disclosed |
| US-7115750-B1 | Melanin concentrating hormone antagonist | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-10-03 | — | — | US | disclosed |
| EP-1705176-A1 | CARBOXAMIDE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2006-09-27 | — | — | EP | disclosed |
| US-7101867-B2 | Benzofuran derivatives, their production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-09-05 | — | — | US | disclosed |
| US-7101899-B1 | 5-pyridyl-1,3-azole compounds, process for producing the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-09-05 | — | — | US | disclosed |
| EP-1688138-A1 | RECEPTOR FUNCTION REGULATING AGENT | Takeda Pharmaceutical Company Limited (JP) | 2006-08-09 | — | — | EP | disclosed |
| CN-1816536-A | Cannabinoid receptor modulators | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2006-08-09 | — | — | CN | disclosed |
| US-20060167052-A1 | Piperidine derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-07-27 | — | — | US | disclosed |
| US-20060142598-A1 | Process for producing benzofuran derivative | TAWADA HIROYUKI | 2006-06-29 | — | — | US | disclosed |
| US-20060142337-A1 | Piperidine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-06-29 | — | — | US | disclosed |
| US-7067537-B2 | Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-06-27 | — | — | US | disclosed |
| WO-2006064944-A1 | SUBSTITUTED PYRROLE DERIVATIVE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-06-22 | — | — | WO | disclosed |
| US-20060135566-A1 | 5-pyridyl-1,3-azole compounds, process for producing the same and use thereof | OHKAWA SHIGENORI | 2006-06-22 | — | — | US | disclosed |
| US-20060128690-A1 | Amine derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-06-15 | — | — | US | disclosed |
| EP-1666880-A1 | SCREENING METHOD | Takeda Pharmaceutical Company Limited (JP) | 2006-06-07 | — | — | EP | disclosed |
| US-7056915-B2 | Compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-06-06 | — | — | US | disclosed |
| EP-1661898-A1 | BICYCLIC PIPERAZINE COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2006-05-31 | — | — | EP | disclosed |
| US-20060088786-A1 | Rewritable optical information recording medium, recording and reproducing methods, as well as recording and reproducing apparatus | MITSUI CHEMICALS, INC. (JP) | 2006-04-27 | — | — | US | disclosed |
| US-7034166-B2 | Process for producing benzofuran derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-04-25 | — | — | US | disclosed |
| CN-1761680-A | Metastin derivative and use thereof | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2006-04-19 | — | — | CN | disclosed |
| EP-1637527-A1 | CANNABINOID RECEPTOR MODULATOR | Takeda Pharmaceutical Company Limited (JP) | 2006-03-22 | — | — | EP | disclosed |
| US-20060052371-A1 | 1,3-Benzothiazinone derivatives, process for producing the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-03-09 | — | — | US | disclosed |
| US-7008950-B1 | Benzofurans as suppressors of neurodegeneration | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2006-03-07 | — | — | US | disclosed |
| CN-1738798-A | Indole derivatives as somatostatin agonists or antagonists | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2006-02-22 | — | — | CN | disclosed |
| CN-1735408-A | Receptor function controlling agent | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2006-02-15 | — | — | CN | disclosed |
| WO-2006006691-A2 | SOLID DISPERSION OF A P38 MAP KINASE INHIBITOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-01-19 | — | — | WO | disclosed |
| WO-2006004708-A1 | ONE POT SYNTHESIS OF TAXANE DERIVATIVES AND THEIR CONVERSION TO PACLITAXEL AND DOCETAXEL | CHATHAM BIOTEC LTD. (CA) | 2006-01-12 | — | — | WO | disclosed |
| WO-2006004898-A2 | SEMI-SYNTHETIC CONVERSION OF PACLITAXEL TO DOCETAXEL | CHATHAM BIOTEC LTD (CA) | 2006-01-12 | — | — | WO | disclosed |
| WO-2006001499-A2 | METASTIN DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-01-05 | — | — | WO | disclosed |
| US-6982272-B2 | Compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-01-03 | — | — | US | disclosed |
| US-20050288520-A1 | One pot synthesis of taxane derivatives and their conversion to paclitaxel and docetaxel | PHYTOGEN LIFE SCIENCES INC. (CA) | 2005-12-29 | — | — | US | disclosed |
| US-20050288521-A1 | Semi-synthetic conversion of paclitaxel to docetaxel | PHYTOGEN LIFE SCIENCES INC. (CA) | 2005-12-29 | — | — | US | disclosed |
| WO-2005118587-A1 | INDOLE DERIVATIVE AND USE FOR TREATMENT OF CANCER | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-12-15 | — | — | WO | disclosed |
| WO-2005118563-A1 | SEMI-SYNTHESIS OF TAXANE INTERMEDIATES AND THEIR CONVERSION TO PACLITAXEL AND DOCETAXEL | CHATHAM BIOTEC LTD. (CA) | 2005-12-15 | — | — | WO | disclosed |
| US-20050272807-A1 | Using protected taxane chemical intermediates; beta-lactam oxazolidine, or oxazoline as blocking agents | PHYTOGEN LIFE SCIENCES INC. (CA) | 2005-12-08 | — | — | US | disclosed |
| CN-1703409-A | Novel taxanes and methods related to use and preparation thereof | PHYTOGEN LIFE SCIENCES INC (CA) | 2005-11-30 | — | — | CN | disclosed |
| WO-2005111046-A1 | THIENOPYRIDINE DERIVATIVES, PRODUCTION METHOD AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-11-24 | — | — | WO | disclosed |
| WO-2005105767-A1 | SEMI-SYNTHESIS AND ISOLATION OF TAXANE INTERMEDIATES FROM A MIXTURE OF TAXANES | CHATHAM BIOTEC LTD. (CA) | 2005-11-10 | — | — | WO | disclosed |
| US-20050250954-A1 | Semi-synthesis and isolation of taxane intermediates from a mixture of taxanes | PHYTOGEN LIFE SCIENCES INC. (CA) | 2005-11-10 | — | — | US | disclosed |
| EP-1593667-A1 | AMINE DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2005-11-09 | — | — | EP | disclosed |
| US-6962933-B1 | Method for inhibiting p38 MAP kinase or TNF-α production using a 1,3-thiazole | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-11-08 | — | — | US | disclosed |
| US-20050245571-A1 | Amine derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-11-03 | — | — | US | disclosed |
| US-20050240036-A1 | Semi-synthesis of taxane intermediates from a mixture of taxanes | PHYTOGEN LIFE SCIENCES INC. (CA) | 2005-10-27 | — | — | US | disclosed |
| WO-2005097129-A2 | 6-AZAINDOLE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-10-20 | — | — | WO | disclosed |
| US-20050228020-A1 | Beta secretase inhibitors | MIYAMOTO MASAOMI | 2005-10-13 | — | — | US | disclosed |
| CN-1680280-A | Method for producing amine derivative | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2005-10-12 | — | — | CN | disclosed |
| CN-1680332-A | Method for producing amine derivative | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2005-10-12 | — | — | CN | disclosed |
| US-20050209213-A1 | Quinoline compound | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2005-09-22 | — | — | US | disclosed |
| EP-1577323-A1 | METASTIN DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2005-09-21 | — | — | EP | disclosed |
| CN-1671662-A | Piperidine derivatives, process for their preparation and their use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2005-09-21 | — | — | CN | disclosed |
| WO-2005082875-A2 | SEMI-SYNTHESIS OF TAXANE INTERMEDIATES AND AZIRIDINE ANALOGUES AND THEIR CONVERSION TO PACLITAXEL AND DOCETAXEL | PHYTOGEN LIFE SCIENCES INC. (CA) | 2005-09-09 | — | — | WO | disclosed |
| US-20050192445-A1 | Semi-synthesis of taxane intermediates and aziridine analogues and their conversion to paclitaxel and docetaxel | PHYTOGEN LIFE SCIENCES INC. (CA) | 2005-09-01 | — | — | US | disclosed |
| EP-1568697-A1 | 1,3-BENZOTHIAZINONE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2005-08-31 | — | — | EP | disclosed |
| US-6936606-B2 | Cyanoamido-containing heterocyclic compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-08-30 | — | — | US | disclosed |
| US-20050187238-A1 | Benzofuran derivatives, their production and use | OHKAWA SHIGENORI (JP) | 2005-08-25 | — | — | US | disclosed |
| EP-1562898-A1 | INDOLE DERIVATIVES AS SOMATOSTATIN AGONISTS OR ANTAGONISTS | Takeda Pharmaceutical Company Limited (JP) | 2005-08-17 | — | — | EP | disclosed |
| EP-1562927-A2 | THIO-ANALOGUES OF PACLITAXEL AND INTERMEDIATES THEREOF | Phytogen Life Sciences Inc. (CA) | 2005-08-17 | — | — | EP | disclosed |
| US-6930104-B2 | Heterocyclic derivatives | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2005-08-16 | — | — | US | disclosed |
| US-6930185-B2 | Melanin-concentrating hormone antagonist | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2005-08-16 | — | — | US | disclosed |
| US-20050171196-A1 | 2-Furancarboxylic acid hydrazides and pharmaceutical compositions containing the same | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2005-08-04 | — | — | US | disclosed |
| US-20050171184-A1 | Process for preparing optically active 2,3-dihydrobenzofuran compounds | AOKI ISAO (JP) | 2005-08-04 | — | — | US | disclosed |
| EP-1559428-A1 | RECEPTOR REGULATOR | Takeda Pharmaceutical Company Limited (JP) | 2005-08-03 | — | — | EP | disclosed |
| EP-1559422-A1 | RECEPTOR FUNCTION CONTROLLING AGENT | Takeda Pharmaceutical Company Limited (JP) | 2005-08-03 | — | — | EP | disclosed |
| US-20050154190-A1 | Screening method | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-07-14 | — | — | US | disclosed |
| EP-1553084-A1 | PIPERIDINE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Pharmaceutical Company Limited (JP) | 2005-07-13 | — | — | EP | disclosed |
| CN-1638763-A | antidepressants | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2005-07-13 | — | — | CN | disclosed |
| US-20050148650-A1 | Antidepressant | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-07-07 | — | — | US | disclosed |
| US-6911468-B2 | Tyrosine phosphatase inhibitors | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2005-06-28 | — | — | US | disclosed |
| US-20050118202-A1 | Solid compositions containing compounds unstable to oxygen and method for stabilization thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-06-02 | — | — | US | disclosed |
| WO-2005044811-A2 | SEMI-SYNTHESIS OF TAXANE INTERMEDIATES FROM 9-DIHYDRO-13-ACETYLBACCATIN III | PHYTOGEN LIFE SCIENCES INC. (CA) | 2005-05-19 | — | — | WO | disclosed |
| US-20050101657-A1 | Pyrrole derivatives for preventing or treating cancer sensitive to hormones; administered with luteininzing hormone releasing hormone derivative | TAKEDA CHEMICAL INDUSTRIES LTD. (JP) | 2005-05-12 | — | — | US | disclosed |
| US-20050101789-A1 | Semi-synthesis of taxane intermediates from 9-dihydro-13-acetylbaccatin III | PHYTOGEN LIFE SCIENCES INC. (CA) | 2005-05-12 | — | — | US | disclosed |
| US-20050085553-A1 | Remedies for mild recognition deflict | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-04-21 | — | — | US | disclosed |
| US-20050080113-A1 | Medicinal compositions | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-04-14 | — | — | US | disclosed |
| US-6878831-B2 | Process for preparing optically active 2,3-dihydrobenzofuran compounds | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2005-04-12 | — | — | US | disclosed |
| EP-1507757-A1 | LACTAMS USED AS ANTI-VIRAL AGENTS | Bayer HealthCare AG (DE) | 2005-02-23 | — | — | EP | disclosed |
| CN-1585751-A | Quinoline compound | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2005-02-23 | — | — | CN | disclosed |
| US-6858623-B2 | Compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-02-22 | — | — | US | disclosed |
| US-20050038072-A1 | Nitrogeneous cyclic ketone derivative, process for producing the same, and use | TAKEDA CHEMICAL INDUSTRIES, LTD. | 2005-02-17 | — | — | US | disclosed |
| US-20050032786-A1 | 1, 3-benzothiazinone derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-02-10 | — | — | US | disclosed |
| US-20050032792-A1 | Compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-02-10 | — | — | US | disclosed |
| US-20050032772-A1 | Compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-02-10 | — | — | US | disclosed |
| US-20050026904-A1 | Pryanone compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-02-03 | — | — | US | disclosed |
| US-6841571-B2 | Compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-01-11 | — | — | US | disclosed |
| EP-1148059-B1 | THIAZOLOPYRIMIDINE COMPOUNDS, PROCESS FOR THE PREPARATION OF THE SAME AND USES THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2004-12-29 | — | — | EP | disclosed |
| EP-1489077-A1 | 2-FURANCARBOXYLIC ACID HYDRAZIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2004-12-22 | — | — | EP | disclosed |
| EP-1484191-A1 | REWRITABLE OPTICAL INFORMATION RECORDING MEDIUM AND RECORDING/REPRODUCING METHOD, RECORDING/REPRODUCING DEVICE | Sony Corporation (JP) | 2004-12-08 | — | — | EP | disclosed |
| EP-1481679-A1 | ANTIDEPRESSANT | Takeda Chemical Industries, Ltd. (JP) | 2004-12-01 | — | — | EP | disclosed |
| US-20040210066-A1 | Process for producing benzofuran derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-10-21 | — | — | US | disclosed |
| EP-1466902-A1 | ANDROGEN RECEPTOR ANTAGONISTS | Takeda Chemical Industries, Ltd. (JP) | 2004-10-13 | — | — | EP | disclosed |
| EP-1460062-A1 | NITROGENOUS CYCLIC KETONE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Chemical Industries, Ltd. (JP) | 2004-09-22 | — | — | EP | disclosed |
| EP-1459764-A1 | REMEDIES FOR MILD RECOGNITION DEFLICT | Takeda Chemical Industries, Ltd. (JP) | 2004-09-22 | — | — | EP | disclosed |
| EP-1457207-A1 | SOLID COMPOSITIONS CONTAINNG COMPOUNDS UNSTABLE TO OXYGEN AND METHOD FOR STABILIZATION THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2004-09-15 | — | — | EP | disclosed |
| EP-1455186-A1 | SCREENING METHOD | Takeda Chemical Industries, Ltd. (JP) | 2004-09-08 | — | — | EP | disclosed |
| US-6787540-B2 | FOR THERAPY OF AUTOIMMUNE DISEASES, ASTHMA, OSTEOPOROSIS, ATHEROSCLEROSIS, ALZHEIMER'S DISEASE | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-09-07 | — | — | US | disclosed |
| US-6784314-B2 | HAVING THE ACTION OF INHIBITING THE SECRETION AND ACCUMULATION OF AMYLOID BETA PROTEIN | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2004-08-31 | — | — | US | disclosed |
| US-20040167171-A1 | Benzo-fused 5-membered hetrocycle compounds, process for preparation of the same, and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-08-26 | — | — | US | disclosed |
| EP-1447402-A1 | QUINOLINE COMPOUND | Takeda Chemical Industries, Ltd. (JP) | 2004-08-18 | — | — | EP | disclosed |
| US-20040157850-A1 | Novel heterocyclic derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-08-12 | — | — | US | disclosed |
| EP-1444226-A1 | COMPOUNDS USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2004-08-11 | — | — | EP | disclosed |
| EP-1437351-A1 | AMINE DERIVATIVE | Takeda Chemical Industries, Ltd. (JP) | 2004-07-14 | — | — | EP | disclosed |
| US-20040132991-A1 | Novel taxanes and methods related to use and preparation thereof | PHYTOGEN LIFE SCIENCES INC. (CA) | 2004-07-08 | — | — | US | disclosed |
| EP-1434769-A2 | COMPOUNDS USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2004-07-07 | — | — | EP | disclosed |
| CN-1156471-C | 5-pyridyl-1, 3-azole compounds, their preparation and use | ����ҩƷ��ҵ��ʽ���� | 2004-07-07 | — | — | CN | disclosed |
| US-6756372-B2 | FOR THERAPY OF AUTOIMMUNE DISEASES, ALZHEIMER'S DISEASE, ATHEROSCLEROSIS, OSTEOPOROSIS, RHEUMATOID ARTHRITIS, SYSTEMIC LUPUS ERYTHEMATOSUS, CROHN'S DISEASE, ULCERATIVE COLITIS, MULTIPLE SCLEROSIS, GUILLAIN-BARRE SYNDROME, PSORIASIS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-06-29 | — | — | US | disclosed |
| US-20040110743-A1 | -Secretase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-06-10 | — | — | US | disclosed |
| WO-2004046107-A1 | INDOLE DERIVATIVES AS SOMATOSTATIN AGONISTS OR ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-06-03 | — | — | WO | disclosed |
| US-20040106803-A1 | Production method of 1-substituted-1,2,3-triazole derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-06-03 | — | — | US | disclosed |
| EP-1424336-A1 | 1,3-BENZOTHIAZINONE DERIVATIVES AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2004-06-02 | — | — | EP | disclosed |
| US-6743924-B2 | EFFICIENT, HIGH YEILD SYNTHESIS OF TYROSINE KINASE INHIBITORS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2004-06-01 | — | — | US | disclosed |
| US-20040097555-A1 | Concomitant drugs | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-05-20 | — | — | US | disclosed |
| WO-2004033442-A2 | NOVEL TAXANES AND METHODS RELATED TO USE AND PREPARATION THEREOF | CHATHAM BIOTEC LTD. (CA) | 2004-04-22 | — | — | WO | disclosed |
| US-20040077628-A1 | Melanin-concentrating hormone antagonist | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-22 | — | — | US | disclosed |
| US-20040077712-A1 | Process for preparing optically active 2,3-dihydrobenzofuran compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-22 | — | — | US | disclosed |
| US-20040077867-A1 | Amine compounds, their production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-22 | — | — | US | disclosed |
| EP-1411052-A1 | BENZO-FUSED 5-MEMBERED HETROCYCLE COMPOUNDS,PROCESS FOR PREPARATION OF THE SAME, AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2004-04-21 | — | — | EP | disclosed |
| US-20040072876-A1 | Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-15 | — | — | US | disclosed |
| EP-1408036-A1 | PROCESS FOR PRODUCING BENZOFURAN DERIVATIVE | Takeda Chemical Industries, Ltd. (JP) | 2004-04-14 | — | — | EP | disclosed |
| US-6720319-B2 | ((1-(4-CYANO-1-(2-MORPHOLIN-4-YL-ETHYL)-PIPERIDIN-4 -YLCARBAMOYL)- 2-CYCLOHEXYL-ETHYLAMINO) -MORPHOLIN-4-YL-METHYLENE)- CARBAMIC ACID ISOBUTYL ESTER; CATHEPSINS S, K, F, L AND B; AUTOIMMUNE DISEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-04-13 | — | — | US | disclosed |
| US-20040063679-A1 | Compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. | 2004-04-01 | — | — | US | disclosed |
| US-20040063946-A1 | Jnk inhibitor | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-01 | — | — | US | disclosed |
| EP-1402900-A1 | MEDICINAL COMPOSITIONS | Takeda Chemical Industries, Ltd. (JP) | 2004-03-31 | — | — | EP | disclosed |
| US-20040053921-A1 | Amidino and guanidino peptidyl compounds useful for treating autoimmune diseases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-03-18 | — | — | US | disclosed |
| US-20040053973-A1 | Substituted 1,3-thiazole compounds, their production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-03-18 | — | — | US | disclosed |
| EP-1136477-B1 | BENZOFURAN DERIVATIVES, PROCESS FOR THE PREPARATION OF THE SAME AND USES THEREOF | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2004-03-10 | — | — | EP | disclosed |
| US-20040034049-A1 | Promoters for the proliferation and differentiation of stem cells and/or neuron precursor cells | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-02-19 | — | — | US | disclosed |
| US-20040018239-A1 | Pharmaceutical preparation containing copolyvidone | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-01-29 | — | — | US | disclosed |
| EP-1382598-A1 | NOVEL HETEROCYCLIC DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 2004-01-21 | — | — | EP | disclosed |
| EP-1027050-B1 | 1,3-THIAZOLES AS ADENOSINE A3 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF ALLERGY, ASTHMA AND DIABETES | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2004-01-14 | — | — | EP | disclosed |
| US-20040006078-A1 | Compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-01-08 | — | — | US | disclosed |
| US-20030232826-A1 | Compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACIUTICALS, INC. (US) | 2003-12-18 | — | — | US | disclosed |
| US-20030225270-A1 | Compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-12-04 | — | — | US | disclosed |
| US-20030225271-A1 | Compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-12-04 | — | — | US | disclosed |
| WO-2003097595-A1 | LACTAMS USED AS ANTI-VIRAL AGENTS | BAYER HEALTHCARE AG (DE) | 2003-11-27 | — | — | WO | disclosed |
| EP-1364949-A1 | JNK INHIBITOR | Takeda Chemical Industries, Ltd. (JP) | 2003-11-26 | — | — | EP | disclosed |
| US-20030216398-A1 | Soluble beta amyloid precursor protein secretion promoters | TAKEDA CHEMICAL INDUSTRIES LTD. (JP) | 2003-11-20 | — | — | US | disclosed |
| US-20030216383-A1 | Compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-11-20 | — | — | US | disclosed |
| EP-1354603-A1 | CONCOMITANT DRUGS | Takeda Chemical Industries, Ltd. (JP) | 2003-10-22 | — | — | EP | disclosed |
| EP-1348706-A1 | SUBSTITUTED THIAZOLE DERIVATIVES BEARING 3-PYRIDYL GROUPS, PROCESS FOR PREPARING THE SAME AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2003-10-01 | — | — | EP | disclosed |
| EP-1346988-A1 | PROCESS FOR PREPARING OPTICALLY ACTIVE 2,3-DIHYDRO- BENZOFURAN COMPOUNDS | Takeda Chemical Industries, Ltd. (JP) | 2003-09-24 | — | — | EP | disclosed |
| US-6620825-B1 | 1,3-Azole compound substituted by pyridyl; administering as antiasthmatic, antiinflammatory or antiallergen agents | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-09-16 | — | — | US | disclosed |
| US-6613805-B2 | For therapy and prophylaxis of neurodegenerative diseases such as Alzheimer's disease, Down's syndrome, Parkinson's disease, Creutzfeldt-Jacob disease, amyotrophic sclerosis on lateral fasciculus, multiple sclerosis, and neurological disorders | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-09-02 | — | — | US | disclosed |
| US-20030158177-A1 | Treating or preventing obesity | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-08-21 | — | — | US | disclosed |
| EP-1334732-A1 | PHARMACEUTICAL PREPARATION CONTAINING COPOLYVIDONE | Takeda Chemical Industries, Ltd. (JP) | 2003-08-13 | — | — | EP | disclosed |
| US-20030144338-A1 | Tyrosine phosphatase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-07-31 | — | — | US | disclosed |
| US-20030139602-A1 | Process for producing amine derivatives | TAKEDA CHEMICAL INDUSTRIES LTD. (JP) | 2003-07-24 | — | — | US | disclosed |
| EP-1322613-A1 | SPIROHETEROCYCLIC NITRILES USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2003-07-02 | — | — | EP | disclosed |
| EP-1323716-A1 | PROMOTERS FOR THE PROLIFERATION AND DIFFERENTIATION OF STEM CELLS AND/OR NEURON PRECURSOR CELLS | Takeda Chemical Industries, Ltd. (JP) | 2003-07-02 | — | — | EP | disclosed |
| EP-1218372-B1 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES | BOEHRINGER INGELHEIM PHARMA (US) | 2003-07-02 | — | — | EP | disclosed |
| US-6586475-B1 | 5-chloro-N-(2-N,N-diethylamino)ethyl)-2- methoxy-4-(1-naphthoylamino)benzamide and prodrugs, used for prevention of neurodegenarative diseases such as Alzheimer's disease | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-07-01 | — | — | US | disclosed |
| US-6583146-B1 | Adenosine A3 receptor antagonist; asthma; 5-amino-3-(4-methoxyphenyl)-2-(4-pyridyl)-7H-thiazolo(3,2-a) pyrimidin-7-one | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-06-24 | — | — | US | disclosed |
| CN-1422244-A | Process for preparing amine derivatives | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2003-06-04 | — | — | CN | disclosed |
| EP-1310491-A1 | METHOD FOR PRODUCING 1-SUBSTITUTED-1,2,3-TRIAZOLE DERIVATIVE | Takeda Chemical Industries, Ltd. (JP) | 2003-05-14 | — | — | EP | disclosed |
| WO-2003037892-A1 | COMPOUNDS USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-05-08 | — | — | WO | disclosed |
| US-20030069419-A1 | Method for producing 1-substituted-1,2,3- triazole derivative | TAKEDA PHARMACEUTICAL COMPANY, LIMITED (JP) | 2003-04-10 | — | — | US | disclosed |
| WO-2003029200-A2 | COMPOUNDS USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-04-10 | — | — | WO | disclosed |
| EP-1285651-A1 | MELANIN CONCENTRATING HORMONE ANTAGONISTS | Takeda Chemical Industries, Ltd. (JP) | 2003-02-26 | — | — | EP | disclosed |
| US-6525052-B2 | Treating autoimmune diseases, Alzheimer's disease, atherosclerosis, osteoporosis, and asthma | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-02-25 | — | — | US | disclosed |
| EP-1284260-A1 | TYROSINE PHOSPHATASE INHIBITORS | Takeda Chemical Industries, Ltd. (JP) | 2003-02-19 | — | — | EP | disclosed |
| EP-1283055-A1 | SOLUBLE BETA AMYLOID PRECURSOR PROTEIN SECRETION PROMOTERS | Takeda Chemical Industries, Ltd. (JP) | 2003-02-12 | — | — | EP | disclosed |
| EP-1283199-A1 | MELANIN-CONCENTRATING HORMONE ANTAGONIST | Takeda Chemical Industries, Ltd. (JP) | 2003-02-12 | — | — | EP | disclosed |
| EP-1283039-A1 | -SECRETASE INHIBITORS | Takeda Chemical Industries, Ltd. (JP) | 2003-02-12 | — | — | EP | disclosed |
| EP-1270545-A1 | PROCESS FOR PRODUCING AMINE DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 2003-01-02 | — | — | EP | disclosed |
| CN-1388120-A | Intermediate used as new industrial products in preparation of new cephalosporin containing sbstituted benzyloxy imino on 7-position | ROUSSEL UCLAF (FR) | 2003-01-01 | — | — | CN | disclosed |
| US-6479536-B1 | Benzofuran derivatives, process for the preparation of the same and uses thereof | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-11-12 | — | — | US | disclosed |
| US-20020160996-A1 | Benzofuran derivatives, their production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2002-10-31 | — | — | US | disclosed |
| US-20020137932-A1 | Novel compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2002-09-26 | — | — | US | disclosed |
| US-6436966-B1 | Adenosine A3 receptor antagonists | TAKEDA CHEMICAL IND., LTD. (JP) | 2002-08-20 | — | — | US | disclosed |
| EP-1227090-A1 | AMINE DERIVATIVES | Tadeka Chemical Industries, Ltd. (JP) | 2002-07-31 | — | — | EP | disclosed |
| US-6420364-B1 | TREATING AUTOIMMUNE DISEASES,ALZHEIMER'S DISEASE, ATHEROSCLEROSIS, OSTEOPOROSIS, | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2002-07-16 | — | — | US | disclosed |
| EP-1218336-A2 | MELANIN CONCENTRATING HORMONE ANTAGONIST | Takeda Chemical Industries, Ltd. (JP) | 2002-07-03 | — | — | EP | disclosed |
| EP-1218372-A1 | NOVEL SPIROHETEROCYCLIC COMPOUNDS USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES | Boehringer Ingelheim Pharmaceuticals, Inc. (US) | 2002-07-03 | — | — | EP | disclosed |
| CN-1353710-A | 5-pyridyl-1,3-azole compounds, process for producing the same and use thereof | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2002-06-12 | — | — | CN | disclosed |
| US-20020058809-A1 | Compounds useful as reversible inhibitors of cysteine proteases | EMMANUEL MICHEL JOSE (US) | 2002-05-16 | — | — | US | disclosed |
| EP-1205478-A1 | p38MAP KINASE INHIBITORS | Takeda Chemical Industries, Ltd. (JP) | 2002-05-15 | — | — | EP | disclosed |
| US-20020032189-A1 | For therapy and prophylaxis of neurodegenerative diseases such as Alzheimer's disease, Down's syndrome, Parkinson's disease, Creutzfeldt-Jacob disease, amyotrophic sclerosis on lateral fasciculus, multiple sclerosis, and neurological disorders | THE UNIVERSITY OF TOKYO (JP) | 2002-03-14 | — | — | US | disclosed |
| WO-2002020485-A1 | SPIROHETEROCYCLIC NITRILES USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2002-03-14 | — | — | WO | disclosed |
| EP-1180518-A1 | 5-PYRIDYL-1,3-AZOLE COMPOUNDS, PROCESS FOR PRODUCING THE SAME AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2002-02-20 | — | — | EP | disclosed |
| CN-1333764-A | Benzofuran derivatives, their preparation and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2002-01-30 | — | — | CN | disclosed |
| WO-2001098370-A1 | MATERIALS COMPRISING OLIGO- OR POLYSACCHARIDE CROSS LINKED AND CHEMICALLY BONDED TO A SUPPORT VIA UREA LINKAGES USEFUL FOR CHROMATOGRAPHY AND ELECTROPHORESIS APPLICATIONS | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2001-12-27 | — | — | WO | disclosed |
| US-6329389-B1 | HETEROCYCLIC AMINES AND DERIVATIVES, SOMATOSTATIN AND ANTIDIABETIC AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-12-11 | — | — | US | disclosed |
| US-6326369-B1 | ALZHEIMER'S DISEASE | TAKEDA CHEMICALS INDUSTRIES, LTD. (JP) | 2001-12-04 | — | — | US | disclosed |
| EP-0761672-B1 | Cephalosporins containing in position 7 a substituted benzyloxyimino radical, processes for their preparation and intermediates for their preparation, their use as medicaments | AVENTIS PHARMA SA (FR) | 2001-11-07 | — | — | EP | disclosed |
| US-6313305-B1 | ANTIBIOTICS, BACTERICIDES | HOECHST MARION ROUSSEL (FR) | 2001-11-06 | — | — | US | disclosed |
| US-6310107-B1 | (+)-6-(4-BIPHENYLYL)METHOXY-2-(2-(N,N-DIMETHYLAMINO)ETHYL)TETR ALIN, OR A SALT IS USEFUL FOR INHIBITING PRODUCTION AND/OR SECRETION OF AMYLOID-BETA PROTEIN | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-10-30 | — | — | US | disclosed |
| EP-1148059-A1 | THIAZOLOPYRIMIDINE COMPOUNDS, PROCESS FOR THE PREPARATION OF THE SAME AND USES THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2001-10-24 | — | — | EP | disclosed |
| EP-1136477-A1 | BENZOFURAN DERIVATIVES, PROCESS FOR THE PREPARATION OF THE SAME AND USES THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2001-09-26 | — | — | EP | disclosed |
| EP-1132376-A1 | BETA-AMYLOID PROTEIN PRODUCTION/SECRETION INHIBITORS | Takeda Chemical Industries, Ltd. (JP) | 2001-09-12 | — | — | EP | disclosed |
| WO-2001021577-A2 | MELANIN CONCENTRATING HORMONE ANTAGONIST | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-03-29 | — | — | WO | disclosed |
| WO-2001019816-A1 | NOVEL SPIROHETEROCYCLIC COMPOUNDS USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2001-03-22 | — | — | WO | disclosed |
| EP-1070054-A1 | AMINE COMPOUNDS, THEIR PRODUCTION AND THEIR USE AS SOMATOSTATIN RECEPTOR ANTAGONISTS OR AGONISTS | Takeda Chemical Industries, Ltd. (JP) | 2001-01-24 | — | — | EP | disclosed |
| CN-1061045-C | Process for the preparation of novel cephalosporins containing a substituted benzyloxyimino group in position 7 | ROUSSEL UCLAF (FR) | 2001-01-24 | — | — | CN | disclosed |
| EP-0551034-B1 | Antibiotic cephalosporins having in position 7 a substituted benzyloxyimino radical | HOECHST MARION ROUSSEL INC (FR) | 2000-09-20 | — | — | EP | disclosed |
| EP-1027050-A2 | ADENOSINE A3 RECEPTOR ANTAGONISTS | Takeda Chemical Industries, Ltd. (JP) | 2000-08-16 | — | — | EP | disclosed |
| EP-1016646-A1 | Intermediates for the preparation of cephalosporines containing on the 7-position a substituted benzyloximino radical | HOECHST MARION ROUSSEL (FR) | 2000-07-05 | — | — | EP | disclosed |
| EP-0988289-A2 | HETEROCYCLIC COMPOUNDS, THEIR PRODUCTION AND USE | Takeda Pharmaceutical Company Limited (JP) | 2000-03-29 | — | — | EP | disclosed |
| EP-0971878-A1 | AMINE COMPOUNDS, THEIR PRODUCTION AND USE AS AMYLOID-BETA PRODUCTION INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2000-01-19 | — | — | EP | disclosed |
| EP-0968164-A1 | BICYCLIC QUINONE COMPOUNDS, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 2000-01-05 | — | — | EP | disclosed |
| WO-1999052875-A1 | AMINE COMPOUNDS, THEIR PRODUCTION AND THEIR USE AS SOMATOSTATIN RECEPTOR ANTAGONISTS OR AGONISTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-10-21 | — | — | WO | disclosed |
| WO-1999021555-A2 | ADENOSINE A3 RECEPTOR ANTAGONISTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-05-06 | — | — | WO | disclosed |
| US-5883248-A | QUATERNARY AMMONIUM INTERMEDIATES | ROUSSEL UCLAF (FR) | 1999-03-16 | — | — | US | disclosed |
| WO-1998055454-A2 | BENZOFURANS AND BENZOTHOPHENES AS SUPPRESSORS OF NEURODEGENERATION | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-12-10 | — | — | WO | disclosed |
| WO-1998038156-A1 | AMINE COMPOUNDS, THEIR PRODUCTION AND USE AS AMYLOID-BETA PRODUCTION INHIBITORS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-09-03 | — | — | WO | disclosed |
| WO-1998033758-A1 | BICYCLIC QUINONE COMPOUNDS, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-08-06 | — | — | WO | disclosed |
| US-5763617-A | Cephalosporins | ROUSSEL UCLAF (FR) | 1998-06-09 | — | — | US | disclosed |
| CN-1178671-A | Method for preparing novel cephalosporin medicine composition containing substituted benzyloxy imino on the 7 th position | ROUSSEL UCLAF CO (FR) | 1998-04-15 | — | — | CN | disclosed |
| US-5728828-A | A 3-(3-CHLORO- OR IODOPROP-1-EN-1-YL),7-(2-AMINOTHIAZOL-4-YL) ((CARBOXY)(PHENYL)METHOXYIMINO)ACETAMIDO-3-CEPHEM; GRAMNEGATIVE AND -POSITIVE BACTERIA, ESP. ANTIBIOTIC-RESISTANCE STAPHYLOCOCCUS | ROUSSEL UCLAF (FR) | 1998-03-17 | — | — | US | disclosed |
| US-5712266-A | Cephalosporins | ROUSSEL UCLAF (FR) | 1998-01-27 | — | — | US | disclosed |
| WO-1998002432-A1 | BICYCLIC COMPOUNDS FOR CONTROLLING MICTURITION | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-01-22 | — | — | WO | disclosed |
| US-5710147-A | ANTIBIOTICS | ROUSSEL UCLAF (FR) | 1998-01-20 | — | — | US | disclosed |
| CN-1152575-A | Novel cephalosporins containing a substituted benzyloxyimino group in position 7, process and intermediates for their preparation and their use as medicaments | ROUSSEL UCLAF (FR) | 1997-06-25 | — | — | CN | disclosed |
| EP-0761672-A1 | Cephalosporin containing in position 7 a substituted benzyloxyimino radical, processes for their preparation and intermediates for their preparation, their use as medicaments | ROUSSEL UCLAF (FR) | 1997-03-12 | — | — | EP | disclosed |
| US-5587372-A | BACERICIDES | ROUSSEL UCLAF (FR) | 1996-12-24 | — | — | US | disclosed |
| CN-1120045-A | New cephalosporins containing in position 7 a substituted benzyloxyimino radical, their preparation process, their use as medicaments | ROUSSEL UCLAF (FR) | 1996-04-10 | — | — | CN | disclosed |
| EP-0693496-A1 | Novel cephalosporins having a substituted benzyloxyimino radical in position 7, process for their preparation and their use as medicaments | ROUSSEL UCLAF (FR) | 1996-01-24 | — | — | EP | disclosed |
| US-5455238-A | Bactericides | ROUSSEL UCLAF (FR) | 1995-10-03 | — | — | US | disclosed |
| EP-0628562-A1 | Cephalospornis having in position 7 as substituted axymino radical, intermediates, processes for their preparation and their use as medicaments | ROUSSEL UCLAF (FR) | 1994-12-14 | — | — | EP | disclosed |
| CN-1096298-A | Contain the novel cephalosporin of the oxyimino group of replacement, their preparation method and intermediate on seven and as the purposes of medicine | ROUSSEL UCLAF (FR) | 1994-12-14 | — | — | CN | disclosed |
| US-5359055-A | Chemical intermediate for vitamin D3 | KURARAY CO., LTD. (JP) | 1994-10-25 | — | — | US | disclosed |
| EP-0551034-A2 | Cephalosporins having in position 7 a benzyloxyimino radical substitute, process for their preparation and their use as medicaments | ROUSSEL UCLAF (FR) | 1993-07-14 | — | — | EP | disclosed |
| CN-1073177-A | Novel cephalosporins containing a substituted benzyloxyimino radical in position 7, process for their preparation and their use as medicaments | ROUSSEL UCLAF (FR) | 1993-06-16 | — | — | CN | disclosed |
| EP-0321572-B1 | PREGNANE DERIVATIVES AND PROCESS FOR THEIR PREPARATION | KURARAY CO., LTD. (JP) | 1993-06-09 | — | — | EP | disclosed |
| US-5112998-A | Intermediates for vitamin D3 | KURARAY CO., LTD. (JP) | 1992-05-12 | — | — | US | disclosed |
| EP-0321572-A1 | PREGNANE DERIVATIVES AND PROCESS FOR THEIR PREPARATION | KURARAY CO., LTD. (JP) | 1989-06-28 | — | — | EP | disclosed |
| US-4191574-A | AZO-METHINE DYES | KONISHIROKU PHOTO INDUSTRY CO., LTD. (JP) | 1980-03-04 | — | — | US | disclosed |
| US-4138264-A | Silver halide emulsion containing two equivalent type coupler for use in photography | KONISHIROKU PHOTO INDUSTRY CO., LTD. (JP) | 1979-02-06 | — | — | US | disclosed |
| US-4138264-A | Silver halide emulsion containing two equivalent type coupler for use in photography | KONISHIROKU PHOTO INDUSTRY CO., LTD. (JP) | 1979-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040210066-A1 | Process for producing benzofuran derivative | IWS1, HAT1, BRD1 | KDM4E 469/4885GAA 3304/4885RAB9A 3092/4885 |
| US-20030144338-A1 | Tyrosine phosphatase inhibitors | PTPRC, PTPN1, PTPRM | KDM4E 171/4885GAA 3493/4885RAB9A 3961/4885 |
| US-20240066047-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE | STING1, TLR9, CGAS | KDM4E 3337/4885GAA 127/4885RAB9A 642/4885 |
| US-10787462-B2 | Heterocyclic compound | RIPK1, RIPK4, RIPK3 | KDM4E 2413/4885GAA 142/4885RAB9A 651/4885 |
| US-20070027330-A1 | One pot synthesis of taxane derivatives and their conversion to paclitaxel and docetaxel | DHCR7, TRRAP, TERT | KDM4E 3159/4885GAA 4195/4885RAB9A 2002/4885 |
| US-20200163970-A1 | HETEROCYCLIC COMPOUND | SQSTM1, BECN1, ATG7 | KDM4E 3374/4885GAA 478/4885RAB9A 281/4885 |
| US-20170121286-A1 | METHOD FOR PRODUCING HETEROCYCLIC COMPOUND | REN, AGT, AGTR1 | KDM4E 3110/4885GAA 506/4885RAB9A 682/4885 |
| US-20190040010-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | HCRTR2, HCRTR1, CNR2 | KDM4E 706/4885GAA 2303/4885RAB9A 2613/4885 |
| US-20170020841-A1 | PHARMACEUTICAL PREPARATION CONTAINING COPOLYVIDONE | PRCP, COPS6, COPS5 | KDM4E 672/4885GAA 474/4885RAB9A 563/4885 |
| US-20120277431-A1 | PYRIDAZINONE COMPOUNDS | PDE3A, PDE5A, PDE3B | KDM4E 1514/4885GAA 1517/4885RAB9A 479/4885 |
| US-20230271939-A1 | 4-ETHYNYLPYRIDINE DERIVATIVES USEFUL AS GCN2 INHIBITORS | EIF2AK4, GCN1, EIF5B | KDM4E 1955/4885GAA 790/4885RAB9A 2203/4885 |
| US-20200140505-A1 | PEPTIDE COMPOUND | GIPR, GLP1R, GRPR | KDM4E 4844/4885GAA 2595/4885RAB9A 1785/4885 |
| US-11986480-B2 | Heterocyclic compound | SQSTM1, BECN1, ATG7 | KDM4E 3374/4885GAA 478/4885RAB9A 281/4885 |
| US-10189785-B2 | Heterocyclic compound | SPTLC1, SPTLC2, NPC1 | KDM4E 3051/4885GAA 23/4885RAB9A 680/4885 |
| US-20230149560-A1 | LIPID COMPOSITIONS FOR DELIVERY OF STING AGONIST COMPOUNDS AND USES THEREOF | STING1, CGAS, TLR9 | KDM4E 3466/4885GAA 1037/4885RAB9A 582/4885 |
| US-20070149570-A1 | Piperidine derivative and use thereof | TACR1, OPRL1, TRPV1 | KDM4E 3038/4885GAA 4468/4885RAB9A 3025/4885 |
| US-20160152598-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | CHRM1, CHRM5, CHRM2 | KDM4E 1279/4885GAA 3174/4885RAB9A 1060/4885 |
| US-20190315735-A1 | CYCLOPROPANAMINE COMPOUND AND USE THEREOF | KDM1A, KDM1B, KDM2A | KDM4E 14/4885GAA 665/4885RAB9A 1508/4885 |
| US-20160311811-A1 | HETEROCYCLIC COMPOUND | IRAK4, IRAK1, IRAK2 | KDM4E 125/4885GAA 4235/4885RAB9A 3929/4885 |
| US-20120277430-A1 | PYRIDAZINONE COMPOUNDS | PDE3A, PDE5A, PDE3B | KDM4E 1514/4885GAA 1517/4885RAB9A 479/4885 |
| US-20160311808-A1 | CYCLOPROPANAMINE COMPOUND AND USE THEREOF | KDM1A, KDM1B, KDM2A | KDM4E 14/4885GAA 665/4885RAB9A 1508/4885 |
| US-20060167052-A1 | Piperidine derivative, process for producing the same, and use | OPRL1, OXTR, OPRM1 | KDM4E 1093/4885GAA 4559/4885RAB9A 3175/4885 |
| US-10919891-B2 | Heterocyclic compound | CASR, AGTR2, AGTR1 | KDM4E 3607/4885GAA 4704/4885RAB9A 1737/4885 |
| US-10053468-B2 | Heterocyclic compound | RORC, RORB, RORA | KDM4E 925/4885GAA 4321/4885RAB9A 2318/4885 |
| US-11059780-B2 | Substituted pyrrolidine compound and use thereof | HCRTR2, HCRTR1, CRHR2 | KDM4E 523/4885GAA 2894/4885RAB9A 2513/4885 |
| US-10899752-B2 | 2,3-dihydro-4H-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic M1 receptor | CHRM1, CHRM4, CHRM2 | KDM4E 742/4885GAA 3333/4885RAB9A 1524/4885 |
| US-20190151295-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 POLYPEPTIDES | IRAK1, IRAK4, IRAK2 | KDM4E 1071/4885GAA 1149/4885RAB9A 3342/4885 |
| US-20180155333-A1 | Heterocyclic Compound | HCRTR1, HCRTR2, OXTR | KDM4E 2226/4885GAA 2020/4885RAB9A 2077/4885 |
| US-20120015868-A1 | Metastin derivatives and use thereof | MET, HGFAC, HGF | KDM4E 4350/4885GAA 2525/4885RAB9A 687/4885 |
| US-20210024512-A1 | HETEROCYCLIC COMPOUND | TNNI3, TNNT2, TNNC1 | KDM4E 834/4885GAA 3573/4885RAB9A 2089/4885 |
| US-20110178060-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME | NTSR2, BDKRB1, AVPR1B | KDM4E 4083/4885GAA 4829/4885RAB9A 2851/4885 |
| US-20070027331-A1 | Semi-synthesis of taxane intermediates and aziridine analogues and their conversion to paclitaxel and docetaxel | CIAPIN1, CYP1B1, BRPF1 | KDM4E 1812/4885GAA 1990/4885RAB9A 691/4885 |
| US-20180303841-A1 | HETEROCYCLIC COMPOUND | CHRM1, CHRM2, CHRM5 | KDM4E 970/4885GAA 2448/4885RAB9A 1506/4885 |
| US-20090215700-A1 | Metastin derivatives and use thereof | SHBG, GNRHR, INHA | KDM4E 4035/4885GAA 2465/4885RAB9A 1107/4885 |
| US-20170050974-A1 | HETEROCYCLIC COMPOUND | RORC, RORB, RORA | KDM4E 925/4885GAA 4321/4885RAB9A 2318/4885 |
| US-20030232826-A1 | Compounds useful as reversible inhibitors of cysteine proteases | CTSS, CTSK, CTSB | KDM4E 3097/4885GAA 293/4885RAB9A 269/4885 |
| US-10745397-B2 | 1-Substituted 1,2,3,4-tetrahydro-1,7-naphthyridin-8-amine derivatives and their use as EP4 receptor antagonists | PTGER4, PTGER1, PTGER3 | KDM4E 2520/4885GAA 4824/4885RAB9A 1616/4885 |
| US-20230242529-A1 | HETEROCYCLIC COMPOUND | XIAP, BIRC5, BIRC3 | KDM4E 2577/4885GAA 1957/4885RAB9A 2828/4885 |
| US-20170008874-A1 | Method for Producing Sulfonyl Chloride Compound | P2RY4, P2RY6, P2RX4 | KDM4E 1646/4885GAA 2771/4885RAB9A 2864/4885 |
| US-20140163001-A1 | HETEROCYCLIC COMPOUND | RORC, RORB, RORA | KDM4E 1641/4885GAA 4519/4885RAB9A 2329/4885 |
| US-11230541-B2 | Heterocyclic compound | GRIN1, GRIN2A, GRIN2B | KDM4E 3433/4885GAA 4568/4885RAB9A 3105/4885 |
| US-20080262042-A1 | 1-[5-(2-Fluoropyridin-3-yl)-1-(phenylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine or a salt thereof; acid secretion inhibitor; potassium-competitive acid blocker | REN, HRH2, ATP4A | KDM4E 1715/4885GAA 549/4885RAB9A 443/4885 |
| US-20220133704-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | ZFX, TBL1XR1, TRIM28 | KDM4E 1129/4885GAA 3403/4885RAB9A 1093/4885 |
| US-20090143444-A1 | ACID SECRETION INHIBITOR | HRH2, VIP, CCKBR | KDM4E 4187/4885GAA 57/4885RAB9A 578/4885 |
| US-20140080817-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | GRIN1, GRIN2C, GRIN2A | KDM4E 1330/4885GAA 759/4885RAB9A 2581/4885 |
| US-10865200-B2 | Nitrogen-containing heterocyclic compound | CHRM1, CHRM5, CHRM2 | KDM4E 1279/4885GAA 3174/4885RAB9A 1060/4885 |
| US-20090274733-A1 | Pharmaceutical preparation containing copolyvidone | PRCP, COPS6, COPS5 | KDM4E 672/4885GAA 474/4885RAB9A 563/4885 |
| US-20200339577-A1 | 1-SUBSTITUTED 1,2,3,4-TETRAHYDRO-1,7-NAPHTHYRIDIN-8-AMINE DERIVATIVES AND THEIR USE AS EP4 RECEPTOR ANTAGONISTS | PTGER4, PTGER1, PTGER3 | KDM4E 2520/4885GAA 4824/4885RAB9A 1616/4885 |
| US-10093629-B2 | Heterocyclic compounds and their use as retinoid-related orphan receptor (ROR) gamma-T inhibitors | RORC, RORB, RORA | KDM4E 2167/4885GAA 2406/4885RAB9A 1282/4885 |
| US-11186565-B2 | Aromatic compound | GLP1R, GPR119, GPR39 | KDM4E 733/4885GAA 2819/4885RAB9A 2752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.